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Following a review of the published literature regarding insulin secretion and action,
with particular reference to non-insulin-dependent diabetes (NIDDM) and insulin
resistance, four major studies have been undertaken and are described here.
In a cross-sectional survey of coronary risk factors in subjects with recently
diagnosed NIDDM I confirm the high prevalence of individual risk factors described
by others, and show a broadly normal distribution pattern for the clustering of risk
factors forming Reaven's Syndrome X, in contrast to that reported in other
populations. I suggest that the risk factor clustering present may be better described
by a three-component model than by a single underlying factor as proposed by
Reaven.
In a study to examine the effects of the new oral hypoglycaemic drug A4166 in
NIDDM I confirm its major effect as an insulin secretagogue but find limited effects
on intermediary metabolism when assessed during an intravenous glucose tolerance
test. Any enhancement of glucose clearance appears to be secondary to the increase in
insulin secretion.
Ifhypertriglyceridaernia exacerbates insulin resistance in NIDDM, then its treatment
may reverse this process. In a randomised study comparing the fibrate drug
gemfibrozil with placebo I show that reduction in serum triglyceride concentrations
with gemfibrozil is associated with lower concentrations of non-esterified fatty acid
(NEFA) and ketones but not glucose, when assessed using a low-dose incremental
insulin infusion technique; this suggests a direct effect of the drug on lipid metabolism
rather than any effect on insulin sensitivity.
In established diabetes (NIDDM) the contribution of body fat to insulin resistance is
less clear than among non-diabetic subjects. In a group ofNIDDM subjects I show no
consistent effects of body fat on insulin resistance using the low-dose incremental
insulin infusion, and no relation between body fat indices and euglycaemic clamp
measures of insulin sensitivity. From the insulin infusion data I show that fasting
glucose concentration has the greatest impact on insulin resistance, suggesting that
hyperglycaemia or perhaps glucose toxicity has an effect overwhelming that of other
factors.
Using the data from the body fat studies described, I compare measures of insulin
resistance derived from insulin infusions, euglycarnic clamps and homeostatic
modelling (HOMA-R) in NIDDM, and discuss uses and limitations of these
techniques.
In a concluding chapter I attempt to summarise the findings from these studies and







The discovery of insulin and its introduction into clinical use in 1922 permitted a
revolution not only in treatment of diabetes but also in concepts of the disease. That
diabetes was a heterogeneous condition had been recognised by Arab and Indian
physicians during the latter part of the first millennium with observations recorded of
two types of diabetes, one predominantly affecting young thin individuals and
proceeding to rapid death, and the other seen in older more obese people and running
a less acute course.
Little more than a decade after the discovery of insulin Himsworth had proposed
(Himsworth, 1934) and then described (Himsworth, 1936) a distinction between
insulin-sensitive and insulin-resistant diabetic subjects. Lawrence (1951), from clinical
observations, proposed a division into an insulin-deficient group and one which he
supposed not to be insulin-deficient, subdividing this latter into a rare 'lipoatrophic'
category and the much more common 'lipoplethoric' - representing a predominantly
older, more obese and usually female population with typical symptoms at
presentation but characteristically absent ketosis and a relative insensitivity to insulin
therapy.
Hugh-Jones (1955), in an epidemiological study ofhis Jamaican patients, introduced
the terms type I and type II diabetes, noting the similarities ofhis type II subjects to
Lawrence's lipoplethoric group. He observed that such patients rarely required insulin
treatment except during intercurrent infections as they were not ketosis-prone under
normal conditions, and that they were also relatively insulin resistant.
These observations and much subsequent debate paved the way for the detailed
consensus classifications of diabetes defined first by the U.S. National Diabetes Data
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Group (1979) and then the World Health Organisation (1980). These give detailed
definitions of the categories we recognise today. The NDDG allows the use of the
terms type I and type II diabetes interchangeably with insulin-dependent (EDDM) and
non-insulin dependent diabetes (NIDDM) respectively as well as dividing type II
diabetes into obese and non-obese groups. Within the category of type II diabetes are
included individuals who may be hyperinsulinaemic and insulin resistant, to be
considered further below.
Synthesis and secretion of insulin
The insulin gene has been sequenced and located to the short arm of chromosome
11 (Owerbach et al, 1981). It encodes an mRNA precursor from which insulin rnRNA
is derived. This in turn controls synthesis ofpre-proinsulin in the (3-cell.
After cleavage to proinsulin on the rough endoplasmic reticulum the molecule is
transferred to the Golgi apparatus for conversion to insulin and C-(connecting)
peptide in clathrin-coated granules with subsequent storage prior to release from
uncoated mature secretory granules (Orci, 1985). Glucose is a potent stimulus to
proinsulin synthesis showing a sigmoidal dose-response curve with (in rats) maximal
effect at 10mmol/l and greatest change at 2-5mmol/l, thus distinct from its effect on
insulin secretion (Schuit et al, 1988).
Within the secretory granule proinsulin may be converted to insulin via either of two
routes, as cleavage at both the 32-33 and 65-66 positions is required. Two
endopeptidases, currently known as PC3 and PC2 respectively, perform these
functions, with subsequent removal of the exposed C-terrninal amino acid pair by a
carboxypeptidase. Thus the intermediate molecules generated may be either split 32-
33 and des 31-32 proinsulin or split 65-66 and des 64-65 proinsulin (Hutton, 1989;
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Rhodes and Alarcon, 1994). The work of Hales and his colleagues in developing
specific assays for these molecules has clarified the processes involved and suggested
that the favoured pathway is normally via split 32-33 and des 31-32 proinsulin. Only
very low concentrations of split 65-66 and des 64-65 proinsulin are detected, as PC2
is thought to work more efficiently on split than on whole proinsulin (Sobey et al,
1989; Rhodes and Alarcon, 1994).
The insulin molecule thus produced is composed of two polypeptide chains - an A
chain of 21 amino acids and a B chain of 30 amino acids, linked by two disulphide
bonds. Insulin and C-peptide are secreted in equimolar quantities from the islet (3 cell
along with a small amount ofunmodified proinsulin (Howell and Bird, 1989). Interest
has been aroused by the possibility that defective proinsulin processing and abnormal
secretion of proinsulin and intermediates may contribute to both development and
complications of type II diabetes.
Although glucose is the principal regulator ofproinsulin synthesis it has no influence
on the rate of conversion to insulin. Some other sugars (eg. mannose) and metabolites
(eg. dihydroxyacetone) (Ashcroft et al, 1978) can also stimulate proinsulin synthesis
directly although most stimulants are believed to work via glucose. Similarly, the
major stimulus for insulin secretion is also glucose, becoming effective only at
extracellular concentrations above 5 mmol/L and with maximal effects seen at
concentrations between 5.5 and 17 mmol/L (Howell and Bird, 1989), measurably
higher than those required for proinsulin synthesis. A limited number of other agents
are capable of independently stimulating insulin release (i.e. without requiring the
presence of glucose); these include amino acids - most notably lysine and arginine,
ketones, non-esterified fatty acids (NEFA), and the sulphonylurea group of oral
hypoglycaemic drugs.
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Insulin secretion enhancers or potentiators also have an important physiological role
and these include cyclic AMP, cholinergic neurones (predominantly of muscarinic
type), P2 adrenergic stimulation, and some of the gut peptides, notably glucagon,
glucagon-like peptide-1 (GLP-1) and possibly gastric inhibitory peptide (GIP)
(Kreymann et al, 1987; Ahren et al,1986). Important inhibitors of insulin secretion
include somatostatin, a-adrenergic neuronal activity (mainly 0C2), circulating
adrenaline and noradrenaline, and other neurotransmitters such as galanin and
neuropeptide Y (Kreymann et al, 1987).
Stimulus-secretion coupling (the mechanism linking extracellular glucose
concentration with the release from the P cell of insulin) requires the presence of Ca2+
whose uptake into the cell is stimulated by glucose and appears to be mediated by
protein kinases within the islet P cell cytoplasm (Howell and Bird, 1989). In common
with that ofmany other hoimones secretion of insulin can be shown to be pulsatile,
with oscillations observed in studies ofminute-to-minute variations (Lang et al, 1979)
and of diurnal patterns (Polonsky et al, 1988a). Although most modifiers of insulin
secretion seem to influence amphtude rather than frequency of secretory oscillations
(Matthews et al, 1983) diabetes disrupts normal frequency patterns (Lang et al, 1981;
Polonsky et al, 1988b). However the significance of these observations remains
unknown and it has not been possible to restore normal secretory activity in type II
diabetic subjects.
The insulin secretory response to intravenous injection of glucose has been
demonstrated to be biphasic (Porte and Pupo, 1969), with an initial rapid release of
insulin within about one minute of the onset of the stimulus and lasting up to 10
minutes, followed by a second phase beginning 10 minutes after the stimulus and
lasting for the duration of hyperglycaernia (i.e as long as the stimulus persists). It has
been suggested that this reflects release of stored insulin from secretory granules (1st
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phase) followed by de novo synthesis (Pfeifer et al, 1981), although this hypothesis is
currently undergoing critical reappraisal. This phenomenon is not observed following
oral glucose ingestion where intestinal absorption, incretins and hepatic factors have
important influences on the secretory response, and the resulting insulin secretory
response is in fact greater.
Insulin-receptor interactions
The insulin receptor gene is located on the short arm of chromosome 19; genetic
defects in the receptor are associated with some of the rare syndromes of severe
insulin resistance (Krook and O'Rahilly, 1996). Insulin receptors are found, in varying
concentrations, in almost all mammalian cell types; the number and affinity of insulin
receptors varies under different conditions. The receptor is a heterodimer comprising
two a subunits on the extracellular surface of the cell to which the insulin molecule
binds, and two (3 subunits which are transmembrane protein structures and are
responsible for insulin signalling (Czech, 1985). Maximal effects of insulin are often
demonstrable at very low concentrations (eg. in adipose tissue) and hyperinsulinaemia
appears to reduce receptor affinity, suggesting a critical role in some insulin-resistant
states (Kolterman et al, 1981).
The initial biochemical changes leading to intracellular effects occur in the (3 subunit
with activation of a tyrosine kinase resulting in a phosphorylation cascade within the
molecule (Shia and Pilch, 1983; Kahn and White, 1988). Further phosphorylation
takes place on the intracellular signalling protein IRS-1 (insulin receptor substrate-1)
(Sun et al, 1991). In man the gene coding for IRS-1 is on chromosome 2. Although
IRS-1 is probably important for most actions of insulin, signalling pathways
independent of IRS-1 have been demonstrated and an alternative insulin receptor
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substrate has been identified and designated IRS-2 (insulin receptor substrate-2)
(Araki et al, 1994).
Phosphorylated IRS-1 appears to act primarily as a docking site for a number of
intracellular proteins having SHE (src homology 2) domains. Of major importance
among these is the enzyme phosphatidylinositol 3-kinase (PI3-kinase), part of whose
function may involve modulation of insulin action by phosphorylation at serine
residues on IRS-1 (Tanti et al, 1994). Phosphorylation of serine and threonine sites on
the insulin receptor itself may have an inhibitory role (Lavan and Lienhard, 1994).
Association of IRS-1 with other SH2-domain proteins also takes place; among them
Grb2 which stimulates a kinase cascade activating Ras and MAP kinase (mitogen-
activated protein kinase). These proteins may be responsible for controlling the
phosphorylation-dephosphorylation reactions which characterise insulin's regulatory
action on several metabolic processes (White and Kahn, 1994).
Detailed characterisation and understanding of the effects of these signalling
cascades is as yet incomplete, and individual pathways cannot yet be related to
individual actions of insulin. The integrity of several signalling pathways may be
required for some effects and these may vary under different conditions.
These findings have been largely established in rodents, and although similar
phenomena may reasonably be expected in man direct extrapolation to human tissues
must be cautious at this stage. Nonetheless, the emergence of details of the molecular
signalling required for insulin action has offered insights into potential mechanisms for
the development of insulin resistance. Recent findings in mice deficient in IRS-1
suggest that muscle glucose transport and protein synthesis may be significantly
impaired (i.e. insulin resistant) in this situation but hepatic effects of insulin can be
preserved by a compensatory effect of ERS-2 (Yamauchi et al, 1996). Future
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examination both of molecular signalling defects and underlying genetic abnormalities
is likely to prove fruitful.
Probably the most important endpoint of the insulin signalling cascade is the
facilitated entry of glucose into the cell and this role is fulfilled by the glucose
transporter proteins, designated in order of discovery GLUT1 to GLUT5 (GLUT7
also exists but its role is thought to be at intracellular organelle level, mainly in the
fiver). GLUT1 appears to be ubiquitous, and GLUT2 is found in fiver and importantly
in the pancreatic islet, where it has a role in glucose-stimulated insulin secretion.
GLUT3 predominates in neural tissue, while GLUT4 is found principally in brown and
white adipose tissue, and in cardiac and skeletal muscle. GLUT5 is primarily a
fructose transporter (Kahn, 1995; Thorens, 1996). Although hepatic glucose
metabohsm is regulated by insulin this is not true ofhepatic glucose transport, and the
search for a glucose transport defect underlying insulin resistance has focused on the
insulin-sensitive tissues and GLUT4 (Mueckler, 1990; Pessin and Bell, 1992; Kahn,
1995).
In both muscle and adipose tissue insulin acutely stimulates the translocation of
GLUT4 from intracellular vesicles to the plasma membrane, possibly via a pathway
involving 1RS-1 and PI3-kinase (Yang et al, 1996). Tissue-specific regulation can be
demonstrated: with increasing insulin resistance in rats, adipose tissue GLUT4
downregulates while muscle GLUT4 does not. Present and future studies are
expected to address more closely the site of this defect (which may be in the insulin
signalling pathway, at the level of GLUT4 translocation or GLUT4 activation); to
date genetic defects in the GLUT4 molecule have not been identified.
An exciting recent development in this area has been the finding in vitro that in
conditions of high ambient glucose concentration adipose cells become refractory to
insulin-stimulated glucose transport (Marshall et al, 1991). The mechanism for this
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appears to be the routing of glucose metabolism via the hexosamine synthesis
pathway, whose rate-limiting step is the enzyme glutamine: fructose-6-phosphate
amidotransferase. The presence of L-glutamine is essential to activate this pathway. A
similar process has been impheated in muscle (Karam, 1996). While clearly of direct
relevance primarily in diabetes, this represents the first description of a specific
molecular mechanism inducing insulin resistance.
Physiological effects of insulin
As insulin receptors are present on almost all cell types, insulin can exert effects in
most tissues. However its most important regulatory roles concern metabolism in
fiver, muscle and adipose tissue. Insulin can modify tissue uptake and intracellular
transport of glucose and has a regulatory effect on several metabolic pathways,
particularly those of glucose and lipid metabolism, but also to a lesser extent on
protein metabolism. Most of the effects of insulin are anabolic or at least anti-
catabolic and in normal metabohsm a tight balance is maintained between these effects
and those of other, antagonistic, hormones. In recent years evidence has emerged to
show that insulin can modify gene expression of certain proteins directly, as well as
affecting enzyme activity. Thus it can be shown that insulin enhances transcription of
genes coding for the enzymes glucokinase, pyruvate kinase, glucose-6-phosphate
dehydrogenase, 6-phosphoffuctose-2-kinase/fructose-2,6-bisphosphatase, glycerol-3-
phosphate dehydrogenase and others as well as the glucose transporters GLUT1,
GLUT2 and GLUT4. Insulin reduces transcription of fructose- 1,6-bisphosphatase and
phosphoenolpyruvate carboxykinase among others (O'Brien and Granner, 1991). The
importance of some of these actions remains unclear, and measurement of the impact
and extent of these effects may be confounded by regulatory effects at the level of the
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enzyme involved and the fact that insulin may not be the major modulator of gene
expression for individual enzymes.
Glucose metabolism
Utilisation of glucose as a metabolic fuel requires its uptake into the cell and this is
achieved by a process of facilitated diffusion. The membrane glycoprotein glucose
transporters (GLUT 1-4; see above) perform this function; each has different tissue
specificity.
Insulin promotes uptake and utilisation of glucose by cells for oxidation, storage as
glycogen and, via glycolysis, for storage as fat. The action of insulin on glucose
uptake varies between tissues, and to some extent this is dependent on prevailing
blood glucose concentrations. DeFronzo et al (1983) demonstrated differing dose-
response characteristics for stimulation of peripheral glucose uptake and inhibition of
hepatic glucose output, the latter requiring much lower concentrations of insulin.
Insulin alone had little influence on splanchnic glucose uptake, whereas glucose, in the
presence of insulin, enhanced its own uptake by splanchnic tissues. Others have
argued that hepatic glucose uptake, mainly for storage as glycogen, is critically
dependent on portal insulin concentration (Pagliassotti and Cherrington, 1992).
Only in muscle and adipose tissue does insulin acutely regulate glucose uptake and
in these tissues this is a rate-limiting step for glucose metabolism. It has been
estimated using glucose clamp techniques in healthy volunteers that approximately
75% of whole body glucose uptake from plasma, largely by the brain, is independent
of insulin and is regulated only by blood glucose levels until saturation of glucose
transport channels takes place. The process follows Michaelis-Menten (i.e. saturable)
kinetics and uptake can be enhanced by insulin in a linear fashion (Gottesman et al,
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1983). These findings have been confirmed in post-absorptive diabetic subjects whose
absolute glucose uptake was greater than that of controls because of their higher basal
plasma glucose levels (Baron et al, 1985).
Following entry into the cell cytoplasm glucose is converted to glucose-6-phosphate
by the enzyme hexokinase prior to any further metabolism. In the liver, and also in the
pancreatic islet cell, this reaction is carried out by glucokinase (hexokinase IV) which
as its name suggests is more specific for glucose. This process is essentially
irreversible although in the fiver free glucose can be regenerated for release into the
circulation by the action of glucose-6-phosphatase. From glucose-6-phosphate several
metabolic pathways are accessible.
In the liver glycogen synthesis is stimulated by insulin and glycogenolysis is
simultaneously inhibited. Insulin stimulates glycogen synthase by dephosphorylation of
the enzyme to its active form. This effect appears to be independent of any lowering
of cytoplasmic cyclic AMP levels. (The stimulatory effect of glucagon and adrenaline
on glycogenolysis is mediated by cyclic AMP.) Under basal conditions (i.e. in the
post-absorptive state following an overnight fast) the suppression of hepatic glucose
output by insulin is almost entirely mediated by inhibition of glycogenolysis with a
much smaller contribution from inhibition of gluconeogenesis (McGuinness et al,
1987).
Gluconeogenesis can only occur in fiver and kidney as these are the only organs
possessing all the enzyme systems required. The fiver has normally been considered to
account for the vast majority of gluconeogenic activity, at least in the postabsorptive
state, although this view has recently been challenged (Stumvoll et al, 1997). The
process can be regulated by substrate supply, enzyme regulation and product
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inhibition (it is inhibited by glucose). It is promoted principally by glucagon and
inhibited by insulin (Krauss-Friedrnann, 1984).
Glycolysis and gluconeogenesis can be seen as almost exact opposites, with enzyme
reactions differing only at three steps - glucose/glucose-6-phosphate (mediated by
glucokinase and glucose-6-phosphatase respectively), fructose-6-phosphate/fructose-
1,6-bisphosphate (phosphoffuctokinase-l/fructose-l,6-bisphosphatase) and
phosphoenolpyruvate/pyruvate (pyruvate kinase/pyruvate carboxylase and
phosphoenolpyruvate carboxykinase) interconversion. These are thus the key
regulatory steps governing the overall direction of reaction. In the fasted state, where
the effects of glucagon, glucocorticoids and catecholamines predominate,
gluconeogenesis is favoured, while in the fed state with insulin dominant, the process
is reversed in favour of glycolysis (Pilkis and Granner, 1992; Van Schaftingen, 1993).
Using an isotopic method Consoli et al (1987) found that in healthy volunteers studied
in the post-absorptive state acetyl CoA entered Krebs' cycle at twice the rate of
pyruvate. Under these conditions gluconeogenesis accounted for approximately 28%
of total (hepatic) glucose output.
Gluconeogenesis is enhanced in type II diabetes (Consoli et al, 1989; Magnusson et
al, 1992) as might be expected by the predominant action of pro-gluconeogenic
hormones in conditions of insulin deficiency or resistance. Glycogenolysis appears to
be relatively little affected; thus gluconeogenesis is the greater contributor to
increased hepatic glucose output. Although greater absolute concentrations of both
lactate and alanine substrates are available for this process in NIDDM, only the
proportion of lactate used is increased and the major source of this appears not to be
muscle (Consoli et al, 1990).
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Studies of muscle glucose disposal suggest that pyruvate dehydrogenase may be a
critical regulatory step in oxidative glucose metabolism, while glycogen synthase is a
regulatory step for nonoxidative metabolism (Mandarino et al, 1987). Reduced muscle
glycogen synthase activity has been found in obese nondiabetic and diabetic subjects
(Damsbo et al, 1991) as web as nonobese type II diabetics (Johnson et al, 1991) and
their first degree relatives (Vaag et al, 1992a) suggesting an important role in the
development of insulin resistance and type II diabetes. Further study in diabetic
subjects has suggested that hyperglycaemia itself may have a compensatory effect,
allowing glycogen synthase activity to be preserved by increased availability of
substrate (Vaag et al, 1992b).
Thiebaud et al (1982) reported that with increasing insulin levels whole body
glucose oxidation was saturable and that nonoxidative metabolism then predominated.
In a study ofmuscle metabolism, which was found to account for only a quarter of an
oral glucose load, 50% was found to be oxidised, leaving only 35% for storage, with
the remainder undergoing glycolysis to release lactate, pyruvate and alanine (Kelley et
al, 1988). This finding is somewhat at variance with previously reported data
suggesting that some 50-70% of an oral glucose load is accounted for by peripheral
tissues (Ferrannini et al, 1985). The same group reported in a separate study that,
although splanchnic glucose uptake was relatively little altered by diabetes, peripheral
(lower limb muscle) glucose uptake was reduced by up to 50% compared with
nondiabetics (DeFronzo et al, 1985). More recent studies using magnetic resonance
imaging have shown that skeletal muscle glucose uptake, glycogen synthesis and total
nonoxidative glucose disposal are all markedly reduced in type II diabetes, suggesting
an important role in insulin resistance (Shuhnan et al, 1990). Examination of
nondiabetic first degree relatives of type II diabetic subjects has shown that they share
this defect in nonoxidative glucose metabolism (Eriksson et al, 1989).
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Mitrakou et al (1990) found evidence that excessive hepatic glucose output was a
more important contributor to hyperglycaemia than was reduced muscle glucose
uptake. The relative contribution of these two processes has been vigorously debated
(Gerich, 1991; DeFronzo, 1992; DeFronzo et al, 1992) and it has also been suggested
that the impact of each may alter with progression of hyperglycaemia and diabetes,
hepatic glucose output taking on a greater role with increasing glucose concentrations
(DeFronzo et al, 1989). Problems of methodology which may account for the
discrepancies in results reported have been discussed by Beck-Nielsen et al (1994).
Lipid metabolism
In its role as a hormone promoting the use ofglucose as the major metabolic fuel the
effects of insulin on lipid metabolism are predominantly anabolic. Uptake of fatty
acids from the circulation by adipose tissue and subsequent esterification for
lipogenesis is enhanced, while fatty acid release and oxidation is suppressed. Fatty
acid metabolism is extremely sensitive to the effects of insulin and this appears to be
independent of effects on glucose metabolism. It has long been recognised that very
low concentrations of insulin are needed to suppress peripheral free fatty acid output,
lower than the concentration required to stimulate glucose uptake (Zierler and
Rabinowitz, 1964). These findings, evidence of the sensitivity of lipolysis to
suppression by insulin, have been confirmed by others (Bakir and Jarrett, 1981;
Nujjhan et al, 1986; Jensen et al, 1989) and shown to remain true in type II diabetic
subjects (Swislocki et al, 1987), although impairment of insulin action is observed in
this group indicating insulin resistance.
With a continued flux of free fatty acid into and out of the cell, assessment directly
of the influence of insulin on reesterification of fatty acids is difficult and has produced
conflicting findings (Coppack et al, 1989; Groop et al, 1991). Adipocytes from
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different sites have been shown to have different metabolic activities, those from
abdominal fat being more active than femoral fat cells (Smith et al, 1979).
The relative circulating concentrations of insulin and glucagon are more important to
hepatic lipid metabolism than absolute concentrations of either hormone. A relative
excess of glucagon inhibits the hepatic conversion of acetyl CoA to malonyl CoA,
thus limiting inhibition by the latter of the enzyme carnitine acyltransferase I on the
mitochondrial membrane surface. Malonyl CoA inhibits fatty acid oxidation and
consequent ketogenesis. Insulin enhances malonyl CoA synthesis and thus limits the
use of acetyl CoA in ketogenesis (McGarry and Foster, 1980). Insulin can also be
shown to reduce uptake of ketones and release of NEFA and glycerol by adipose
tissue (Coppack et al, 1989).
In contrast to the tight regulation of glucose metabolism, fatty acid turnover is very
loosely governed by interaction between a number of factors, chiefly insulin
concentration and adrenergic activity (Coppack et al, 1994). Insulin increases
synthesis of adipose tissue lipoprotein lipase thus enhancing removal of lipoprotein
triglyceride from the circulation (Eckel, 1989). It is a potent inhibitor of hormone
sensitive lipase which hydrolyses stored triglyceride to NEFA and glycerol; these two
enzymes thus maintain a balance between fatty acid retention for esterification and
release for oxidation (Coppack et al, 1994).
Protein metabolism
Insulin promotes protein synthesis in muscle by a direct ribosomal action. It inhibits
proteolysis along with its action inhibiting gluconeogenesis. Its importance is most
easily observed in insulin-deficient states (eg. diabetes or starvation), where
proteolysis may be prominent resulting in loss ofmuscle mass. As previously indicated
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insulin can modify gene transcription of a number of proteins, both enzymes and
others, in this context notably including glucagon and the insulin-like growth factor
binding protein IGFBP-1. It can enhance synthesis of ribosomal RNA and appears to
increase amino acid uptake in cells, probably by a gene-related mechanism. It is
thought that many of insulin's actions on protein synthesis are mediated by
phosphorylation/dephosphorylation reactions on specific proteins but detailed
mechanisms remain uncertain (Kimball et al, 1994).
Studies of amino acid flux in vivo have shown evidence of both inhibition of
proteolysis and enhancement of tissue uptake by insulin. During euglycaemic
hyperinsulinaemia net uptake of phenylalanine and leucine is enhanced (Bennet et al,
1990) and release into plasma, especially of branched-chain amino acids which appear
most sensitive to the influence of insulin, is reduced (Fukagawa et al, 1986). A dose-
response effect can be shown for a progressive reduction in leucine flux by increasing
concentrations of insulin, implying reduced proteolysis limiting entry of leucine into
the plasma (Fukagawa et al, 1985). In this studies insulin was also observed to
increase de novo alanine synthesis although the source of alanine was not established.
In a further study the same group was able to show that, despite evidence of an age-
related decline in insulin sensitivity of glucose metabolism, leucine disposal remained
sensitive to insulin in the elderly (Fukagawa et al, 1989).
The relative importance of insulin to protein metabolism under physiological
conditions has been difficult to define with certainty; much of its contribution seems
to be as a stabilising influence inhibiting excessive catabolism rather than any major
anabolic effect per se (Gelfand and Barrett, 1987). As a result studies of insulin action
in isolation have often tended to suggest little or no role for insulin although its




Metabolic processes cannot be considered in isolation, and the pathways outlined
above interact with one another, not only within but often between tissues, especially
liver, muscle and fat. The regulation of these systems depends on both feedback
control and the ability to vary the direction and degree of flux of enzyme systems with
great sensitivity. The concept of substrate cycles was proposed several years ago to
explain this and has received widespread experimental support (Newsholme and
Crabtree, 1976). Such cycles may exist on any scale, from a single enzyme reaction to
the involvement of several reactions, sometimes across a number of tissues.
The observation that fatty acid levels were often elevated in diabetes led to the
concept of the glucose-fatty acid cycle (Randle et al, 1963) whereby stable plasma
glucose concentrations may be maintained by a balance between (muscle and adipose)
tissue uptake of glucose inhibiting release of fatty acids into the circulation, and
availability of fatty acids restricting tissue glucose uptake. Insulin favours glucose
uptake and the esterification of fatty acid and where insulin deficiency or resistance is
present, as in diabetes, both blood glucose and circulating fatty acid levels are
elevated. Extensive experimental work has supported the existence of this cycle and
emphasised its significance, as well as suggesting a role for defective fatty acid
metabolism in the genesis of insulin resistance (Ferrannini et al, 1983; Vouillamoz et
al, 1987; Groop et al, 1989; Chambrier et al, 1990; Boden and Jadali, 1991). Fatty
acids can also be shown to enhance gluconeogenesis (largely from lactate) although in
normal man there appear to be protective mechanisms to prevent a rise in hepatic
glucose output (Clore et al, 1991).
The glucose-lactate cycle of Cori is well-defined and is probably important in
regulating both gluconeogenesis and glycogen synthesis via the indirect pathway.
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Glucose taken up in muscle can be converted to lactate which is then released for the
synthesis of glucose again in liver. A similar process has been postulated for alanine
(Felig et al, 1970), whose importance as a gluconeogenic precursor is probably
second only to that of lactate, and which accounts with glutamine for some 50% of
amino acid-derived gluconeogenesis. Insulin lowers plasma alanine concentrations at
the muscle level, thus making it unavailable to the liver. In a study including
examination of the role of glycerol in gluconeogenesis, evidence for competitive
inhibition among gluconeogenic substrates has been found in normal volunteers,
although feedback inhibition was not addressed (Jahoor et al, 1990).
Thus insulin, acting in a number of tissues by several separate but interrelated
effects, mainly anabolic or anticatabolic, contributes to glucose homeostasis and
regulates availability of alternative metabolic fuels. Clearly insulin deficiency, as in
type I diabetes, will derange all of these processes, while insulin insensitivity or
resistance to one or more of these effects will, directly or indirectly, have deleterious
consequences on several other systems.
Assessment of insulin secretion, action and sensitivity
Historical Background
Since the introduction of insulin preparations into clinical use variation between
individuals in response to given doses has been apparent. HImsworth (1936) was able
to divide patients into insulin-sensitive and insulin-insensitive categories on the basis
of the dose of injected insulin required to abolish glycosuria and/or provoke a fall in
measured blood glucose. He described an insulin-glucose test (sometimes called an
insulin sensitivity test) whereby intravenous insulin and oral glucose were given
according to body surface area in fasting subjects with blood glucose estimations over
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60 or 90 minutes. This resulted in a clear separation between subjects who showed a
fall in blood glucose in the first 30 minutes and those in whom blood glucose
continued to rise without any apparent effect of insulin (Himsworth and Kerr, 1939a).
Using this method in healthy subjects they (Himsworth and Kerr, 1939b) showed a
tendency for insulin sensitivity to decline with age, a finding confirmed by Lister et al
(1951) in a study of 100 diabetic subjects. In this latter study it was concluded that the
effect of age may have been confounded by increasing weight, and a curve of
approximately Gaussian distribution could be constructed for insulin sensitivity over
the whole group without clear separation between insulin-sensitive and -insensitive
categories.
Prior to 1960 estimation of insulin concentration in plasma could only be inferred
from indirect measures such as the degree of hypoglycaemia provoked in laboratory
animals or effects on isolated tissue preparations. The work of researchers such as
Grodsky and Forsham (1960) and more particularly Yalow and Berson (1960a) for
the first time enabled direct measurement of plasma insulin concentration and
permitted examination of relationships between concentration and effects on
metabolic processes.
Yalow and Berson (1960b) used their new method to demonstrate that following a
1 OOg oral glucose load, while fasting plasma insulin levels were comparable between
diabetic and non-diabetic subjects, the former tended to show higher insulin
concentrations one and two hours later despite also having higher blood glucose
levels.
Martin et al (1968), in a study of healthy non-obese siblings of juvenile-onset
diabetics, showed a significant positive correlation between 2hr blood glucose and 2hr
plasma insulin after a 50g oral glucose load and, following this with a short insulin
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tolerance test (lOOmU/kg insulin injected intravenously with a single blood glucose
measurement 15 minutes later) also showed an inverse association of 2hr plasma
insulin with insulin sensitivity. Fasting insulin concentration was associated with
neither blood glucose nor insulin sensitivity.
Franckson et al (1966) had used a number of dynamic tests (IVGTT, lOmU/kg
insulin tolerance test with blood glucose measured for 30 mins, glucose-insulin tests
and tolbutamide response test) to compare healthy and obese non-diabetic subjects
and found a reduction in the peripheral action of (exogenous) insulin on the glucose
utilisation rate in obese subjects, noting only a modest effect of ageing in both groups.
A classification of tests of insulin resistance in modern use is given in table 1.1, and
the major techniques are reviewed below.
Basal insulinaemia and plasma insulin-glucose relationships
Especially in large-scale studies a simple index of insulin secretion and sensitivity is
preferable and intuitively a fasting plasma insulin estimation might appear to provide
this. However, in isolation this has important limitations in terms of estimating both
insulin secretory capacity and insulin sensitivity. It has been widely recognised that
over time in subjects progressing from normal to impaired glucose tolerance insulin
levels tend to rise before falling again with the onset of frank diabetes. A similar
problem arises in subjects destined to develop type I diabetes in whom insulin
secretion, whether acutely or subacutely, declines. Furthermore, it can be shown
(Lang et al 1979, 1981; Matthews et al, 1983) that insulin is secreted in a pulsatile
fashion in the resting state and this pulsatility is deranged in NIDDM. Nonetheless it is
worth noting that a linear correlation has been demonstrated between fasting insulin
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levels and insulin resistance as measured by the insulin suppression test (Olefsky et al,
1973).
In an attempt to take account of, and estimate the contributions of, both 3 cell
function and insulin sensitivity to plasma insulin and glucose concentrations Turner
and colleagues devised (Turner et al, 1979) and refined (Matthews et al, 1985) a
mathematical model which they termed HOMA (homeostasis model assessment). This
technique allows a quantitative estimation of both insulin secretory function and
relative insulin sensitivity using a computer model based on the interaction between
fasting plasma glucose and insulin concentrations. The authors were able to compare
the technique (Matthews et al, 1985) with other established methods of assessing
insulin secretion and sensitivity and its use has been favoured by some investigators
although it is less widely accepted than the glucose clamp or the IVGTT. Recently a
simplified version of the insulin sensitivity equation, with a small modification, has
been put forward (Duncan et al, 1995) which may encourage its wider use.
Oral glucose tolerance test
The oral glucose tolerance test (OGTT) is used as the standard for determining
glucose tolerance status and thus in the diagnosis of diabetes. Aspects of insulin
secretion, insulin action and glucose clearance are thus integral to the test.
A relationship can be shown between plasma insulin response and oral glucose
tolerance in different pathological states (Berson and Yalow, 1965; Perley and Kipnis,
1966; Reaven and Miller, 1968). However the test itself can be criticised because of
the degree of intra-individual variation on repeated testing, particularly noted in the
in-between category of impaired glucose tolerance (McDonald et al, 1965; Yudkin et
al, 1990) and it has been found unhelpful in quantitative estimation of insulin
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resistance (Hollenbeck et al, 1984). Nonetheless it has recently been suggested that
the 30-minute plasma insulin value derived during the OGTT may be a useful index of
insulin secretion, particularly in population studies (Phillips et al, 1994a; Wareham et
al, 1995). Differences in test standards between the USA (50g or lOOg glucose load)
and elsewhere (75g glucose), and the general absence in its application of any
adjustment to glucose load for body weight, hamper the validity of the test in
assessment specifically of insulin secretion or action.
Intravenous glucose tolerance test (IVGTT)
The principle of measuring the effects of an acute intravenous glucose load date
back at least to 1923. Early studies examined changes in blood glucose concentration
under a variety of protocols and extensive debate took place about the most suitable
calculations to perform in order to extract meaningful information from the data
obtained. Even in recent times a lack of a universal standard protocol has hindered
comparisons over time and between centres (Bingley et al, 1992), and there is as yet
no consensus on the most appropriate calculations to apply (Smith et al, 1988;
Colman et al,1992). Furthermore, the reproducibility of the test remains disputed
(Raynian et al, 1990; Koschmann et al, 1992).
The two most studied effects of an intravenous bolus are the rapid rise followed by a
more gradual decline in blood glucose concentration and the stimulation of insulin
secretion which in normal man is biphasic (Porte and Pupo, 1969). Most studies
assessing insulin secretion concentrate mainly on the first phase response which is lost
in NIDDM and in certain study populations helps predict subjects at risk of LDDM.
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Table 1.1. Tests of insulin resistance in vivo
Static tests
Fasting plasma insulin concentration
Homeostasis model assessment (HOMA)
Dynamic tests
(a) tests ofendogenous insulin activity
oral glucose tolerance test (OGTT)
intravenous glucose tolerance test (IVGTT)
frequently sampled IVGTT (FSIGT) with minimal modelling*
continuous infiision ofglucose with modelling analysis (CIGMA)
hyperglycaemic clamp
(b) tests ofexogenous insulin action
euglycaernic hyperinsulinaemic clamp
insulin suppression test (1ST)
somatostatin-modified 1ST
graded and low-dose insulin infusions:
(i) with clamped glucose levels
(ii) with glucose levels allowed to fall
short insulin tolerance test (ITT)
*FSIGT may be modified by injection of exogenous insulin
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The use of the intravenous glucose tolerance test (IVGTT) in assessing insulin
sensitivity or resistance has been developed and promoted by Bergman and his
colleagues (Bergman et al, 1979 and 1981) who have devised a mathematical model
(minimal model) to describe the insulin and glucose dynamics following a glucose load
and thus estimate quantitatively the contribution of endogenous insulin to metabolic
glucose clearance. A single value (insulin sensitivity index) can be calculated from the
plasma insulin and glucose concentrations obtained, using the model to predict the
effect of insulin on glucose disappearance. Following criticism of poor comparability
with euglycaemic clamp results (Donner et al, 1985) the original protocol has been
modified by the use of an injection of tolbutamide some 20 minutes after the glucose
load which further stimulates insulin secretion (Beard et al, 1986) and has since
allowed claims of equivalence with clamp data (Bergman et al, 1987). Further
modification by using insulin instead of tolbutamide permits the use of the technique
in diabetic subjects with little or no endogenous insulin response (Welch et al, 1990).
Other refinements have been proposed to improve the model's reliability including the
use of somatostatin (Yang et al, 1987) and radiolabeled glucose infusion (Cobelh et
al, 1986) although more recently Caumo et al (1991) have cast doubt on the validity
of some of the assumptions made in the model, which may help explain some of the
discrepancies in comparison studies with clamp methods.
Although its proponents claim simplicity, the protocol is long and intensive,
requiring approximately 30 samples at precise time points over three hours (hence
FSIGT - frequently sampled IVGTT) and is not adaptable for large-scale studies
outside a research centre. Galvin et al (1992) have proposed a simplified IVGTT
protocol allowing measurement ofboth insulin secretion and sensitivity (by estimating
glucose disappearance per change in insulin level) over the first 40 minutes after a
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glucose bolus. However they advise caution in extrapolating this method to subjects
who may be particularly insulin resistant.
The application of the minimal model to assessing 3 cell function was developed
alongside its use in insulin sensitivity studies (Toffolo et al, 1980; Bergman et al,
1981) but the modifications made to enhance its applicability in the latter have
resulted in much of its value in the former being lost. Weber et al (1989) have
proposed adaptations to retain its usefulness in assessment of insulin secretion.
However simpler and shorter IVGTT protocols are more generally favoured for this
purpose (Bingley et al, 1992; Koschmann et al, 1992).
Bergman (1989) has reviewed in detail the development and principles of the
minimal model technique.
Continuous glucose infusions
In contrast to the highly dynamic changes associated with an intravenous bolus of
glucose in an IVGTT continuous infusions ofglucose can explore effects more closely
corresponding to steady state conditions. Such techniques have been in use for many
years both in the form of the hyperglycaemic clamp (DeFronzo et al, 1979) and
without clamping. Reaven and Farquhar (1969) used a protocol which enabled them
to demonstrate that hyperglycaemia in type II diabetes was not merely a result of
peripheral hypoinsulinaemia but that it occurred despite an apparently appropriate
pancreatic secretory response thus implicating insulin resistance in the pathogenesis of
the condition.
The hyperglycaemic clamp is more often used as an alternative to the IVGTT in
assessing P cell function but has recently been used to estimate insulin resistance
(Hosker et al, 1985; Mitrakou et al, 1992). This potential to examine both insulin
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secretion and sensitivity simultaneously may offer an advantage in versatility over the
euglycaemic clamp; Mitrakou et al (1992) showed a close correlation between
estimates of insulin sensitivity generated from hyperglycaemic and euglycaemic clamp
procedures.
A more sophisticated technique, incorporating a simpler experimental protocol, for
measuring both (3 cell function and insulin resistance has been proposed by Hosker et
al (1985). Developed alongside the same group's HOMA method, CIGMA
(continuous infusion of glucose with model assessment) uses a computer-derived
model to estimate P cell response and insulin resistance from the plasma insulin and
glucose data produced during a one hour fixed-rate infusion of glucose. The authors
validated this method against both the hyperglycaemic clamp and IVGTT. The
hyperglycaemic clamp is restricted in use to subjects whose basal plasma glucose does
not exceed the level at which the clamp is to be set (most often lOmmol/L) and all of
these techniques require that urinary glucose losses should be negligible.
Euglycaemic hyperinsulinaemic clamp
The glucose clamp developed by Andres and his colleagues has acquired the status
ofthe 'gold standard' against which other techniques of assessing insulin sensitivity are
now usually measured. Early reports of its use came in the context of modelling
insulin and glucose kinetics in vivo (Sherwin et al, 1974; Insel et al, 1975) but the
description of both the hyperglycaemic clamp to assess P cell responsiveness and
more especially the euglycaemic insulin (hyperinsulinaemic) clamp to assess insulin
resistance (DeFronzo et al, 1979) contributed significantly in bringing the use of
clamp studies to their present pre-eminence.
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Although labour-intensive the principles of the technique are essentially simple: by
using a variable infusion of intravenous glucose, with (euglycaemic or hypoglycaemic
clamps) or without (hyperglycaemic clamp) infusion of a predetermined dose of
insulin, the plasma glucose concentration may be fixed or 'clamped' at any desired
level. A quantitative measure of insulin sensitivity can be derived using the
euglycaemic hyperinsulinaemic clamp from the amount of glucose infusate required to
maintain the desired blood glucose level and counter the effect of the infused insulin
(i.e. the more glucose infused under stable conditions the more insulin-sensitive the
subject).
Insulin suppression test and variants
The insulin suppression test (1ST) was developed specifically to examine insulin
resistance (or 'impedance') by Shen et al (1970). The technique employs a fixed
infusion of insulin and glucose, along with adrenaline to suppress endogenous insulin
secretion, and propranolol both to suppress insulin secretion and inhibit any tendency
of the adrenaline to restore hepatic glucose output suppressed by the insulin infusion.
Stable conditions are usually achieved within 90 minutes of starting the test and
subsequent values can then be averaged to yield figures for steady-state plasma
glucose and insulin concentrations. By this means endogenous glucose production is
suppressed and so tissue glucose uptake is equal to glucose infused; thus a higher
steady state plasma glucose concentration would imply a greater degree of resistance
to insulin-stimulated glucose uptake. The technique has been compared favourably
with the euglycaemic hyperinsulinaemic clamp (Greenfield et al, 1981).
The need for propranolol and adrenaline renders the procedure somewhat
cumbersome, and in order to address this drawback the substitution for these of
somatostatin was proposed (Harano et al, 1977 and 1978; Nagulesparan et al, 1979).
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This modification is probably now more widely used than the original method. Further
modification is sometimes employed by omitting somatostatin from the infusate
(modified Harano method). Some minor variations exist between protocols regarding
whether to vary infusion of glucose (1ST), insulin (Nagulesparan's method) or both
(Harano technique) according to body weight.
Graded and low-dose insulin infusions
Both the insulin suppression test and the euglycaemic clamp produce steady-state
plasma insulin concentrations at or above the limit of the physiological range (about
100 ± 20 mU/L or 600-800 pmol/L). Although these concentrations are clearly
adequate to ensure that hepatic glucose production is suppressed, allowing attention
to be directed more specifically at peripheral insulin sensitivity (Groop et al, 1989),
other aspects of insulin action become more difficult to study with these techniques. It
has long been recognised that other effects of insulin on peripheral tissues occur
independently of and at lower concentrations than effects on glucose uptake (Zierler
and Rabinowitz,1964; Schade and Eaton, 1977; Brown et al, 1978). In order then to
study the effects of insulin on these aspects of intermediary metabolism procedures
more closely reproducing physiological conditions are required. Dose-response
studies for insulin actions can be performed with or without clamping blood glucose
level and insulin infusion can be set to achieve low-, mid-, or high-physiological or
supraphysiological plasma concentrations allowing comparison of effects over the
range studied. The techniques used have been successfully combined with indirect
calorimetry techniques to assess glucose oxidation and storage, or have incorporated
infusion of isotopic glucose tracer to measure glucose turnover.
Study methods which involve clamping blood glucose follow the basic procedure of
the euglycaemic clamp of Andres (DeFronzo et al, 1979) but usually with stepwise
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increments in the insulin dose infused (Rizza et al, 1981; Thiebaud et al, 1982;
Proietto et al, 1982; Nurjhan et al, 1985; Groop et al,1989).
Protocols which do not involve clamping of blood glucose concentration permit
more direct comparison of the effects of insulin on glucose metabolism with those on
other metabolites. Most of these feature stepwise increments in the dose of insulin
infused, allowing the blood glucose level to fall naturally. The two main disadvantages
of this approach are, firstly, concern about the extent to which the level of glycaemia
itself influences glucose uptake and thus possibly affects results (DeFronzo and
Ferrannini, 1982; Proietto et al, 1983), and secondly, the risk of inducing
hypoglycaemia - an unwanted outcome both for investigator, in view of the
confounding effects of counterregulatory hormones, and also for the subject. A third
disadvantage is shared with glucose clamp studies where graded insulin infusions are
used hi that continuous perturbation of the steady state is taking place resulting in
greater uncertainty about the validity of conclusions reached (Cobelli et al, 1987).
A number of protocols have been described using either fixed (Bakir and Jarrett,
1981) or incremental (Schade and Eaton, 1977; Sacca et al, 1979; Hale et al, 1986)
infusion of insulin according to the effects under investigation. The low-dose
incremental insulin infusion technique ofHale and Nattrass (Hale et al, 1986) has been
used extensively in this laboratory to examine aspects of insulin resistance in a variety
of physiological and pathological conditions (Hale et al, 1985; Singh et al, 1987;
Singh and Nattrass, 1989; Krentz et al, 1991a and 1991b; Robertson et al, 1992).
Short insulin tolerance test
The rate of disappearance of glucose from plasma following an intravenous bolus of
insulin can be used to estimate insulin sensitivity. Greater sensitivity to insulin will
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result in more rapid glucose clearance. The technique has been in use for many years
(Alford et al,1971; Harrison et al, 1976), and with some modification has more
recently been shown to give estimates of insulin resistance comparable with clamp
data (Bonora et al, 1989; Akinmokun et al, 1992). It is often favoured in
circumstances where more intensive techniques are impracticable.
Conclusions from earlier studies may be of questionable value because of the
confounding eftects of counterregulatory hormones arresting the fall in plasma
glucose some 15-30 minutes after the onset of the hypoglycaemic stimulus; this has
been addressed more recently by studying only the glucose disappearance rate in the
first 15 minutes after insulin injection.
The test is clearly unphysiological and the dose of insulin commonly used (0. lU/kg)
represents a supraphysiological stimulus. In common with other simple methods of
measuring insulin resistance it provides limited information and is likely to have most
value in large-group studies and in situations where longer and more intensive
protocols are impractical.
Other modifications
Further information regarding insulin action, glucose clearance and specific sites of
metabolic activity may be combined with many of the above techniques by the use of
additional measurement devices. Thus forearm muscle metabolite exchange, whole
body glucose turnover and indirect calorimetry have often been incorporated into
studies using these methods.
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Other tests of insulin secretion
In addition to tests of (3-cell responsiveness to glucose other agents can be used to
measure insulin secretion. Responses to certain amino acids, (3-adrenergic agonists,
glucagon and other hormones, and sulphonylureas have all been assessed. Most
commonly used are tests employing arginine, tolbutamide or glucagon. First phase
insulin secretion in response to arginine can be shown to persist even in diabetic
subjects whose response to glucose has been lost (Palmer et al, 1976). Tests using
these agents require pharmacological doses to exert their effect on the P-cell and for
more physiological studies glucose is usually preferred.
Insulin resistance
Concepts of insulin resistance
Himsworth (1936) was probably the first observer to characterise a difference
between diabetic individuals requiring only small doses of exogenous insulin to abolish
glycosuria and those in whom glycosuria persisted despite much larger doses of
insulin. Evidence that diabetes was not solely a result of absent or defective insulin
secretion came from the work ofYalow and Berson (1960) who found fasting plasma
insulin concentrations in their diabetic subjects to be at least equal to those of
nondiabetic controls; this led to the conclusion that the tissues of diabetic subjects
were less sensitive to the influence of endogenous insulin. The appreciation of
differences between individuals in their responses to endogenous or exogenous insulin
has therefore existed for many years. Understanding of these differences in sensitivity
or resistance to insulin requires a clear definition of the concept, and this has proved
more difficult.
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Reaven and his colleagues (Shen et al, 1970; Reaven, 1983; Reaven, 1988) have
preferred to confine their use of the term insulin resistance to describe impairment of
insulin-stimulated glucose uptake; this takes a somewhat restricted view of insulin
action with no account of effects on other aspects of intermediary metabolism, but
does offer a rational starting point. Other authors have referred to insulin resistance or
insensitivity without further clarification.
Kahn (1978) offered a broad definition in which "insulin resistance may be said to
exist whenever normal concentrations of hormone produce a less than normal
biological response". He further argued for clarity of terminology in distinguishing
decreased sensitivity to insulin (shift of the dose-response curve to the right but with
maintained maximal effect) from decreased responsiveness (normal dose-response but
decreased maximal effect) and intermediate or combined states. In this definition
assessment of dose-response characteristics is crucial. This is probably the best
available definition of insulin resistance although in practice the distinctions
recommended are infrequently observed.
The range of insulin sensitivities (for glucose metabolism) across even a group of
normal glucose tolerant individuals is considerable (Hollenbeck et al, 1987) and it is
probably simplest and most useful to assess insulin resistance or sensitivity as a
concept relative either to a suitable control or between intervention categories rather
than against a more elusive definition ofnormality.
The ability to measure plasma insulin concentrations directly has made it apparent
that insulin resistance is not limited to glucose-intolerant individuals. Indeed, the
degree of compensatory hyperinsulinaemia is critical in determining clinical
consequences such that some individuals may maintain norrno- or near-
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normoglycaemia (and not develop diabetes) while others may be severely
hyperglycaemic despite large doses of exogenous insulin (Moller and Flier, 1991).
States of severe insulin resistance
Syndromes of severe insulin resistance represent an extreme end of the clinical
spectrum. These rare syndromes are usually recognised initially by their massive
insulin requirements or by their associated clinical features. They will be considered
here only briefly; their major importance in this context is to highlight mechanisms of
impairment of insulin action. These conditions are summarised in table 1.2.
This subject has been reviewed in detail by Goldstein (1994) who proposed that in
diabetic patients daily insulin requirements exceeding 1.5-2U/kg would warrant
clinical assessment ofpossible extreme insulin resistance.
Three major categories of extreme insulin resistant conditions have so far been
described: those with a defined genetic insulin receptor defect (Type A and related
conditions eg. Rabson-Mendenhall syndrome, leprechaunism), those associated with
insulin receptor antibodies (Type B and related conditions, usually associated with
systemic autoimmune disease), and those of unknown aetiology (pseudoacromegaly
and lipodystrophy types, both congenital and acquired). Numerous mutations of the
insulin receptor have been identified (Taylor et al, 1990; Krook and O'Rahilly, 1996)
and are associated with variable degrees of insulin resistance; with continuing
developments in molecular biology it is likely that further reclassification of these
disorders will result from elucidation ofpost-receptor events and defects therein.
Many of these syndromes are characterised by extreme hyperinsulinaemia to the
extent that some of the associated features may reflect insulin action at IGF-1 or
hybrid receptors (King et al, 1980; Taylor, 1985; Geffiier and Golde, 1988).
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Table 1.2. Syndromes of severe insulin resistance
(a) with defined insulin receptor defect: Type A syndrome (some phenotypes only)
Rabson-Mendenhall syndrome
leprechaunism
NIDDM (occasional case reports)











Pathological conditions associated with insulin resistance
A number of pathological conditions are recognised in which insulin resistance may
develop. Often this will go unnoticed clinically as compensatory hyperinsulinaemia
supervenes but in some situations insulin resistance may exacerbate the clinical
disorder or defective glucose tolerance may result when hyperinsulinaemia fails to
compensate adequately. An extensive list of conditions associated with insulin
resistance is shown in table 1.3, and some ofthese are reviewed further below.
Endocrine cotiditions
In view of the antagonistic relationship between insulin and several other hormones
it is to be expected that many of these will reduce sensitivity to insulin under
conditions of deranged homeostasis and this is indeed the case.
Glucagon, as a counter-regulatory hormone protecting against hypoglycaemia,
antagonises the effects of insulin on hepatic glucose metabolism, although its
stimulatory effect on insulin secretion and other feedback adjustments mean that this
effect is shortlived (Ferrannini et al, 1982). Chronic hyperglucagonaernia also appears
to induce insulin resistance and may reduce peripheral insulin-mediated glucose
uptake (Kotzmann et al, 1995).
Noradrenaline impedes both insulin-mediated glucose uptake (Lembo et al, 1994)
and suppression of lipolysis (Marangou et al, 1988). Similar effects of adrenaline have
been shown both in nondiabetic (Capaldo et al, 1992) and in insulin-dependent
diabetic subjects (Walters et al, 1992), and have been reported hi
phaeochromocytoma.
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Physiological concentrations of growth hormone can be shown to enhance lipolysis
and ketogenesis, thus antagonising the effects of insulin (Gerich et al, 1976) and to
shift to the right the dose-response curves for suppression of hepatic glucose output
and stimulation of glucose uptake (Rizza et al, 1982a). Studies of forearm muscle
glucose metabolism in acromegaly confirm this impairment of insulin action prior to
any deterioration in glucose tolerance (Foss et al, 1991).
Similar findings have been reported from related studies on the effects of adrenal
glucocorticoids (Rizza et al, 1982b) and pharmacological doses of steroids have been
found to impair insulin sensitivity when measured by insulin tolerance test (Yasuda et
al, 1982).
The effects of thyroid disease on insulin sensitivity are less clear. While it is widely
accepted that glucose tolerance tends to deteriorate in hyperthyroidism, many of the
changes in carbohydrate metabolism may be linked to changes in insulin secretion and
effects on insulin sensitivity may differ between substrates and also between tissues.
Pharmacologically induced tri-iodothyronine excess has been found to promote both
hepatic glucose output and forearm muscle glucose uptake in both nondiabetic
(Sandler et al, 1983) and type II diabetic subjects (Bratusch-Marrain et al, 1985). The
effects on forearm muscle have been confirmed in spontaneously hyperthyroid
subjects (Foss et al, 1990). In their study Bratusch-Marrain's group, using clamp
techniques, found evidence of impaired insulin sensitivity as did Shen et al (1988) in a
study of Chinese subjects. However others (Randin et al, 1986) have claimed that
insulin sensitivity is not influenced by hyperthyroidism although insulin clearance is
increased. Harris et al (1993) have reported no differences between euthyroid and
hypothyroid subjects in insulin sensitivity for glucose or lipid metabolism.
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Primary hyperparathyroidism has been reported to show an association with
hyperinsulinaemia and insulin resistance which was reversible with surgical treatment
ofthe primary lesion (Kim et al, 1971; Ginsberg et al, 1975).
Relationships between insulin resistance and hyperandrogenism are complex. The
two frequently coexist, most notably in polycystic ovary syndrome, and are often
found in conjunction with obesity and acanthosis nigricans (Flier et al, 1985) although
obesity is not a prerequisite (Chang et al, 1983). There has been controversy as to
which is the primary defect (Stuart et al, 1986; Barbieri et al, 1988) but support for
the contention that insulin resistance contributes more to hyperandrogenism than vice
versa has come from the finding that suppression of hyperandrogenism does not
restore insulin sensitivity (Dxmaif et al, 1990) while suppression of hyperinsulinaemia
may improve hyperandrogenism (Nestler et al, 1989).
Other conditions
Both chronic fiver disease (Cavallo-Perin et al, 1985) and chronic renal disease
(DeFronzo et al, 1978) are recognised as causing insulin resistance. DeFronzo et al
(1978) found the defect in uraernic subjects to be greatly improved following dialysis.
A number of degenerative neuromuscular disorders are associated with insulin
resistance (Krentz et al, 1991) and the resulting defects in muscle metabolism may
contribute adversely to the course ofthe underlying clinical condition.
Several drugs, including corticosteroids (Yasuda et al, 1982), oral contraceptives
(Singh and Nattrass, 1989), |3-adrenergic antagonists (Totterman et al, 1984) and the
lipid-lowering agent nicotinic acid (Kahn et al, 1989) have also been reported to
induce insulin resistance in man.
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Physiological influences on insulin sensitivity
It can be shown that insulin sensitivity may vary by a factor of 2.5 even in healthy
glucose tolerant subjects (Hollenbeck et al, 1987) and a number of factors have been
examined as contributors to this variability.
Higher fasting and stimulated plasma insulin levels have been found in women than
in men during an oral glucose tolerance test (Boyns et al, 1969; Welborn et al, 1969)
and using a low dose insulin infusion Hale et al (1985) reported lower insulin
sensitivity in healthy women than in men. However Yki-Jarvinen (1984) found no
differences in either fasting plasma insulin concentrations or in euglycaemic clamp-
derived measures of insulin resistance, and further suggested that weight for weight
muscle metabolism may be more insulin-sensitive in women than in men.
More controversy surrounds the effects of age. During puberty Amiel et al (1986)
reported a fall in insulin-stimulated glucose uptake both in type I diabetic subjects and
in a control group of nondiabetic members of their families, when compared with
prepubertal subjects. Later in life glucose tolerance is generally acknowledged to
decline but the role of insulin resistance is less clear. Rowe et al (1983) described a
shift to the right in the insulin dose-response curve in older subjects, after controlling
for lean body mass; these findings were supported by Fink et al (1983) whose older
subjects had lower lean body mass than younger comparisons. Although there remains
support for an effect of ageing per se in increasing insulin resistance more recent
studies have increasingly emphasised the importance of changes in body fat
distribution and in particular increasing abdominal adiposity with age (Coon et al,
1992; Kohrt et al, 1993; Boden et al, 1993).
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Effects of exercise on insulin resistance show consistent benefits. Highly trained
athletes have lower basal and stimulated plasma insulin concentrations than controls
for similar blood glucose levels achieved during an IVGTT, implying enhanced insulin
sensitivity (Lohmann et al, 1978). Although this advantage is lost after as little as 14
days abstinence (King et al, 1988), improvements in insulin sensitivity have been
shown even after a single episode of exercise in lean and obese diabetic and
nondiabetic subjects (Devlin and Horton, 1985; Devlin et al, 1987).
The effect of race on insulin resistance is complex and to some extent confounded
by other influences such as obesity, but patterns emerge from studies of declining
glucose tolerance from normal to diabetic in defined populations. Among Pima
Indians the degree of insulin resistance correlates only to a limited extent with glucose
tolerance or obesity (Bogardus, 1993). In a black American population Baneiji and
Lebovitz (1989) have identified two distinct subgroups: one with insulin-resistant type
13 diabetes and one with an insulin-sensitive and relatively insulin-deficient state. How
representative this study population is remains questionable, but using subjects
carefully matched for degree and distribution of obesity Dowling and colleagues
(Dowling and Pi-Sunyer, 1993; Dowling et al, 1995) were able to report greater
insulin sensitivity in black than in white women. McKeigue et al (1988 and 1991) have
described higher stimulated plasma insulin levels (using this as a surrogate for insulin
resistance) in South Asians living in Britain than in white controls, allowing for body
fat distribution.
Along with race genetic factors are clearly of note although no gene for insulin
resistance has yet been identified. Evidence of insulin resistance, using various
measures, has been described among non-diabetic first degree relatives of NIDDM
subjects in comparison with controls (Haflher et al, 1988; Gelding et al, 1995;
Migdalis et al, 1996; Vaag et al, 1996) although here again obesity and body fat
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distribution may be important confounders (Osei et al, 1991). Among Pima Indians
insulin resistance is clearly familial, and predates the onset of NIDDM (Bogardus,
1993).
To some extent it might be expected that as insulin sensitivity declines so will
glucose tolerance but many instances can be found of comparable degrees of insulin
resistance in glucose tolerant and diabetic subjects (Hollenbeck and Reaven, 1987).
The converse, that declining glucose tolerance may exacerbate insulin resistance, is
lent some support by demonstrations that, in comparison with healthy controls,
subjects with impaired glucose tolerance (Krentz et al, 1991) and type II diabetes
(Swislocki et al, 1987) have defective insulin action on intermediary metabolism. In
type I diabetes these defects are more apparent with greater duration of disease
(Singh et al, 1987).
Obesity, body fat distribution and insulin resistance
Obesity per se, whether measured by reference to actuarial ideal body weight or by
body mass (Quetelet) index (Keys et al, 1972), has a well recognised association with
insulin resistance and many studies have examined this relationship with respect to
glucose metabolism (Kolterman et al, 1980; Prager et al, 1986; Laakso et al, 1990),
lipid metabolism (Bakir and Jarrett,1981; Meylan et al, 1987; Hale et al, 1988) and
with regard to broader aspects of intermediary metabolism (Robertson et al, 1991 and
1992). Kolterman et al (1980) reported a predominant receptor defect in both liver
and peripheral tissues (insulin dose-response curve shifted to the right) but found
evidence of a mixed receptor and postreceptor defect at the periphery with increasing
obesity. However this study and that of Laakso et al (1990) in particular can be
criticised for failing to exclude subjects with abnormal glucose tolerance in the obese
group. This may account for the contrary findings reported by others (Hollenbeck et
51
al, 1984; Firth et al, 1987; Ludvik et al, 1995) with the conclusion that any effect of
obesity is negligible in comparison with that of diabetes. Bogardus et al (1985), in a
study of Caucasian and Pima Indian men, reported a non-linear association between
obesity (measured by percent body fat) and insulin resistance but more recent data
(Campbell and Gerich, 1990) have suggested that a threshold (BMI 27kg/m^ or
>120% of IBW) exists above which a deterioration in insulin sensitivity may be
detected.
Studies from this department (Hale et al, 1988; Robertson et al, 1991 and 1992),
with careful regard to the confounding effects of abnormal glucose tolerance, have
consistently been able to show an important role for obesity. Hale et al (1988) showed
improvements in insulin sensitivity following significant weight reduction, exposing
different rates of change in different metabolic processes.
While the impact of android (male pattern or upper body) versus gynoid (female
pattern or lower body) fat distribution on health has been recognised for many years
(Vague, 1956), only in recent times has its relation to insulin resistance come under
scrutiny, partly in an attempt to explain differences between individuals with
comparable overall obesity.
hi obese subjects an upper body fat distribution (usually measured by waist-hip ratio
or skinfold ratios) has been shown to be associated with reduced glucose tolerance,
byperinsulinaemia and hypertriglyceridaemia (Kissebah et al, 1982; Krotkiewski et al,
1983) and subsequently with increased insulin resistance in premenopausal women
(Evans et al, 1984; Peiris et al, 1988), postmenopausal women (Landin et al, 1989)
and in men (Haflner et al, 1994). The work of Landin et al (1989, 1990) and Peiris et
al (1988) has suggested that in women at least overall leanness may protect from the
adverse effects of an upper body fat distribution but this may not be true in men. The
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effect of body fat pattern in combination with defective glucose tolerance is as yet
unknown. More recent attention has focused on the role of visceral adipose tissue in
modulating insulin sensitivity, and in this regard the validity of the indices of obesity
and body fat distribution in conventional clinical use has been questioned as these
measure predominantly superficial fat. As yet though, visceral fat mass can only be
accurately estimated using magnetic resonance imaging whose availability is limited
and costly.
Hypertension and cardiovascular disease
The preceding section has attempted to review aspects of insulin resistance in terms
of factors which may influence insulin resistance in both pathological and
physiological situations. Great efforts have been addressed to the question ofwhether
and how insulin resistance may affect health, especially cardiovascular disease. Much
of the literature in this area is hampered by blurring of the distinctions between
glucose intolerance, hyperinsulinaemia and insulin resistance, which although clearly
related are not synonymous.
Hugh-Jones (1955) observed high rates ofhypertension in Jamaican diabetic patients
and this relationship has been confirmed in other populations. Modan et al (1985)
further demonstrated a link with hyperinsulinaemia. Lind et al (1993) showed that
insulin resistance correlated better than hyperinsulinaemia with hypertension and other
metabolic abnormalities. Evidence has been proposed for a genetic or at least familial
component with the implication that insulin resistance precedes hypertension (Ferrari
et al, 1991). Although hyperinsulinaemia is not a prerequisite for the development of
hypertension (Zavaroni et al, 1992) overall insulin sensitivity within a population does
appear to decline in association with raised blood pressure (Pollare et al, 1990).
However the nature of the relationship has been complicated by observations firstly,
53
that hyperinsulinaemia may only be a feature of hypertension in diabetic (NIDDM)
subjects (Mbanya et al, 1988), although this finding has not been supported
elsewhere, and secondly that in insulinoma, despite hyperinsulinaemia and insulin
resistance, hypertension is not a feature (Pontiroli et al, 1992; Vettor et al, 1994).
Furthermore, in a large study of Pima Indian subjects Saad et al (1990) found
associations of hypertension with glucose tolerance and obesity but not with fasting
insulin concentration; in a further study the same group (Saad et al, 1991)
demonstrated higher plasma insulin levels and reduced glucose disposal with
increasing blood pressure in white subjects but no association in black or Pima Indian
subjects. A recent epidemiological study (Muller et al, 1993) reported no association
between hypertension and hyperinsulinaemia after adjustment for age, body fat and fat
distribution.
Dyslipidaemia
The commonest lipid abnormalities in type II diabetes are raised serum triglyceride
concentration and reduced HDL-cholesterol level (Gibbons, 1985). The association of
these abnormalities with hyperinsulinaemia has been noted in both diabetic and
nondiabetic subjects (Laakso et al, 1987). Treatment of type II diabetes with insulin
improves hpid profiles, a finding somewhat at odds with the association of
endogenous hyperinsulinaemia with lipid disorders (Taskinen et al, 1987; Lindstrom et
al, 1990) unless this is explained by the improvement in insulin sensitivity observed
with insulin treatment (Scarlett et al, 1982). An association between
hypertriglyceridaemia and insulin resistance has been recognised for many years
(Olefsky et al, 1974; Bernstein et al, 1978; Steiner et al, 1980) and there is evidence
that the metabolic defect is primarily peripheral rather than hepatic in both diabetic
(Widen et al, 1992) and nondiabetic subjects (Bernstein et al, 1978; McKane et al,
1990). Hypertriglyceridaemia appears to be closely linked to defective antilipolytic
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action of insulin and a causal relationship has been proposed although which is the
primary factor remains unclear (Yki-Jarvinen and Taskinen, 1988). As with
hypertension, hypertriglyceridaemia is said not to be a feature of the insulin resistance
associated with insulinoma (Vettor et al, 1994).
If hypertriglyceridaemia causes or exacerbates insulin resistance then studies
addressing the effects of its treatment assume great importance. The fibrate group of
lipid-lowering drugs, comprising clofibrate, bezafibrate and gemfibrozil among others,
has been studied most extensively because of the prominent triglyceride-lowering
component of these agents' action. When used to lower triglyceride levels in type II
diabetic subjects no significant effect on glucose tolerance has been found with these
drugs (Marks and Howard, 1982; Garg and Grundy, 1989; Vinik et al, 1993). In a
predominantly nondiabetic, although rather poorly defined, group a fall in plasma
insulin response to oral glucose challenge was found only in those whose plasma
triglycerides fell by more than 1.7mmol/l with gemfibrozil (Steiner, 1991). However
neither gemfibrozil in diabetic subjects (Vuorinen-Markkola et al, 1993) nor
bezafibrate in diabetic and nondiabetic subjects (Riccardi et al, 1989; Karhapaa et al,
1992) has been shown to influence insulin sensitivity despite producing significant
reductions in serum triglyceride concentrations. Shen et al (1991) found no overall
effect of gemfibrozil on glycaemic control or insulin sensitivity in NEDDM but
reported significant reduction in hepatic glucose output in the subgroup with fasting
blood glucose above 9mmol/l although not in better-controlled subjects. This study
group consisted ofChinese men on sulphonylurea treatment and these findings may be
difficult to extrapolate. Interestingly, benfluorex, an unrelated agent with lipid-
lowering properties derived from the amphetamine family of drugs, has been reported
to improve insulin sensitivity in comparison with placebo (Bianchi et al, 1993), but as
the achieved reduction in triglyceride levels was not significantly different from that of
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placebo, its mode of action on insulin sensitivity may not be related to its lipid-
lowering effect.
Reaven and his coworkers (Olefsky et al, 1974; Reaven, 1988) have maintained that
hypertriglyceridaemia is secondary to insulin resistance, resulting from increased
hepatic VLDL-triglyceride synthesis in the presence of hyperinsulinaemia; the lack of
evidence favouring a primary role for hypertriglyceridaemia may give credence to this
view.
Coronary heart disease
Links between defective glucose tolerance and coronary heart disease have been
well-defined in impaired glucose tolerance (the Whitehall Study - Fuller et al, 1980)
and in diabetes (the Framingham Study - Kannel and McGee, 1979). The Whitehall
Study reported a doubling in 7/4 year coronary mortality in IGT compared with
euglycaemic subjects among middle-aged British male civil servants; the Framingham
Study found an incidence of coronary heart disease doubled in men and trebled in
women with diabetes compared with nondiabetics. Data from the Paris Prospective
Study (Fontbonne et al, 1988) suggested that fasting plasma insulin concentration was
a better indicator of coronary risk than was glucose intolerance, at least in obese
subjects (BMI>26). A report on the men screened for the MRFIT Study concluded
that diabetes conferred an additional risk to the effects of smoking, blood pressure
and serum cholesterol (Stamler et al, 1984). Despite this, insulin resistance per se has
not so far been shown directly to correlate with incidence of coronary heart disease,
although Martin and Hopper (1987) have made a limited attempt to address this issue
in type I diabetes.
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Various lipid abnormalities have been well-defined as coronary risk factors although
controversy persists as to which hpid or lipoprotein components operate as
independent risk factors in different populations. Pocock et al (1989), in a study of
middle-aged British men, found total cholesterol and low HDL-cholesterol levels to
be independent predictors of coronary heart disease but found triglyceride level not to
be an independent risk factor after taking HDL-cholesterol into account. While the
independent and inverse association of HDL-cholesterol with CHD has been
supported by the PROCAM Study (Assmann and Schulte, 1992) and by follow-up
work from the Lipid Research Clinics Prevalence Study (Jacobs et al, 1990), the
effect of triglycerides has remained much more contentious with findings from the
Framingham Study indicating no independent role (Kannel, 1985) but an important
contributory role in women, and also in men with high (>4.5) total/HDL- cholesterol
ratios (Castelli, 1986). The Lipid Research Clinics Follow-up Study found no
independent role for triglyceride levels when HDL-cholesterol was taken hito account
(Criqui et al, 1993) and the PROCAM Study found an association only when
LDL/HDL-cholesterol ratio exceeded 5.0 (Assmann and Schulte, 1992).
However a British study (Bainton et al, 1992) regarded triglyceride concentration as
a better predictor of CHD than total cholesterol was, and in a subgroup with
abnormal glucose tolerance the Paris Prospective Study found a strong association for
triglyceride in both univariate and multivariate analyses (Fontbonne et al, 1989).
Bengtsson et al (1993) have reported that triglyceride concentration is, and total
cholesterol level is not, an independent risk factor for coronary heart disease in
women.
In view of the consistently strong inverse relationship found between FIDL-
cholesterol and triglyceride concentrations (Davis et al, 1980) it may be disingenuous
to seek independent roles for these risk factors. In this respect a retrospective analysis
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of the Helsinki Heart Study data has concluded that a very good index of coronary
risk can be obtained by combined assessment - the greatest risk being found hi
subjects with LDL/HDL-cholesterol ratio >5 and triglyceride level >2.3mmol/l
(Manninen et al, 1992).
In the context of diabetes, Rosengren et al (1989), using a rather weak definition of
diabetes (self-reported by subjects), found serum cholesterol and smoking habit to be
independent risk factors for myocardial infarction, although in contrast Uusitupa et al
(1990) found no association between plasma insulin or any other expected risk factor
with myocardial infarction.
Clustering ofmetabobc coronary risk factors
The coexistence in individual subjects of some or all of the abnormalities of blood
pressure,obesity, and lipid and carbohydrate metabobsm indicated above has led to the
definition of a number of closely overlapping cardiovascular risk syndromes differing
mainly in then emphasis on obesity (Kaplan, 1989), hyperinsulinaemia (Modan et al,
1985; Ferrannini et al, 1991) or insulin resistance (Reaven, 1988; DeFronzo and
Ferrannini, 1991) as the favoured unifying or primary factor. Glucose intolerance,
hypertension, hypertriglyceridaemia and hyperinsulinaernia are usually included in
these definitions; insulin resistance may be excluded only by not being measured, with
hyperinsulinaemia taken as a surrogate. By contrast, however, the role of obesity has
been strongly contested (Reaven, 1994).
Nonetheless, perhaps the most coherent and widely acknowledged attempt to draw
together a metabolic syndrome of cardiovascular risk has been that of Reaven (1988)
who proposed a 'Syndrome X' (also referred to as the (pluri)metabohc syndrome,
insulin resistance syndrome or Reaven's syndrome) comprising resistance to insulin-
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stimulated glucose uptake as its core feature with consequent hyperinsulinaemia,
glucose intolerance, hypertension, increased VLDL-triglyceride concentration and
reduced HDL-cholesterol level. Although clear cutoff points for definition of these
variables have been elusive, widespread support has been offered for the existence of
such a syndrome (Zavaroni et al, 1989; Haffner et al, 1992). Various new features
have been proposed for addition to the definition of the syndrome; these have most
plausibly included small dense LDL particles, raised PAI-1 activity, impaired urate
metabolism and truncal or upper body obesity. A number of issues remain unresolved
regarding the clinical relevance and validity of such a syndrome, including its
applicability to different populations. It has not yet been tested in a prospective study
predicting coronary risk so that questions such as how many features must be present
to define an individual as having the syndrome, whether risk accumulates with an
increasing number of features, and whether the individual factors described can be
considered as independent enough of each other to warrant separate inclusion, remain
as yet without clear answers. The absence of a direct link between insulin resistance
and coronary artery disease remains a problem. Furthermore, it is not clear whether
insulin resistance itself is a risk factor in all or only in some populations; most notably
the frequently cited highly insulin resistant Pima Indians have much lower rates of
coronary artery disease than do white Americans (Sievers, 1967; Ingelfinger et al,
1976). The main disadvantage of using such a syndrome to assess coronary risk may
be to detract attention from smoking and cholesterol as important modifiable risk
factors for coronary heart disease.
Other hypotheses have also been proposed. In 1962 Neel (Neel, 1962) proposed the
thrifty genotype hypothesis - that an increased metabolic efficiency advantageous to
our hunter-gatherer ancestors during periods of famine might now predispose to
NEDDM in a modem world with more plentiful and reliable sources of food. With
increasing interest in the role of hyperinsulinaemia and insulin resistance the concept
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has been revived (Zimmet, 1993; Swinburn, 1996) and remodelled, notably with the
suggestion that the phenotypic expression of the thrifty genotype may come in the
form of insulin resistance (in muscle) leading to obesity and NIDDM (Wendorf and
Goldfine, 1991). Support for this view has waxed and waned, and there has been a
lack of substantial supporting evidence; it has been widely recognised that European
subjects seem to have a low prevalence of the genotype, whether through selection or
a constitutional low risk, and may therefore be an inappropriate group to study in this
context.
From almost the opposite standpoint, using epidemiological data from Britain, has
come the 'thrifty phenotype' hypothesis, arguing that fetal undernutrition at crucial
stages of in utero development may have a major influence on susceptibility to disease
in later life, notably including coronary heart disease, hypertension, NIDDM and
dyslipidaemia (Barker, 1995). Barker and his colleagues have published data showing
associations of low birthweight with increased frequency of certain features of
Reaven's syndrome X (Barker et al, 1993) in adult life and also of small babies
(specifically thin babies) with subsequent insulin resistance (Phillips et al, 1994b).
From these data increased fatness in utero and in later life appear to have contrasting
effects on the development of insulin resistance. This has led these authors to suggest
that insulin resistance may be a consequence of a failure of prenatal muscle
development.
More recently has come the suggestion that the clustering ofmetabolic abnormalities
observed arises not because of the effect of one factor on the others but from sharing
common genetic and environmental influences. This has become known as the
'common soil' hypothesis (Stern, 1995) and takes account of the findings of Barker
and his colleagues indicated above, as well as epidemiological data supporting the
existence of a metabolic or insulin resistance 'syndrome' (Zavaroni et al, 1989; Hafiner
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et al, 1992). The common soil hypothesis also offers a means of resolving the
controversy over the possible atherogenic effect of exogenous insulin in NEDDM
(Stout, 1979 and 1987; Jarrett, 1988 and 1992) and may help to explain the absence
alluded to above of any measured direct association between insulin resistance and
coronary heart disease. Indeed, part of the intrinsic appeal of this model hes in its
avoidance of a commitment to support any single factor as pre-eminent or causative.
Summary and Objectives
A clear excess morbidity and mortality from coronary artery disease is well defined
among diabetic subjects. To what extent insulin resistance contributes to this excess is
less clearly defined. Further, it is not clear whether other known coronary risk factors
make a major contribution to the excess risk among diabetic subjects, or whether the
diabetic state itself is the most important risk factor. There is no a priori reason to
suppose that contributory factors to coronary risk in diabetic subjects differ from
those in non-diabetic individuals, or are intrinsically less modifiable.
The work described herein attempts to address a number of these issues, and
developed largely by a process of evolution. The starting point for the work in this
thesis came with a study designed to examine the relationship between
hypertriglyceridaemia and insulin resistance (chapter 5). If these two disorders are
closely linked, then would reducing circulating triglyceride concentrations improve
insulin resistance in subjects with NIDDM? In addition, might improvements in these
components of the metabolic syndrome be associated with any changes in other
components of the syndrome?
From this starting point came the ideas for the studies described in chapters 3 and 6.
While epidemiological data exist regarding the metabohc syndrome in the general
population, ther are no reports in diabetic subjects. Can the metabohc syndrome be
said to exist in a diabetic population? Is it truly a syndrome, and if so which features
61
predominate or are necessary to diagnose it in an individual? The exclusion of obesity
from Reaven's description of the metabolic syndrome seems surprising, and it features
in the clusters described by most other authors. The relationship of obesity with other
features of the metabolic syndrome is addressed in chapter 3; in addition I attempt to
examine more closely the relationships between obesity and insulin resistance in
diabetic subjects in chapter 6.
The study of a new insulin secretagogue developed separately, and is linked to the
other studies mainly by the exploration of changes in intermediary metabolite
concentrations during the intravenous glucose tolerance test, and by a brief
assessment of insulin resistance measuring glucose disappearance rates (chapter 4).
Finally, I have made use of the data derived from the small cohort of diabetic
subjects studied in chapter 6 to compare different methods of assessing insulin
resistance, and in particular to try and vahdate the low-dose incremental insulin
infusion technique against alternative methods in this population.
Each chapter ends with a brief summary; I have attempted to draw together the







In this chapter are outlined the procedures followed in the studies and experiments
described in the succeeding chapters. Where specific deviations from the procedures
described below have taken place, these are explained in the relevant chapters.
Subjects
All subjects were recruited from the Diabetic Clinic at the General Hospital and
Selly Oak Hospital, Birmingham with the exception of a small number of subjects with
newly-diagnosed diabetes who were recruited, with the permission of their general
practitioners, into the study examining effects ofA4166 (chapter 4). All subjects were
diagnosed as having diabetes mellitus according to conventional clinical practice
whereby the diagnostic criteria of the World Health Organisation (1980) for definition
of diabetes were followed, i.e fasting venous plasma glucose concentration >7.8
mmol/L and/or random (or 2 hours after 75g oral glucose load) venous plasma
glucose concentration >11.1 mmol/L.
Ethical Considerations
Protocols for all studies were submitted for, and received, approval by the Research
Ethics Committee of South Birmingham Health Authority prior to commencement.
All subjects received written and verbal explanations of the procedures involved and
gave signed informed consent to take part.
The recommendations of the Declaration of Helsinki by the World Medical
Assembly (reprinted in Randle et al, 1978) were complied with. In addition,
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particularly in those studies which involved the participation of a pharmaceutical
company, guidelines on good clinical practice (Hutchinson, 1993) were also followed.
Protocols
For all procedures subjects attended following an overnight fast (minimum 8-10
hours) so that all studies were conducted under postabsorptive conditions. Subjects
were asked not to consume alcohol on the day prior to attending and were requested
not to take any medications on the morning of the study.
Intravenous glucose tolerance test (IVGTT)
After any preliminary assessments (eg. weight, resting blood pressure) an 18G
cannula was inserted into an antecubital vein for sampling. A 20G cannula was
inserted into a contralateral forearm vein for infusion ofglucose. After 30 minutes rest
two basal blood samples were withdrawn via the antecubital cannula. Following this a
single tablet of either active drug (60mg A4166) or placebo was given at time -20
minutes (relative to start of glucose infusion). Further blood samples were taken at
times -10 and 0 minutes. At time 0 an infusion was started of 50% glucose (Baxter
Healthcare, Thetford, UK) given via an IMED 960 volumetric infusion pump (EVEED
Corp., San Diego, USA) to provide a bolus of 0.3g/kg glucose over 3 minutes. Blood
samples were taken at 3, 5 7, 10, 15, 20, 30, 40, 50 and 60 minutes. Infusion cannulae
were flushed with 0.9% saline to prevent phlebitis. Subjects were allowed to drink
water during the procedure and were offered a meal at the end. After an observation
period of one hour subjects were permitted to return home.
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Low-dose incremental insulin infusion
Following any preliminary measurements an 18G canula was inserted into an
antecubital vein for sampling. A 20G cannula was inserted into a contralateral forearm
vein for infusing insulin. After 30 minutes rest the first of four sequential hourly
infusions was started. These contained, in order, 0.9% saline (no insulin), insulin
0.005 IU/kg, insulin 0.01 IU/kg and insulin 0.05 IU/kg. Infusions were prepared using
Human Actrapid Insulin U100 (Novo Nordisk Pharmaceuticals Ltd., Crawley, UK)
diluted to the required concentration in 0.9% saline. To each infiisate 2.5ml Human
Albumin Solution 20% (Immuno Ltd., Sevenoaks, UK) was added to prevent
adsorption of insulin to syringes or plastic tubing. Infusions were administered
continuously at a controlled rate via a Braun Perfusor VI infusion pump (B. Braun
Melsungen AG, Melsungen, Germany).
Blood samples were withdrawn via the antecubital cannula 30, 40, 50 and 60
minutes after the start of each infusion. Blood glucose levels were monitored
throughout using capillary testing strips and a glucose meter, and the test was
terminated either at the end of the sampling schedule (i.e. the end of the fourth
infusion period) or when symptoms or biochemical signs of hypoglycaemia (defined as
blood glucose <3.3 mmol/L) appeared, whichever was the earhest. Subjects were
permitted to drink water throughout the procedure and were offered a meal at its end.
After an observation period of one hour subjects were allowed home.
For studies in which comparison was made between low-dose intravenous insulin
infusion and euglycaemic hyperinsulinaemic clamp techniques the above procedure
was modified as follows. Instead of the sampling cannula being placed in an
antecubital vein the cannula was sited in a vein on the dorsum of the hand to allow
samples to be taken from arterialised blood. The cannula, once inserted, was
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connected to a 7cm extension with 3-way tap so that blood could be sampled without
removing the hand from a temperature-controlled hot box (on loan from Amylin
Europe Ltd.,Oxford, UK) and to enable continuous slow infusion of 0.9% saline
(Baxter Healthcare Ltd., Thetford, UK) to maintain cannula patency.
Infusions were carried out as above except that the initial infusion of saline alone ran
for only 30 minutes. Blood was sampled at 20 and 30 minutes after commencement of
this infusion. During infusion of insulin at concentrations of 0.005 and 0.01
units/kg/hr samples were taken at 30, 45 and 60 minutes; during the final infusion of
0.05 units/kg/hr samples were taken at 30, 40, 50 and 60 minutes. Blood glucose
concentrations were monitored using a YSI Stat Plus glucose analyser (Yellow
Springs Instrument Co. Inc., Yellow Springs, USA) and the test terminated according
to the criteria outlined above.
Euglycaemic hyperinsulinaemic clamp
After preliminary measurements a 20G cannula was inserted into a forearm vein for
infusing insulin and glucose. A flexible 20G cannula was inserted retrogradely into a
vein on the dorsum of the contralateral hand for arterialised blood sampling. The
retrograde cannula was connected to a 7cm extension with 3-way tap attachment to
allow blood sampling without withdrawal of the hand from a temperature-controlled
hot box (on loan from Amylin Europe Ltd.,Oxford, UK) and to enable continuous
slow infusion of 0.9% saline (Baxter Healthcare Ltd., Thetford, UK) to maintain
cannula patency. Insulin infusion was prepared by diluting 30 Units Human Actrapid
Insulin U100 (Novo Nordisk Pharmaceuticals Ltd., Crawley UK) in 58ml 0.9% saline
with 2ml of the subject's own blood to prevent adsorption of insulin to syringe or
plastic tubing.
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After 30 minutes rest two basal blood samples were withdrawn and the insulin
infusion commenced Insulin infusion rate was determined by reference to standard
protocols and calculated according to body weight. Thus infusion was started at [0.75
x body weight] ml/hr for two minutes, followed by infusion (in ml/hr) at 0.33 x wt,
0.30 x wt, 0.28 x wt, 0.26 x wt, each for two minutes,and then a maintenance rate of
[0.24 x body wt] ml/hr for the duration of the procedure. Infusion rate was controlled
using a Graseby MS2000 syringe pump (Graseby Medical Ltd., Watford, UK).
hi order to maintain euglycaemia at a constant 5mmol/L, blood glucose was
measured every five minutes using a YSI Stat Plus glucose analyser (Yellow Springs
Instrument Co. Inc., Yellow Springs, USA). From the glucose concentrations
obtained the rate of infusion of glucose 20% (Baxter Healthcare Ltd., Thetford, UK)
via an IMED 960 volumetric infusion pump (IMED Corp., San Diego, USA) could be
adjusted appropriately. Further blood samples were taken 30 and 60 minutes after
starting insulin infusion. Total infusion time was approximately 180 minutes to allow a
minimum of 30 minutes stable euglycaemia (60 minutes where possible). Three further
blood samples were taken in the final 30 minutes ofthe procedure.
At the end of the test insulin infusion was stopped but glucose infusion was
continued to provide as much glucose as had been required in the previous hour of the
procedure. When this additional infUsion was complete the procedure was terminated.
Subjects were permitted to drink water throughout the procedure and were offered a
meal at its end. After an observation period of one hour subjects were allowed home.
Sampling
Free-flowing blood samples (i.e. without the use of a tourniquet) were obtained at
all times. For dynamic metabolic studies as described above approx. 8-10ml of blood
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was withdrawn at each testing point. Of this sample 1.5-2.0ml was added to a 10ml
glass tube (L.I.P. Ltd., Shipley, UK) which had been prepared in-house with 5ml
0.77M perchloric acid and pre-weighed using digital scales accurate to O.Olg
(Sartorius GmbH, Gottingen, Germany). After the addition of the blood sample the
tube was again weighed to allow an accurate estimate ofblood volume added so that
after analysis correction could be made for the volume ofperchloric acid in the sample
assayed.
The remainder of the blood obtained was added to a 10ml tube commercially
prepared with lithium heparin (Laboratory Services Ltd., UK) to allow plasma
separation.
Samples were stored immediately at 4°C and separated from cells within one hour
using a refrigerated centrifuge (Denley BR401, Denley Instruments Ltd.,Billingshurst,
UK); samples were spun for 12-15 minutes at 4°C.
After centrifiigation supernatant was immediately drawn off and labelled aliquots
were stored at -20°C for later analysis. Storage of samples for metabolite analysis
broadly followed the recommendations ofLloyd et al (1978) whereby samples may be
stored for several months with low risk of deterioration prior to measurement of
glucose, lactate, alanine or 3-hydroxybutyrate; acetoacetate was always measured
within 3 days of sampling and pyruvate within 28 days.
Arterialised versus venous blood sampling
Advantages and disadvantages of venous and arterial or arterialised blood sampling
continue to be debated. It has generally been felt that arterial blood samples reflect
whole body metabolism whereas venous blood samples are necessarily influenced by
tissues draining into the sampling vein. In view of the natural preference of both
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researchers and volunteers to avoid direct arterial cannulation where possible, the use
of arterialised venous blood sampling (by retrograde cannulation of a hand vein in a
heated box) has become widely accepted and in clamp studies is now almost
universally used. Studies of forearm muscle metabolism with simultaneous sampling
from arterial, venous and arterialised venous sites have confirmed the anticipated
arteriovenous differences and the appropriateness of arterialised venous blood as a
substitute for direct arterial sampling (Jackson et al, 1973; McGuire et al, 1976;
Abumrad et al, 1981). More recently, however, arguments have been proposed in
favour ofthe use ofmixed venous blood for estimating glucose requirements in clamp
studies (Andrews et al, 1984; Wahab et al, 1992) and also for IVGTT with minimal
modelling (Godsland et al, 1993).
In the studies undertaken and described here these issues have not been
systematically addressed and a pragmatic approach has been adopted. For single
postabsorptive samples venous blood has consistently been used. For the IVGTT
studies and insulin infusion studies assessing the effects of Gemfibrozil on insulin
sensitivity, venous blood has been used, making the assumption that intra-individual
variability will be too small to have a material effect on paired tests. No data exist for
the low-dose insulin infusion to indicate the extent of intra-individual variation with
this test, nor to compare venous and arterialised venous blood samples. In the study
employing the euglycaemic clamp method arterialised venous blood samples were
used according to convention; hence in order to make comparison with clamp data




Glucose, lactate, pyruvate, acetoacetate, 3-hydroxybutyrate, glycerol and alanine
were all measured in whole blood extracts deproteinated by the use of 0.77M
perchloric acid. All assays were performed using a Cobas Bio centrifugal analyser
with a fluorescence capability following the methods described by Stappenbeck et al
(1990). The laboratory methods employed all make use of enzymatic reactions of the
analyte which depend on the formation or utilisation of the reduced co-enzymes
NADH or NADPH. Each reagent system is either a single enzyme system requiring
the co-conversion of NAD(P) to NAD(P)H, or the reverse, or a coupled system
which involves the metabolite as the initial substrate in a series of reactions, one of
which involves an NAD(P)H-dependent enzyme.
The rate of formation or utilisation of NADH, or NADPH, can be monitored by
taking advantage of the fact that on spectrophotometry both of these reduced co¬
enzymes have an absorption peak at 340 nanometres; this property is not shared by
the oxidised forms NAD or NADP.
Those metabolites present in relatively high concentration (i.e. glucose and lactate)
can be measured by spectrophotometry; for the others, the concentrations of
NAD(P)H present are not adequate for sensitive detection by this means and
fluorimetry is required, using the same excitation wavelength of 340nm and the
emission wavelength of470nm.
For certain reactions the same enzyme may be used to measure both substrates of a
reversible process if reaction conditions are altered appropriately. This applies to
lactate-pyruvate and 3-hydroxybutyrate-acetoacetate interconversions.
Individual reactions are described below and precision data shown in table 2.1.
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Table 2.1. Analytical precision for metabolite and hormone assays
Analyte Units Mean concentration CV (%)
Glucose mmol/L 1.0 1.2
Lactate pmol/L 1000 2.5
Pyruvate pmol/L 50 3.4
Alanine pmol/L 101 3.1
Acetoacetate pmol/L 53 3.0
3-hydroxybutyrate pmol/L 81 2.1
Glycerol pmol/L 42 1.9
NEFA mmol/L 1.07 1.3
Total Insulin pmol/L 369 6.2
C-peptide pmol/L 511 8.4
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Glucose
(1) glucose hexokinase » glucose-6-phosphate
ATP >ADP
(2) glucose-6-phosphate G6Pdehydrogenase > 6-pkosphogluconate
NADP >NADPH
Lactate
Lactate lactate dehydrogenase > pyruvate
NAD >NADH
Pyruvate
Pyruvate lactate dehydrogenase > lactate
NADH >NAD
Alanine
Alanine alanine dehydrogenase > pyruvate
NAD >NADH
Acetoacetate




3-hydroxybutyrate Mroxybutyrate dehydrogenase > acetoacetate
NAD >NADH
Glycerol
(1) Glycerol—glycerokinase ^ glycerol-3-phosphate
ATP »ADP
(2) Glycerol-3-phosphate—glycerol PDH_^ dihydroxyacetone phosphate
NAD >NADH
(glycerol PDH = glycerol phosphate dehydrogenase)
Non-estexified fatty acids (NEFA)
NEFA concentrations were measured in heparinised plasma using a commercial
enzymatic colorimetric assay (Wako NEFA-C test kit; Wako Chemicals GmbH,
Neuss, Germany). A three-step reaction takes place as follows:
(1) NEFA + CoA acylCoA synthetase > acylCoA
ATP >ADP
(2) Acyl CoA acylCoA oxidase > 2,3 trans-enoyl CoA
O2 >H202
(3) H2O2 + chromogen peroxidase; > coloured adduct + H2O
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The coloured adduct has an absorption peak of 550nm; this is measured by
spectrophotometry.
Hormone Assays
Insulin and C-peptide were measured by commercial radioimmunoassay (Pharmacia
AB, Uppsala, Sweden and Guildhay, UK respectively) using a double antibody
technique. Hormone in plasma samples competes with a fixed quantity of
radiolabeled hormone for binding sites on the antibody. After using an
irnmunoadsorbent to separate free from bound hormone the radioactivity of the
sample can be measured and is then inversely proportional to the original plasma
concentration ofhormone.
Where alternative units ofmeasurement are required for certain calculations (eg. for
HOMA-R values from insulin and glucose concentrations) a standard procedure has
been followed. Insulin concentrations (pmol/L) are converted to mU/L by division by
7.46; C-peptide concentrations (pmol/L) can be converted to ng/L by division by 331.
Proinsulin was measured using a Europium irnmunofluorometric assay developed by
Dr PM Clark in conjunction with Professor CN Hales (Cambridge). This assay
measures specific proinsulin with approximately 95% recovery.
Lipids
Cholesterol and triglyceride concentrations were measured using an Instrumentation
Laboratory ELAB900 Clinical Chemistry Analyser; HDL-cholesterol and Lipoprotein
(a) were measured on a Cobas Bio analyser.
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Both cholesterol and triglyceride assays employ enzyme reactions generating
hydrogen peroxide, which in the presence ofperoxidase reacts with 4-aminoantipyrine
and phenol to produce a quinoneirnine with absorption peak at 5 lOnm.
HDL-cholesterol concentration was measured by a modification of the method for
total cholesterol after precipitation ofLDL-cholesterol from serum samples.
Lipoprotein (a) concentration was measured by an immunoturbidimetric assay.
Antiserum to Lp(a) was added to the serum samples for analysis and Lp(a)
concentration determined by the turbidity of the reaction mixture formed by the
resulting antigen-antibody complexes.
Glycosylated haemoglobin
HbAl was measured by an electroendosmosis method to separate haemoglobin
fractions on agar gel after stabilisation of HbA by haemolysis of the whole blood
sample. The gel can then be scanned densitometrically at 420nm and the HbAl
content expressed as a percentage of total haemoglobin. This analysis was used for all
studies except for the study of body fat distribution and insulin resistance; when this
study was carried out the HbAl assay had been superseded by a new HbAlc assay.
This measures HbAlc by latex-enhanced immunoturbidimetry on a Roche Cobas Mira
analyser. Blood samples were haemolysed and antibodies raised against glycated N-
terminal amino acids on the (3-chain of the haemoglobin molecule. After total
haemoglobin has been measured on the same haemolysed sample, HbAlc is again
expressed as a percentage. (An approximate estimate of HbAlc can be obtained by
subtracting 1.85% from measured HbAl values).
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Other analvtes
Uric acid (urate) concentration was determined by a standard method again using
hydrogen peroxide to generate a coloured product (in this case indimine) with
characteristic absorption at 540nm.
Fructosamine was measured by reaction of serum samples with nitroblue
tetrazolium, under alkaline conditions, to produce formazan at a rate directly related
to the fructosamine concentration.
Statistical Analyses
All statistical analyses were carried out by me either manually or using the analytical
tools available on computer software (Microsoft Excel version 4.0 for Windows). The
additional procedures performed on SPSS for Windows were carried out by me with
the assistance of Vicki Allgar. Methods followed those described by Armitage and
Berry (1994).
For the purposes of analysis missing data in dynamic studies have been treated by
inserting the mean concentration of analyte of the two values immediately adjacent for
that subject (i.e. immediately before and immediately after the missing value). I have
regarded this method as having greater biological plausibility than the usually
recommended procedure of inserting the mean for that time point of all subjects in the
group. Missing values for single fasting samples have not been replaced.
Where correlation coefficients have been calculated these have been applied to
ranked data (except where indicated) in order to avoid the distortions produced by
non-normally distributed variables (notably plasma insulin, serum triglyceride and
ketone concentrations, and HOMA-R values). Spearman's rank correlation coefficient
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has then been used, with significance testing on the t distribution. Where multiple
correlation coefficients were obtained appropriate correction has been made in
assessing statistical significance, using the Bonferroni correction or the equivalent
method of multiplying p values by the number of comparisons made (Bland and
Altman, 1995). For calculating regression lines I have used actual data, log
transformed where appropriate.
Multiple regression analysis was used in the analysis of data in chapter 3. The
calculations were carried out using the computer software package SPSS version 5
for Windows. Up to 20 variables were included in the analyses (of data from 231
subjects) and models were derived which allowed for the inclusion of variables at
significance levels up to p=0.1, while variables with p>0.15 were automatically
excluded.
The Kohnogorov-Smirnov test used in chapter 3 to assess for normality of
distribution of the number of features of Syndrome X was also performed using
SPSS.
Factor analysis, or more correctly principal components analysis, again in chapter 3,
was also performed using SPSS for Windows. The methods used follow closely those
described by Meigs et al. (1997). Here variables of interest are examined to see
whether their intercorrelations form a single group or whether the variance in the data
can be better explained by separate subsets of variables, which may overlap. The
procedure attempts to identify a minimum number of components to explain the
maximum amount of variance in the original data; if only one component is identified
then in this instance the metabolic syndrome may be considered as an essentially
homogeneous entity in the population studied.
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Components were identified and defined by Eigenvalues which relate correlations
between original variables and the components identified, and represent the
proportion of variance attributable to a given component. An Eigenvalue of 1 in this
study reflected a component accounting for approximately 10% of total variance; only
components yielding Eigenvalues of one or more were therefore included. To identify
the most important variables contributing to each component, only those variables
with loadings >0.3 were included in the final model. Loadings are derived
mathematically from correlations between individual components and their constituent
variables.
The model derived from these calculations gives a description of the major features
of interest and their interrelationships, and helps to identify clustering of particular
variables within the original group ofvariables selected for analysis.
More detailed explanation of this technique can be found in Armitage and Berry
(1994) and Meigs et al (1997).
Analysis of data generated from the IVGTT studies was carried out by two way
analysis ofvariance. Individual subjects were treated as replicates. Data were grouped
by treatment (A4166 before diet, A4166 after diet, placebo before diet and placebo
after diet) and by time (timepoints at which blood samples were taken relative to
onset ofglucose infusion). Taking the mean of the two baseline blood samples at each
visit, there were therefore four treatment groups and thirteen timepoints for analysis.
Where overall variance ratios were statistically significant comparison of pairs of
treatments was made using Scheffe's test to assess significance. The use of this test
allows for multiple comparisons and reduces the likelihood of significant differences
arising by chance; significance (p value) is tested on the F distribution.
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Data from low-dose insulin infusions were analysed by calculating regression lines
for each metabolite on insulin concentrations. For the studies of gemfibrozil in
hypertriglyceridaemia (chapter 5) and of body fat (chapter 6), regression lines were
calculated for metabolite concentrations on log [mean insulin] for each group in order
to obtain a straight line relationship. For comparison of the low-dose insulin technique
with the euglycaemic clamp (chapter 7) regression lines were calculated for
individuals on their own plasma insulin concentrations (with log transformation of
insulin values).
The regression lines obtained were then subjected to analysis of covariance in order
to examine the relationships between groups by comparison of the parallel regression
lines produced. Significance testing was carried out on the corrected mean values ofy
obtained and follows the approach described by Armitage and Berry (1994). Although
this has certain disadvantages it offers a convenient way of expressing differences
between the regression slopes, comparing derived values ofy at the same x (in this
instance the overall mean plasma insulin concentration for all groups). Again, where
overall variance ratios were statistically significant, differences between groups were
examined using Scheffe's test.
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Chapter 3




Subjects with non-insulin-dependent diabetes (NIDDM) are recognised to have an
increased risk of cardiovascular disease in comparison with the general population.
Extensive interest has been generated in studying and attempting to limit this excess
risk.
The development of concepts of syndromes ofmetabolic risk (Reaven,1988; Kaplan,
1989; Ferrannini et al, 1991; DeFronzo and Ferrannini, 1991) and the related
'common soil' hypothesis (Stem, 1995) have focused attempts to evaluate and
quantify cardiovascular risk.
With particular reference to Reaven's syndrome X, if such a syndrome truly exists,
then it should be possible to identify individuals with the syndrome, compare their
characteristics with subjects not having the syndrome, and intervene to reduce risk.
Reaven's description of syndrome X contains the following features: glucose
intolerance, hyperinsulinaemia, hypertension, hypertriglyceridaemia and low
circulating HDL-cholesterol concentrations, with insulin resistance present as the
unifying or primary factor. Reaven and other authors have since proposed additional
factors for inclusion in the syndrome, among the most plausible being hyperuricaemia
and upper body obesity. The role of obesity, and which index of obesity is most useful
as an indicator of coronary risk, still seems somewhat controversial.
This study set out to examine the characteristics at diagnosis of diabetes of a group
of adults with particular reference to cardiovascular risk factors, to assess whether
any ofthese factors co-segregated more than would be expected by chance, and to try
to establish whether in this group of subjects a subgroup could be defined as having
'syndrome X'.
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Newly-diagnosed diabetic subjects were chosen because they form part of a high
risk group, because of the ready availability of a suitable cohort of subjects, and
because at the time of diagnosis of diabetes, although many risk factors may be
present, confounding features attributable to diabetes itself may be less well
established than in a group with longer duration ofNEDDM.
The study was carried out as a cross-sectional survey.
Subjects and Methods
Subjects were recruited from the Diabetic Clinic at The General Hospital,
Birmingham between September 1993 and June 1995.
Subjects were eligible for inclusion if they fulfilled the following criteria:
1. diagnosis of diabetes within the preceding three months
2. aged over 18 years
3. not already treated with insulin nor considered (by the clinic physician) to need
insulin treatment at the time ofpresentation to the diabetic clinic
4. no identified secondary cause of diabetes (pancreatitis, endocrine disease, etc.)
5. not known to be pregnant
Subjects with a diagnosis of impaired glucose tolerance were also excluded.
Subjects who later started treatment with insulin were excluded from data analysis if
they were known to have started insulin during the recruiting period or within the six
months thereafter; this was regarded as indicating insulin-dependent diabetes. This
exclusion was not applied to any subjects who were known to have been treated
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temporarily with insulin and then reverted to diet or oral hypoglycaemic therapy (one
subject).
Procedure
All eligible subjects attending the Diabetic clinic for the first time were invited to
attend for assessment. Assessment usually took place within 5 days of clinic
attendance. A printed information sheet was supplied and a verbal explanation given;
all participating subjects gave signed consent on the day of assessment. Subjects
already taking oral hypoglycaemic agents at the time of assessment (43 of those
studied; see table 3.1) were asked to omit these for 72 hours prior to assessment;
where this was not possible all subjects omitted such medication for 24 hours. Any
other medication was continued as normal but omitted on the morning ofthe study.
All subjects attended for assessment after overnight fast. All subjects were asked to
confirm that they had fasted and the assessment was rescheduled if anything other
than water had been consumed.
Details of name, date of birth, sex, hospital number, country of birth and
religious/ethnic group were obtained, along with duration since diagnosis of diabetes
(to nearest whole month) and current treatment, family history of diabetes, other drug
treatment, details of alcohol consumption and cigarette smoking, and personal history
of hypertension, ischaemic heart disease (defined as a diagnosis by a doctor of
myocardial infarct or angina), hyperlipidaemia, gout and peripheral vascular disease.
Height, weight, and waist and hip circumferences were measured. The latter were
measured with the subject standing and outer clothing removed; waist circumference
was taken at the horizontal level of the umbilicus and hip circumference at the level of
the greater trochanters.
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Blood pressure was measured twice, at least 5 minutes apart, after a minimum of 5
minutes rest in a semi-recumbent position. All blood pressure readings were carried
out on the subject's right arm. Where identifiable Korotkov phase IV was used for
diastolic pressure.
After the above procedures had been completed, approx. 50ml of free-flowing
venous blood (i.e. taken without a tourniquet) was withdrawn to be separated, frozen
and later analysed for glucose, insulin, NEFA, 3-hydroxybutyrate, urate, total and
HDL-cholesterol, triglycerides, lipoprotein (a), HbAl and fructosamine, along with
electrolytes, creatinine, calcium, protein and liver enzymes.
Definitions
Racial groups were determined by skin colour and self-reported country of origin.
'Caucasian' therefore included all white subjects reporting a European (including
Eastern Mediterranean) or Australasian background; 'Asian' included all subjects of
Indian, Bangladeshi and Pakistani origin, including those born in East Africa. 'Black'
included individuals from both African and Caribbean backgrounds. Probably because
of the predominant age group studied the 'Asian' group included only four subjects,
and the 'Black' group three, who were born in the United Kingdom. The designation
'Other' covered seven subjects studied (as well as one who did not attend for
assessment, from Yemen). These seven were four Arab subjects, all from Yemen, and
three of mixed race - one Afro-Chinese, one Indo-African, and one mixed-race
Mauritian.
Cutoff points for determining the presence or absence of features of Reaven's
syndrome were taken as follows: hypertension - defined as mean diastolic pressure
>95mmHg and/or on treatment for known hypertension; triglycerides >2.30mmol/L;
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HDL-ckolesterol <0.91mmol/L for men and <1.16mmol/L for women;
hyperinsulinaemia was determined by the highest quartile for the study population, i.e.
fasting plasma insulin concentration > 20.83mU/L (155.4pmol/L). These definitions
are broadly in accord with those applied in other epidemiological studies (Uusitupa et
al, 1985; Ferrannini et al, 1991; Haffiier et al, 1992; Criqui et al, 1993). The definition
for hyperinsulinaemia is necessarily arbitrary, especially in the absence of a control
population, although the insulin concentrations observed in the highest quartile are
broadly comparable with those observed in a mixed diabetic and non-diabetic
population studied by Solymoss et al (1995). Insulin resistance was defined as a
HOMA-R value of > 3.5; this allows for some natural variation within and between
normal subjects, although again this cutoff must be accepted as arbitrary. When
examining features of Syndrome X, all subjects were regarded as glucose intolerant by
definition based on their diagnosis of diabetes; in addition, and for examination of the
cluster analysis data the alternative option of considering only those with fasting
blood glucose >6.7mrnol/L (i.e. reflecting the cutoff for WHO definition of diabetes)
was used, allowing further examination of the distribution of abnormalities present.
For examining features of the components derived from cluster analysis, the following
additional cutoffs were used: high BMI was defined as BMI >30; high waist-hip ratio
was defined as >0.9 for women and >1.0 for men; and high HDL-cholesterol taken as
the highest quartile, i.e. >1.16 for women and >1.05 for men.
Statistical Analyses
For all calculations log transformation was made of insulin and triglyceride
concentrations and HOMA-R and HOMA-S values to approximate normal
distributions.
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Comparison of variables between attenders and non-attenders was made by
Student's t-test.
A correlation matrix was obtained for the variables of interest and individual
correlation coefficients calculated. Significance tests were then calculated on the t
distribution and are expressed as p values after applying appropriate correction for
multiple comparisons. Because of the complexity of assessing hypertension (using
both previous diagnosis and current measurement, and also the confounding effect of
treatment) it was not analysed in this form. Correlation coefficients are given for
relationships between absolute values, log transformed where appropriate. Correlation
coefficients from ranked data yielded very similar results (not shown).
The data were then examined using multiple regression analysis. A stepwise method
was applied to develop a series of models. These were used to determine the major
contributors to the number of features of syndrome X: (a) the full model including all
variables studied; (b) the 'clinical model' excluding HOMA-R from the independent
variables, and (c) an 'additional features' model which excluded those features defining
syndrome X from the analysis. The computer programme was run to permit inclusion
of variables of interest in the model up to a maximum significance level of p = 0.1;
variables were automatically excluded if p exceeded 0.15. Following on from this
factor analysis (principal component analysis) was applied to construct a model of risk
factors to examine whether a single syndrome truly describes any clustering of
cardiovascular risk factors. The details of this procedure are described in Chapter 2,
and follow closely the method described by Meigs et al (1997).
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Table 3.1. General characteristics of study group and comparison with subjects
excluded or not assessed.
Study group Excluded Not assessed
Total 231 22 66
Age mean (range) 56 (20-79) 46 (19-80) 53 (23-85)
Sex male 143 17 43
female 88 5 23
Racial group Caucasian 136 16 37
Asian 65 2 24
Black 23 4 4
other 7 0 1
Duration of diabetes
<1 month 106 13 23
1-2 months 88 6 35
2-3 months 37 3 7
Treatment* diet 188 18 49
sulphonylurea 35 4 14
metformin 4 0 2
both drugs 3 0 1
Other drugs yes 103 9 26
no 128 13 40
Hypertension yes 73 1 13
no 158 21 f52
BMI mean (range) 29.57 25.58 31.53
(18.8-47.4) (17.5-39.2) (21.6-48.9)
Fructosamine mean (range) 363.6 467.3 344.9
(212-688) (278-663) (183-618)
* one participant in the study group was taking an unidentified oral hypoglycaemic
agent
+ not known for one subject
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Table 3.2. Characteristics ofwhole study population (231 subjects).
mean median range interquartile range
Waist-hip ratio 0.99 1 0.77-1.18 0.94-1.03
waist circumference (cm) 98.6 97 68-143 92-105
mean systolic BP (mmHg) 150.3 147 102-217 132-168
mean diastolic BP (mmHg) 92.3 92 56-125 85-100
HbAl (%) 11.57 11.3 5.6-18.4 9.5-13.4
Total cholesterol (rnmol/L) 5.88 5.76 2.80-9.59 4.93-6.60
Triglycerides (rnmol/L)* 1.91 1.80 0.49-21.05 1.27-2.53
HDL-cholesterol (mmol/L) 0.96 0.92 0.19-2.15 0.80-1.10
Urate (mmol/L) 0.30 0.30 0.13-0.58 0.25-0.34
Glucose (mmol/L) 8.8 8.4 3.8-21.0 6.6-10.4
Insulin (pmol/L)* 104.5 97.0 29.1-510.3 69.8-155.4
NEFA (mmol/L) 0.74 0.72 0-1.77 0.55-0.90
HOMA-R* 5.19 5.11 1.01-26.75 3.29-8.45
HOMA-S (%)* 62.8 59.1 9.2-680 33.7-123.7
* geometric mean
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Table 3.3 (a). Mean and range ofvalues for racial groups
Caucasian Asian Black
Total numbers 136 65 23
Age (years) 60.1 46.3 55.1
27-79 24-70 20-77
Treatment (numbers)
diet 112 53 18
sulphonylurea 18 12 3
metformin 4 0 0
both 2 0 lf
On no other drugs 83 49 12
Known hypertension 47 13 11
Coronary heart disease 23 3 1
Measured systolic BP 155.3 137.7 158.7
(mean and range) 108-216 102-213 120-217
Measured diastolic BP 93.1 88.4 98.7
64-125 56-116 82-116
BMI (kg/m2) 30.05 28.31 29.81
18.8-47.4 20.8-45.3 24.1-37.8
Waist (cm) 100.3 96.2 94.3
68-143 77-131 74-119




Total cholesterol (mmol/L) 6.00 5.79 5.42
2.92-9.59 2.8-9.2 3.1-8.3
*Triglycerides (mmol/L) 2.04 1.99 1.15
0.69-8.59 0.75-21.1 0.49-4.50
HDL-cholesterol (rnmol/L) 0.936 0.96 1.13
0.19-2.15 0.34-1.46 0.63-1.84
*Lipoprotein (a) (pmol/L) 161.5 176.6 578.7
47-1136 47-1251 203-1453
HbAl (%) 11.51 12.00 11.06
5.6-18.4 7.7-17.4 6.0-17.4
Fructosamine (pmol/L) 359.4 369.2 381.8
212-603 232-657 217-688
Glucose (mmol/L) 8.83 9.04 8.04
3.8-21.0 4.6-16.0 4.3-15.8
*Insulin (pmol/L) 101.3 120.6 79.2
29.1-510 39.5-464 36.6-289
*HOMA-R 5.05 6.24 3.51
1.01-26.8 1.73-25.8 1.05-8.92
*HOMA-S (%) 60.5 65.9 61.86
9.2-680 11.3-249 10.0-485
*3 -hydroxybutyrate (pmol/L) 137.8 73.9 276
5-3639 8-1421 16-1350
NEFA (mmol/L) 0.752 0.688 0.818
0-1.59 0.14-1.38 0.30-1.77
Urate (mmol/L) 0.311 0.285 0.314
0.13-0.54 0.17-0.58 0.17-0.48
Creatinine (pmol/L) 94.3 86.3 103.9
59-214 62-119 72-216
* geometric mean
f unknown drug for one subject
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Table 3.3 (b). Mean and range ofvalues for all male vs. all female subjects.
Male Female
Total numbers 143 88







On no other drugs 81 47
Known hypertension 44 39
Coronary heart disease 16 12
Measured systolic BP 149.1 152.3
(mean and range) 102-217 106-216
Measured diastolic BP 92.4 92.1
56-119 56-125
BMI (kg/m2) 28.96 30.55
20.8-46.3 18.8-47.4
Waist (cm) 99.3 97.4
70-143 68-138
Waist-hip ratio 1.008 0.962
0.79-1.17 0.77-1.18
Male Female
Total cholesterol (mmol/L) 5.78 6.04
3.1-9.2 2.8-9.6
triglycerides (mmol/L) 1.92 1.89
0.62-21.1 0.49-5.07
HDL-cholesterol (mmol/L) 0.92 1.02
0.19-1.69 0.55-2.15
lipoprotein (a) (pmol/L) 180 187.5
47-1453 47-988
HbAl (%) 11.33 11.97
5.6-18.4 6.5-17.4
Fructosamine (pmol/L) 358.2 372.6
217-688 212-657
Glucose (mmol/L) 8.6 9.1
3.8-21.0 4.3-15.6




*HOMA-S (%) 63.5 61.6
9.2-680 11.3-485
*3-hydroxybutyrate (pmol/L) 118.8 103.6
8-3639 5-1757
NEFA (mmol/L) 0.673 0.847
0.06-1.77 0-1.59
Urate (mmol/L) 0.317 0.283
0.16-0.58 0.13-0.54
Creatinine (pmol/L) 97.7 83.8
73-216 59-140
* geometric mean




A total of 319 subjects who were considered to fulfil the inclusion criteria were seen
in the Diabetic Clinic during the study period. Sixty-six of these (21%) either declined
to participate or did not attend for assessment ('non-attenders'). Available relevant
data for these subjects at clinic attendance was obtahied and compared with results
for the study group to ensure that no systematic bias was present (table 3.1).
A further 22 subjects were excluded after assessment; in 16 cases this was as a result
of starting insulin treatment during or within 6 months of completion of the study
period. One subject who started insulin treatment was also thought to have diabetes
secondary to pancreatitis. It was not possible to obtain blood samples in the fasting
state from three subjects, and two further subjects were considered on review of
casenotes to have probable or possible secondary diabetes (one pancreatitis, one
steroid treatment). One other subject may have had diabetes for longer than three
months and was therefore also excluded. Comparable data available for all three
groups are summarised in table 3.1. No clear systematic differences were observed
between the attenders and the non-attenders; t-statistics and p values are not shown.
Formal comparison was not made with the group excluded retrospectively (22
subjects), since these subjects may be expected to belong to a different population.
Data from 231 subjects were therefore available for analysis. Descriptive data are
shown in table 3.2, with breakdown of data by racial group in table 3.3 (a) and by sex
in table 3.3 (b).
Only two subjects reported taking any lipid-lowering treatment (one bezafibrate, one
simvastatin) and no special account has been taken of these in data analysis. Twenty-
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eight subjects (12%) reported a previous diagnosis of coronary heart disease (CHD).
Comparing this group with those not having such a diagnosis showed no differences
other than older age among those with CHD (mean age 65.2 vs. 54.3 years; unpaired
Student's t-test p=0.0001), and the CHD group were also more overweight (mean
BMI 31.97 vs. 29.23; p=0.008). Those with existing CHD were also more likely to be
on drug treatment of any kind (27/28 subjects vs. 76/203; for x2 test p<0.0001).
There were no differences in plasma insulin, blood glucose or serum triglyceride
concentration, or presence ofhypertension.
Frequency of features of the metabolic syndrome
Prevalence figures (percent) for the individual features of syndrome X are shown in
table 3.4. Numbers of features for groups (classified by race and sex) within the study
population are shown in table 3.5 (a), and illustrated for all subjects in figure 3.1,
showing the effect of the two definitions of glucose intolerance used. For the
population studied an assessment ofthe distribution of features was made. This gave a
mean number of features of 3.4 with standard deviation of 1.28. Kolmogorov-
Smirnov test for normality of distribution suggested that there may be skewness
present but this was felt to be a result of the small number of components (i.e. 6)
possible within the distribution curve.
Table 3.5 (b) shows the number of additional features of Syndrome X present in
association with other features of the syndrome. Thus it can be seen that insulin and
triglycerides show the greatest degree of skewness, i.e. are more likely to be
associated with several other features, while the pattern for the other features follows
a more normal distribution. The bottom row of table 3.5 (a) can be seen as a similar
summary for the associations of glucose intolerance (here regarding all subjects as
glucose intolerant).
Table 3.4. Prevalence (%) of individual features of Syndrome X.
(a) whole group, and arranged by sex
all male female
total subjects 231 143 88
glucose intolerance 100 100 100
hypertension 51.9 47.6 59.1
hypertriglyceridaemia 31.2 32.9 28.4
hyperinsulinaemia 25.1 22.4 29.5
low HDL-cholesterol 59.3 50.3 73.9
insulin resistance 72.3 67.1 80.7
(b) arranged by racial group
Caucasian Asian Black Other
total subjects 136 65 23 7
glucose intolerance 100 100 100 100
hypertension 55.9 36.9 69.6 57.1
hypertriglyceridaemia 36.0 29.2 8.7 28.6
hyperinsulinaemia 24.3 32.3 8.7 28.6
low HDL-cholesterol 61.8 56.9 43.5 85.7
insulin resistance 71.3 81.5 43.5 100
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number of features
Figure 3.1. Frequency distribution for features of syndrom X: top - including all
subjects as glucose intolerant; bottom - glucose intolerant defined to include only
subjects with fasting blood glucose >6.7mmol/L.
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Table 3.5 (a). Frequency (absolute numbers) of features of syndrome X; any
combination of features is included here.
1 2 3 4 5 6 total
Caucasian F 0 7 10 21 7 3 48
M 9 19 21 19 12 8 88
Asian F 0 5 6 10 3 3 27
M 1 11 15 5 5 1 38
Black F 025020 9
M 1 7 5 1 0 0 14
Other 0 0 2 3 2 0 7
total 11 51 64 59 31 15 231
Table 3.5 (b). Number of additional risk factors occurring in the presence of any
individual feature of Syndrome X (glucose intolerance always included).
1 2 3 4 5
Hypertension 18 34 35 18 15
Hypertriglyceridaemia 0 8 26 23 15
Low HDL-cholesterol 17 30 46 29 15
Hyperinsulinaemia 0 5 15 23 15
Insulin resistance 16 50 55 31 15
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Relationships between variables studied
Correlation
Each of the main features of Syndrome X was closely related to number of features
of the syndrome; correlation coefficients for number of features against insulin,
HOMA-R, triglycerides and HDL-cholesterol all r>0.45, p<0.00001. Relationship
with fasting glucose was not significant.
As would be expected, since insulin concentration is a factor in calculating the
insulin resistance value, insulin and insulin resistance (HOMA-R) were closely related
(r=0.85; p<0.00001), and both also correlated closely with triglycerides (r>0.35;
p<0.00001) but not with HDL-cholesterol (p>0.1). Triglyceride and HDL-cholesterol
concentrations were inversely related (r=0.36; p=0.00001).
Serum urate concentrations did not correlate to any significant extent with any of
the above features, but did correlate with BMI (r=0.31; p=0.0003) and waist
circumference (r=0.32; p=0.0001).
The three indices of obesity studied (BMI, waist circumference and waist-hip ratio)
all correlated together, the weakest correlation being between BMI and waist-hip
ratio (r=0.38; p<0.00001). All three showed a positive correlation with number of
features of Syndrome X but only waist circumference was related to all four of the
individual features studied (plasma insulin, HOMA-R, serum triglycerides and serum
HDL-cholesterol conentration); BMI and waist-hip ratio showed no significant
association with either triglycerides or HDL-cholesterol.
Multiple regression analysis
Four models were analysed, each using 'number of features of syndrome X' as the
dependent variable. The following twenty factors were included in the main group of
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independent or predictor variables: age, sex, smoking, BMI, waist circumference,
waist-hip ratio, hypertension, history of coronary heart disease, glucose, (log) insulin,
(log) HOMA-R, HbAlc, fructosamine, cholesterol, (log) triglycerides, HDL-
cholesterol, LDL-cholesterol, (log) Lp(a), NEFA and urate. The data are summarised
in table 3.6.
In the full model, where all variables studied were included, only log HOMA-R, log
triglycerides, presence of hypertension, low HDL-cholesterol, lower fasting blood
glucose, and female sex proved to be important, accounting for 79.25% of the
variance in number of features present (table 3.6a). An identical set of independent
variables proved predictive when the model was restricted only to the 188 subjects
who had not previously been exposed to oral hypoglycaemic drugs, again accounting
for 79% ofvariance, p<0.01 (data not shown).
When HOMA-R was removed, since it is a derived variable, log insulin substituted
as the most important predictor, along with log triglycerides, hypertension, low HDL-
cholesterol, and female sex. Fasting blood glucose was also included, just reaching
statistical significance; here a positive association was seen with higher blood glucose.
This suggests that the data from the first model including HOMA-R were distorted by
an interaction between glucose and log HOMA-R. This second model again
accounted for 79% of overall variance (table 3.6b).
A third model was constructed excluding both HOMA-R and plasma insulin; here
BMI substituted in importance for insulin, although ranking third in importance after
triglycerides and hypertension. In this model glucose concentration was no longer a
significant predictor. This model, however , only explained 69% of total variance
(data not shown).
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Finally, in an attempt to see whether a model could be constructed which might
predict the number of features of Syndrome X without measuring known
contributors, and which might suggest additional features which should be included in
definitions of the syndrome, all known features were excluded. In this model waist
circumference, total cholesterol concentration, low calculated LDL-cholesterol,
female sex and lower log Lp(a) were of predctive value but these factors explained
only a third of overall variance (table 3.6c). The contradictory trends for total and
LDL-cholesterol suggest an interaction as may be expected from the method of
calculating LDL-cholesterol values.
Factor analysis
Factor analysis was applied to create two models. The first model included all
factors indicated by Reaven to be components of Syndrome X (Reaven, 1988), with
the exception ofHOMA-R as this is derived directly from insulin and glucose values.
This model also included BMI and WHR since these appeared to be important in the
findings described above, and their inclusion would also aid comparison with the data
in the study of Meigs et al (1997). The model therefore comprised (log) insulin,
glucose, (log) triglycerides, HDL-cholesterol, BMI, WHR, and measured systolic and
diastolic blood pressures. In order to avoid excessive complexity in the calculations
no adjustment was made for use of antihypertensive treatment. The component matrix
derived, showing loadings for each factor contributing to the component and the
resulting Eigenvalues and contributions to overall variance, is shown in table 3.7a.
A second model was constructed to try and examine the role of all potentially
relevant variables and thus included those variables indicated for model 1 above, with
the addition of age, sex, HbAl and (log) HOMA-R; its component matrix is shown in
table 3.7b.
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Using only those factors with loadings >0.3, the three component model obtained in
Model 1 is described pictorially in figure 3.2. From this, and using the original
definition for abnormal values, I have again calculated the frequency of each factor
(for components 1 and 2, and also for component 3 but including only those with
fasting blood glucose > 6.7mmol/L). This is tabulated in table 3.8, and shown
graphically for the whole population studied in figure 3.3 (cf. table 3.5 (a) and figure
3.1).
Conclusions
Features of Syndrome X, using these definitions, are present to a varying degree in
subjects with newly-diagnosed NEDDM, and the number of features present appears
to follow a broadly normal distribution in this population. This finding is somewhat at
variance with some pubhshed data from non-diabetic populations.
The use of multiple regression techniques and factor analysis offers an additional
dimension to the interpretation of these data. The findings from multiple regression
analysis show that the known features of the metabolic syndrome are all major
contributors to it and appear to contribute independently. The apphcation of factor
analysis methods, however suggests that the metabolic syndrome per se may only be
an umbrella for a group ofmore restricted risk factor clusters. This appears to be the
case both in this diabetic population as well as in the general population reported by
others, and again components in this population appear to be broadly normally
distributed.
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Table 3.6. Multiple regression models. For all of these female sex was assigned 0 and
male 1. Variables included after log transfoimation are indicated by *.
(a) independent variables predicting 'number of features of syndrome X'
variable multiple R R2 adjustedR2 SE(R) slope (SE) T
*HOMA-R 0.658 0.433 0.430 0.947 2.36(0.19) 12.71
*Triglycerides 0.770 0.594 0.589 0.804 2.54 (0.26) 9.91
Hypertension 0.843 0.711 0.706 0.680 0.88 (0.09) 10.31
HDL-chol. 0.869 0.756 0.751 0.626 -1.16(0.18) -6.41
Glucose 0.885 0.783 0.777 0.592 -0.08 (0.02) -5.11
Sex 0.890 0.792 0.786 0.580 -0.27 (0.09) -3.0#
+ p<0.0001; #p=0.003
(b) as for model (a) after exclusion ofHOMA-R from the model
variable multiple R R2 adjustedR2 SE(R) slope (SE) T
*Insulin 0.654 0.427 0.424 0.952 2.41 (0.19) 12.51
*Triglycerides 0.797 0.636 0.632 0.760 2.51 (0.26) 9.71
Hypertension 0.858 0.736 0.732 0.650 0.87 (0.09) 10.11
HDL-chol. 0.879 0.772 0.767 0.605 -1.17(0.18) -6.41
Sex 0.887 0.786 0.780 0.588 -0.29 (0.09) -3.2#
Glucose 0.889 0.791 0.784 0.583 0.03 (0.02) 2.0§
lp<0.0001;#p=0.002; §p==0.047
(c) model for predictors ofnumber of features, after excluding known features
variable multiple R R2 adjustedR2 SE(R) slope (SE) T
Waist 0.410 0.168 0.164 1.15 0.03 (0.006) 6.11
Cholesterol 0.470 0.221 0.213 1.11 0.95 (0.21) 4.51
LDL-chol. 0.540 0.291 0.280 1.06 -0.91 (0.25) -3.7§
Sex 0.567 0.321 0.307 1.04 -0.47 (0.15) -3.1#
*Lp(a) 0.581 0.337 0.320 1.03 -0.39 (0.18) -2.111
lp<0.0001;i>p=0.0003;# p=0.003; II p=0.03
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Table 3.7. Factor analysis (factor loadings >0.3 highlighted in bold)
3.7(a). Component matrix for Model 1 showing factor loadings for main variables.
Variable Component 1 Component 2 Component 3
*Insulin 0.74 0.05 -0.25
Glucose 0.12 -0.13 0.89
Triglycerides 0.66 0.08 0.41
HDL-cholesterol -0.56 0.39 0.02
BMI 0.67 0.31 0.01
WHR 0.65 0.13 -0.28
Diastohc BP 0.08 0.90 0.08
Svstohc BP -0.13 0.88 0.15
Eigenvalue 2.21 1.88 1.13
Contribution to variance 27.7 23.5 14.1
Table 3.7(b). Component matrix for Model 2 showing factor loadings for ah major
variables of interest.
Variable Component 1 Component 2 Component 3 Component 4
* Insulin 0.78 0.26 -0.28 -0.33
Glucose 0.37 -0.17 0.77 0.23
Triglycerides 0.63 0.11 0.14 0.19
HDL-cholesterol -0.49 0.22 0.23 -0.35
BMI 0.55 0.44 0.10 -0.11
WHR 0.49 0.21 -0.41 0.41
Diastohc BP -0.07 0.81 0.06 0.17
Systohc BP -0.31 0.85 0.20 0.14
Age -0.40 0.53 0.22 0.11
Sex -0.08 -0.13 -0.44 0.75
l ibA1 0.25 -0.18 0.77 0.31
*HOMA-R 0.89 0.15 0.15 -0.19
Eigenvalue 3.04
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Table 3.8. Frequency data for number ofvariables in each component
3.8 (a). Component 1 (insulin, triglycerides, lowHDL-C, BMI, WHR)
0 1 2 3 4 5 tota
Caucasian F 3 10 12 15 4 4 48
M 19 19 13 15 12 10 88
Asian F 0 0 11 8 6 2 27
M 9 11 10 3 5 0 38
Black F 1 2 4 1 1 0 9
M 3 5 5 0 1 0 14
Other 0 0 3 1 3 0 7
total 35 47 58 43 32 16 231
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3.8 (b). Component 2 (hypertension, BMI, high HDL-C)
0 1 2 3 tota
Caucasian F 8 19 18 3 48
M 25 34 25 4 88
Asian F 9 9 7 2 27
M 16 18 4 0 38
Black F 1 3 2 3 9
M 3 3 6 2 14
Other 2 2 3 0 7
total 64 88 65 14 231
3.8 (c). Component 3 (glucose, triglycerides). Here only fasting blood glucose>6.7
mmol/L has been included in the 'hyperglycaemic' category.
0 1 2 total
Caucasian F 7 30 11 48
M 19 41 28 88
Asian F 2 19 6 27
M 6 22 10 38
Black F 3 6 0 9
M 7 6 1 14
Other 2 3 2 7
total 46 127 58 231
Component 1
Figure 3.3. Frequency distributions for factors contributing to each component
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Chapter 4
Effects of the new oral hypoglycaemic agent A4166 on
secretion and metabolic actions of insulin inNIDDM
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Introduction
A number of oral hypoglycaemic agents are currently under development for use in
the treatment of type II (non-insulin-dependent) diabetes mellitus. Among these are
several structural relatives of meglitinide, the non-sulphonylurea moiety of
glibenclamide (Malaisse, 1995 a). In common with sulphonylureas this group of agents
is thought to act via closure of ATP-sensitive K+ channels (Malaisse, 1995b). The
new phenylalanine derivative A4166 (N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-
phenylalanine), which belongs to this group, has been shown in animal studies to
improve glucose tolerance and to enhance insulin secretion (Sato et al, 1991),
apparently without any adverse effect on islet protein synthesis (Vinambres et al,
1995). A4166 has been shown to have similar effects in healthy human volunteers
(Sandoz Pharmaceuticals Corporation, data on file) although its mechanism of action
has not yet been elucidated.
This study was designed to examine the effects of A4166 on endogenous insulin
secretion and intermediary metabolite concentrations in subjects with NIDDM during
an intravenous glucose tolerance test, and to assess whether this effect was sustained
after a period of intensive dietary treatment of diabetes, by means of a randomised
double-blind placebo-controlled trial.
Subjects and Procedures
Ten male Caucasian subjects with non-insulin dependent diabetes were recruited to
the study. All subjects gave signed informed consent after approval had been received
from the Research Ethical Committee of the South Birmingham Health Authority.
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53 (41 - 65)
after diet
Mean (range)
0-44 (7x0-1 month; 3 x 20-44 months)
27.54 (23.91 - 32.82) 27.39 (24.44 - 32.95)
9.1 (6.7- 13.5)
10.2(5.6- 15.2)
Fasting serum triglycerides (mrnol/L)* 1.67 (0.97 - 3.31)
Fasting plasma insulin (pmol/L)"
Basal C-peptide (pmol/L)*
Basal proinsulin (pmol/L)*
76.7 (44 - 245)
744 (463 - 1059)
18.5 (3.5 - 44.1)
8.3(6.9- 11.8)
9.8(7.8- 13.2)
1.68 (1.02 - 3.95)
79.7(40- 219)




Subjects considered eligible for entry into the study were male Caucasians aged
between 40 and 65 years with non-insulin-dependent diabetes treated with diet alone
and of duration less than four years. Where possible subjects with newly-diagnosed
diabetes were preferred in order to maximise any differences in effects of the study
drug between the pre-diet and post-diet assessments. Subjects were required to be
moderately overweight (BMI 25-32 approx.) and to have fasting blood glucose at
entry of approx. 7-12 mntol/L (i.e. clearly hyperglycaemic but not anticipated to
require additional treatment with oral agents during the period of the study). Routine
biochemical and haematological measures for all subjects were within normal limits
both at entry and at the time of the first post-diet assessment. No subject was taking
any regular prescribed medication, none had any complications of diabetes, nor any
current or past medical conditions of any significance.
Two subjects (no.4 and no. 11) withdrew from the study. Subject 4 withdrew at his
request before undergoing any assessment; subject 11 was considered ineligible after
undergoing one IVGTT because of high fasting blood glucose concentration.
Although all data shown here relates only to the ten subjects who completed the
study, original subject numbers have been retained (figs. 4.7 and 4.8).
All subjects received a detailed dietary assessment and advice by the same dietitian
immediately after the first pah of assessments; this was repeated four weeks later in
an effort to achieve optimal diabetic control.
Each subject initially underwent two intravenous glucose tolerance tests (IVGTT)
separated by 2-7 days. Twenty minutes prior to injection of glucose subjects received
in random order either 60mg A4166 or matching placebo, taken orally. After an eight
week period (±2 weeks) of intensive dietary management of diabetes, including two
assessments by a hospital dietitian, each pah of IVGTTs was repeated, again preceded
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by either 60mg A4166 or placebo in random order. The IVGTT procedures were
carried out according to the protocol described in chapter 2.
Venous blood samples were taken as previously described and prepared for
subsequent analysis of total insulin, proinsulin and C-peptide concentrations, and
glucose, lactate, pyruvate, acetoacetate, 3-hydroxybutyrate, glycerol and NEFA.
Statistical analysis
Data were analysed in three different ways. Overall effects on metabolite and
hormone concentrations were analysed by two-way analysis of variance (2-way
ANOVA) with four groups - (1) IVGTT with A4166 prior to diet treatment, (2)
IVGTT with placebo before diet, (3) IVGTT with A4166 following diet treatment,
and (4) IVGTT with placebo post-diet treatment. Differences between groups were
then assessed for each metabolite, hi view of the large number of potential
comparisons to be made Scheffe's test was used to reduce the likelihood of significant
differences arising by chance. In table 4.2 standard error of the mean (SEM) for each
metabolite is shown; SEM for all groups is the same when this calculation is based on
the within-groups mean square, with variances for all groups assumed to be equal and
the number of samples in each group also equal.
First phase insulin secretion was calculated from areas under the insulin
concentration curves over the first 10 minutes from onset of glucose injection in each
of the four groups indicated above. Student's t-test was used to compare the effect of
A4166 vs placebo.
Glucose disappearance (kg) was calculated from log glucose concentrations from
20-60 minutes after onset of glucose injection using the equation kg =0.693/ti/2 where
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t is the calculated time required for blood glucose concentration to return to that at
baseline, and 0.693 is a constant (loge2) (Amatuzio et al, 1953; Marks and Marrack,
1962). The value of kg is then expressed as percent per minute. Student's t-test was
used to compare the effect ofA4166 vs placebo.
Results
General
During the study period no significant changes (by paired Student's t-test) were
observed in subjects' weight, fasting blood glucose concentrations, or overall diabetic
control measured by HbAl concentration (table 4.1). Mean fasting metabolite and
hormone concentrations for each visit are shown in table 4.2.
Effects ofA4166 and diet on overall metabolite and hormone concentrations
Data are summarised in table 4.3, with mean values and SEM for overall
concentrations of each metabolite shown. There were no significant differences
between visits for fasting concentrations of any of the hormones or metabolites,
measured by one way ANOVA carried out separately from that used to examine
overall changes. Despite the apparent fall in mean fasting C-peptide concentrations
(shown in table 4.2) this change did not reach statistical significance (p=0.20).
Glucose
Trends in mean glucose concentrations for each group are shown in figure 4.1.
Although this is suggestive of a lower blood glucose concentration at each time point
with A4166 than with placebo, overall this trend did not reach statistical significance
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(for A4166 vs placebo glucose concentrations before diet p=0.11, after diet p=0.08).
There was no significant change in overall glucose concentration after the period of
dietary treatment compared with before diet.
Insulin
In each pair of studies comparing A4166 against placebo, overall insulin
concentration was significantly increased by A4166 (before diet p=0.0001; after diet
p=0.0005) (figure 4.1). No effect of the period of diet was observed on overall insulin
concentration.
C-peptide
C-peptide concentration (figure 4.2) was increased significantly with A4166 on both
occasions (before diet p=0.0001, after diet p=0.0001). C-peptide concentrations, both
stimulated (by A4166) and unstimulated (after placebo) showed significant decline
(p<0.001) after dietary treatment. Although fasting values were lower after diet these
differences were not statistically significant (p=0.08).
Proinsulin
Proinsulin concentrations were increased by A4166 before dietary treatment but this
difference was halved and no longer statistically significant after diet (before diet
p=0.01, after diet p=0.12). Diet itself had no effect on overall concentrations (figure
4.2).
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Table 4.2. Mean fasting values for analytes at each visit (mean of two samples prior to
taking A4166 or placebo) with interindividual ranges shown below.
before diet after diet
placebo A4166 placebo A4166
Glucose (mmol/L) 8.7 8.1 8.4 8.2
6.0-13.6 6.6-12.5 6.7-11.6 6.7-12.0
hisulin (pmol/L)* 75.5 77.9 82.7 76.8
44-221 46-238 40-194 48-201
C-peptide (pmol/L)* 729.7 757.7 598.4 551.8
496-1010 579-976 314-1150 305-1192
Proinsulin (pmol/L)* 18.1 18.9 19.7 17.6
3.9-42.7 4.1-37.8 6.2-68.5 3.9-45.0
Lactate (pmol/L) 718.6 802.4 918.2 857.0
336-986 533-1119 550-1841 570-1408
Pyruvate (pmol/L) 85.0 86.4 95.1 99.1
42-212 40-188 44-126 59-153
NEFA (mmol/L) 0.713 0.645 0.575 0.618
0.20-1.15 0.36-1.02 0.09-1.11 0.19-1.11
Glycerol (pmol/L) 51.0 46.3 49.7 56.8
22-82 22-90 19-82 23-106
Ketones (pmol/L)* 170.6 148.4 118.8 149.8
56-464 65-426 44-328 62-408
*geometric mean
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Table 4.3. Overall mean values of analytes
before diet after diet
placebo A4166 placebo A4166 SEM
Glucose (mmol/L) 12.96 12.26 12.96 12.15 0.25
Insulin (pmol/L)* 91.8 149.9 99.2 150.7 1.05
C-peptide (pmol/L)* 827.2 1128.7 642.1 870.5 1.03
Proinsulin (pmol/L)* 19.7 27.2 21.1 25.2 1.07
Lactate (pmol/L) 784.0 894.3 935.8 958.8 29.66
Pyruvate (pmol/L) 75.8 76.0 94.1 108.9 3.43
NEFA (mmol/L) 0.62 0.48 0.46 0.43 0.02
Glycerol (pmol/L) 44.8 34.7 42.0 37.4 1.42
Ketones (pmol/L)* 130.0 96.9 96.5 95.3 1.06
* geometric mean
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time from onset of glucose infusion (mins)
Figure 4.1. Mean blood glucose (mmol/L, top) and plasma insulin (pmol/1, bottom;
geometric mean) concentrations achieved during IVGTT.
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time from onset of glucose infusion
Figure 4.2. Geometric mean plasma C-peptide (pmol/L, top) and proinsulin (pmol/L,
bottom) concentrations reached during IVGTT. (Legends for figs. 4.2-4.5 as shown
in fig. 4.1.)
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Figure 4.3. Mean blood lactate (pmol/L, top) and pyruvate (pmol/L, bottom)
concentrations reached during IVGTT.
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Lactate
Lactate concentrations were elevated after A4166 in comparison with placebo prior
to dietary treatment (p=0.05). Diet itself had no consistent effect on lactate
concentrations and the effect of A4166 was lost after the diet period (p>0.1) (figure
4.3).
Pyruvate
Pyruvate concentrations were not significantly influenced by A4166 in comparison
with placebo at initial assesment (p>0.1). The effects of diet itself were prominent
with a significant rise in pyruvate concentrations post-diet compared with pre-diet
(comparing placebo vs. placebo p=0.01, and active vs. active p=0.0002). At the end
of the diet period pyruvate concentrations were significantly higher with A4166 than
with placebo (p=0.02) (figure 4.3).
NEFA
NEFA concentrations were significantly reduced by A4166 before diet (p=0.002).
No consistent effects of diet were observed. After the period of dietary treatment this
effect ofA4166 was no longer apparent (p>0.1) (figure 4.4).
Glycerol
As with NEFA mean glycerol concentrations fell with A4166 before dietary
treatment (p=0.002); diet itself caused no change but any effect of A4166 was no
longer statistically significant at the end of the study (p=0.08) (figure 4.4).
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Total ketone bodies
A4166 significantly reduced ketone body levels prior to diet treatment (p=0.02). No
consistent trend was observed for changes as a result of dietary treatment. Again, at
the end of the period of diet the initial effect ofA4166 was no longer present (p>0.1)
(figure 4.5).
Effects on first phase insulin secretion
First phase insulin response was restored on both occasions with significant
differences regardless ofwhether area under the curve (AUC) was calculated for total
insulin, incremental insulin, or incremental insulin/glucose during the first 10 minutes
from onset of glucose administration (Koschmann et al, 1992). Comparisons of total
1st phase insulin secretion are illustrated in figure 4.6; before diet mean insulin AUC (
±SEM) for A4166 was 1711 (230) pmol/L/10 minutes compared with 826 (135)
pmol/L/10 mins for placebo (p=0.002); after diet 1993 (509) vs 958 (153) pmol/L/10
mins (p=0.025).
Effects on glucose clearance
Comparison of kg values between A4166 and placebo showed no difference before
diet (mean kg (± SEM) =1.49 %/min ± 0.18 vs. 1.49 ±0.16; p=0.98) whereas after
diet A4166 resulted in a significantly higher mean kg than did placebo (1.98 %/min ±
0.32 vs. 1.07 ±0.10; p=0.025). Comparisons of differences in kg for placebo before
and after diet showed a trend towards a deterioration in glucose clearance after diet of
borderline significance (p=0.052), while the apparently greater glucose clearance rate
seen with A4166 after diet was not significantly different from kg with A4166 before
diet (p=0.28) (figure 4.7).
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Figure 4.4. Mean plasma NEFA (mmol/L, top) and blood glycerol (pmol/L, bottom)
concentrations reached during IVGTT.
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Mean plasma concentrations ofA4166 peaked 27-30 minutes after ingestion (i.e. 7-
10 minnt.es after onset of the glucose infusion) at approx. 2.5p.g/rnl (range 0.16-6.63)
with measurable concentrations of drug detectable within 10 minutes of ingestion,
before any glucose had been given.
Considerable interindividual variation was observed in concentrations of A4166
achieved (figure 4.8). Prior to diet subjects 2 and 7 achieved peak plasma
concentrations of A4166 of <l|iig/rnl and after diet subjects 1, 2 and 6 similarly failed
to reach plasma concentrations of 1 pg/ml. While subject 2 can therefore be regarded
as a persistent non-responder, an explanation for the variation in absorption of drug
by the other subjects is not clear.
Conclusions
The acute administration of 60mg A4166 results in a partial restoration of the first
phase insulin response to intravenous glucose, and a significant increase in overall
plasma insulin and C-peptide concentrations. Although no statistically significant
reduction in blood glucose concentrations was observed there was a trend in this
direction, and after diet glucose uptake was significantly increased in the presence of
A4166. However blood glucose-lowering effect was not a primary objective of this
study which may not have had adequate power to show a significant effect. Individual
responses were related to plasma concentrations of A4166 achieved; failure to
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Hypertriglyceridaemia is a common feature in non-insulin-dependent diabetes.
Although its role as an independent risk factor for coronary heart disease remains
contentious, it is known to be associated with other lipid abnormalities predisposing
to coronary heart disease and is also included in proposed clusters of coronary risk
factors (Reaven, 1988).
Hypertriglyceridaernia has notably been included in descriptions of a metabolic
syndrome of coronary risk, one ofwhose core features is insulin resistance. Efforts to
treat risk factors for CHD are often hampered by diverging effects on different risk
factors. If risk factor intervention is to be truly effective it should have beneficial or at
worst neutral effects on other risk factors.
Gemfibrozil (Lopid®, Parke Davis Pharmaceuticals Ltd, Eastleigh, UK) is a lipid-
lowering agent of proven effectiveness of the fibrate class of drug. It has both
cholesterol- and triglyceride-lowering properties, and has been shown to be safe and
effective in diabetic populations. Although for many years the mode of action of this
class of agent has remained unclear, recent evidence points to an effect on the
peroxisome proliferator activated receptors (PPAR) of the a subtype found in liver
(Staels et al, 1997). Stimulation at PPARa sites results in a number of effects limiting
fatty acid synthesis and reducing triglyceride concentrations.
In a double-blind placebo-controlled study, with insulin resistance assessed by low-
dose incremental insulin infusion, I set out to examine whether Gemfibrozil had any
effect on insulin resistance, studying several aspects of intermediary metabolism in
subjects with non-insulin-dependent diabetes and hypertriglyceridaemia. Following the
observations by Steiner (1992) I also hoped to examine whether the degree of
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kypertriglyceridaemia (or the magnitude of its reduction) was related to any change in
insulin resistance.
Subjects and Methods
All subjects were recruited from the Diabetic Clinic of the General Hospital,
Birmingham between June 1994 and January 1995. Ethical approval was granted by
the local Research Ethics Committee; all subjects gave written informed consent and
received a detailed written and verbal explanation of the study.
The study was designed in collaboration with Parke Davis Pharmaceuticals Ltd
(Eastleigk, Hants,UK) who provided financial support and supplied both Gemfibrozil
and matching placebo.
Entry Criteria
Adult subjects (aged 18-70) with NIDDM of duration in excess of two years,
currently treated with diet alone or oral agents in stable dosage, were considered
ehgible for inclusion if they fulfilled the following additional criteria: BMI <33; stable
diabetic control not expected to need insulin during the 6 month study period; urine
albustix negative; no significant haematological abnormality on baseline testing; no
evidence of significant hepatic or renal impairment on blood testing; no evidence of
other causes of secondary hyperlipidaemia including normal thyroid function; no
known pre-existing (or current treatment for) coronary heart disease; no other serious
illness; not on any other drugs known to affect lipid metabolism (although
antihypertensive medication was permitted so long as treatment and condition were
regarded as stable).
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Subjects were identified as possible candidates for inclusion on the basis of non-
fasting lipid data available in the clinic, when results suggested that fasting cholesterol
and triglyceride levels might fall within the required study range of total cholesterol
5.2 -lOmmol/L and triglycerides 2.3 - 5.6mmol/L. Subjects included whose lipid
values were outwith this range at visit 2 were ineligible to enter the treatment phase
and were withdrawn at this point. This criterion accounted for the majority of
withdrawals.
Protocol
The study protocol provided for the inclusion of 56 subjects, to be randomised to
either active treatment with gemfibrozil or placebo. No formal power calculations
were carried out, although data from previous studies using this technique to assess
insulin resistance suggested that small numbers of subjects (6-12) should be adequate
to find clear differences between two groups where such differences exist. There are
few comparable data examining effects of gemfibrozil or other fibrates on insulin
resistance. (The protocol for this study was written before publication of the findings
of Vuorinen-Markkola et al (1993).) A larger cohort was provided for in the hope
that it might be possible to stratify effects on insulin resistance by the magnitude of
the fall in triglyceride concentration achieved, and clearly the subgroups derived
would need to be large enough themselves to demonstrate any differences. (In
practice the limited numbers proceeding to treatment precluded any attempt at this
analysis.)
Each subject was required to attend on seven occasions over a six month period.
Visit 1 was a recruitment and initial assessment visit, at which baseline height, weight,
blood pressure and details of age, sex, duration of diabetes, and details of medication
and other medical conditions were recorded. Fasting blood samples were taken for
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glucose, HbAl, fructosarnine, total and HDL-cholesterol, triglycerides, urate, thyroid
function, biochemical screen (electrolytes, liver enzymes including y-
glutamyltranspeptidase) and full blood count. Subjects not excluded at this visit were
given a dietary assessment and advice by a dietitian.
At visit 2, eight weeks after visit 1, weight and blood pressure were again measured,
and blood taken for glucose, urate, ffuctosamine, lipid parameters and general
biochemistry.
On the basis of the results from visit 2 subjects were assessed for eligibility to
continue into the treatment phase of the study at visit 3 (two weeks after visit 2).
Those continuing at this stage had the same clinical and laboratory assessments as at
visit 2, with full blood count (safety measure) and HbAl in addition. Subjects then
underwent a low-dose incremental insulin infusion (described in Chapter 2). A dietary
review was undertaken at this point, and supplies ofmedication were given out.
Visits 4 and 5 followed at 4-weekly intervals. At each of these visits treatment
compliance and adverse effects of medication were checked. Weight and blood
pressure were measured, along with fasting glucose and lipids, ffuctosamine, urate
and a biochemical screen.
At visit 6, a further 4 weeks later, a second low-dose insulin infusion was
performed, using the same protocol as for the first. Assessments as for visits 4 and 5
were also carried out, and subjects underwent a dietary review. All supplied tablets
were returned, this visit being the end of the treatment phase.
Visit 7, the final visit, followed about 4 weeks later, when a full symptomatic and
physical review was carried out; fasting blood samples were again taken. Subjects
were discharged back to Diabetic clinic follow-up.
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Conduct of the Study
Forty-seven potentially suitable candidates consented to take part. Thirty-three of
these were withdrawn from the study prior to randomisation, i.e. before visit 3.
Reasons for withdrawal were as follows: ineligible by lipid criteria (23, total
cholesterol and/or fasting triglycerides below required intervention level of 5.2 and
2.3 rnmol/L respectively), dipstick proteinuria (1), subject request or default (4), pre¬
existing coronary heart disease (2), abnormal baseline biochemistry (1, abnormal liver
enzymes), body mass index outwith defined limits for study (1) and intercurrent illness
making insulin infusion inadvisable (1).
Fourteen subjects proceeded to the treatment phase of the study. Two subjects were
withdrawn during the treatment phase: subject 8 developed symptoms suggestive of
new angina (visit 4), and subject 10 requested withdrawal having been unable to
comply with the treatment schedule (visit 5).
All subjects in the treatment phase were supplied with either Gemfibrozil 600mg
tablets or matching placebo to be taken as one tablet twice daily. Drugs were
dispensed at visits 3, 4 and 5; surplus tablets from previous visits were returned at
visits 4, 5 and 6. All other regular medications were continued unchanged.
Laboratory Analyses
Biochemical and haematological screening samples were analysed as part of routine
laboratory testing on the same or next day. All lipid analyses from each visit were
carried out using an identical method. Samples from the low-dose insulin infusions
were stored at -20°C for later measurement of glucose, insulin, lactate, pyruvate,
alanine, 3-hydroxybutyrate, acetoacetate, glycerol and NEFA. Details of laboratory
methods for these analyses are described in Chapter 2.
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Statistical Analyses
Comparison of changes over time in serum triglyceride (log transformed), total and
HDL-cholesterol and ffuctosarnine concentrations, and in weight, were carried out by
one-way analysis ofvariance; treatment and placebo groups were analysed separately.
Comparison between groups of mean fasting metabolite concentrations was also by
one way ANOVA; here gemfibrozil and placebo groups (before and after treatment)
were analysed together.
Regression slopes were calculated from the metabobte data (against log [mean
msulin]) for each group, and analysis of variance appbed to the regression fines
obtained. In view of the large number of potential comparisons, Scheffe's test was
applied when comparing differences between groups. Differences have been expressed
as separations between parallel slopes at a common insulin concentration (i.e.
differences between corrected analyte means). Missing data were treated in as
biologically plausible a way as possible; values were taken as the mean of the
immediately preceding and succeeding values for the individual subject concerned.
For the insulin resistance studies, differences were sought between regression lines
before and after treatment for both gemfibrozil and placebo groups, and also between
gemfibrozil group (before treatment) and placebo group (before), and gemfibrozil
(after treatment) and placebo (after). Clearly the most important differences to
observe would be those occurring between gemfibrozil (after vs. before) which were
not seen in the placebo group (after vs. before), or vice versa if any native tendency to
change might be limited by active treatment.
Insulin and ketone concentrations were log transformed prior to analysis because of
their known non-normal distribution. Total ketone body concentrations were obtained
by adding acetoacetate and 3-hydroxybutyrate concentrations together.
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Table 5.1. Characteristics at baseline (visit 1)



































































































Baseline characteristics of each subject who proceeded to the treatment phase of the
study are given in table 5.1. Seven subjects completing the study received gemfibrozil
and five placebo. Of the two withdrawals during the treatment period (subjects 8 and
10) one received gemfibrozil and one placebo.
Changes from baseline during the study were calculated for total cholesterol, HDL-
cholesterol, triglycerides, glucose, fructosamine and body mass index (BMI). For
these calculations only data from the subjects completing the study were used. Only
for triglycerides (geometric mean falling from 3.68 to 1,79mmol/L (51.4%) with
gemfibrozil, p=0.00003; fall with placebo from 2.78 to 2.70mmol/L (2.9%), p=0.92)
was a statistically significant change observed with gemfibrozil while none of these
variables were altered by placebo. These data are summarised in table 5.2.
There were no statistically significant differences between groups for mean fasting
metabolite concentrations (table 5.3); for all metabolites p>0.5.
Data showing changes in metabolite and insulin concentrations with time during the
low-dose insulin infusions are shown in figures 5.1-5.9. After calculation of regression
lines for metabolite concentration against log [mean insulin], slopes for these data
were subjected to analysis of covariance. Comparisons of both separate and common
slopes are shown in figures 5.10-5.15.
Mean blood glucose concentrations were not significantly altered by gemfibrozil or
placebo. Difference between corrected means for parallel slopes before and after
gemfibrozil was 0. lOmmol/L, and for placebo 0.15mmol/L (p>0.5 for both).
Mean lactate concentrations were slightly higher following gemfibrozil treatment
and fell slightly after placebo. None of these changes were statistically significant, and
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it should be noted that the regression slopes for lactate, and also for alanine, did not
reach statistical significance; i.e changes in x (plasma insulin concentration) did not
produce statistically significant changes in y (lactate or alanine concentrations). Mean
alanine concentrations fell after gemfibrozil but rose after placebo, neither change
reaching statistical significance.
Blood glycerol concentrations fell after gemfibrozil but were unaltered by placebo,
again these differences did not reach statistical significance. Difference between
corrected means for parallel slopes before and after gemfibrozil treatment was 4. lp
mol/L (p=0.28); difference for placebo 0.2pmol/L (p=l).
For both NEFA and log total ketones (TKB), a significant shift of the regression line
downwards and to the left was observed in the gemfibrozil group which was not
present in the placebo group. Taking differences between corrected mean values on
the parallel slopes obtained by analysis of covariance, fall in mean NEFA
concentration with gemfibrozil (after vs. before treatment) was 0.15mmol/L, p=0.003
by Schefife's test; change with placebo (after vs. before treatment) was 0.08mmol/L, p
=0.10. For mean TKB fall was 41.0|j.mol/L, p=0.002 with gemfibrozil; 10.9p.mol/L,
p=0.43 with placebo.
Changes in pyruvate concentrations were not calculated because full data sets were
not available for all subjects.
Analysis by fall in triglyceride concentrations showed that all but two subjects in the
gemfibrozil group had greater absolute or percentage falls in triglyceride levels than
any of the placebo group; therefore reanalysis of the data comparing subjects with
large triglyceride reductions against those with small or absent triglyceride falls
yielded no additional information.
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Table 5.2. Changes with treatment (mean values)
Gemfibrozil Placebo
change(%) p (ANOVA) change(%) p (ANOVA)
Total cholesterol (mmol/L) -0.84 (12.5) 0.14 -0.26(4.1) 0.89
Triglycerides (mmol/L)* -1.89(51) 0.00003 -0.08(2.9) 0.92
HDL-cholesterol (mmol/L)+0.01 (1.1) 0.69 0 1
Glucose (mmol/L) -0.29(3.8) 0.95 -0.29(3.8) 0.98
Fructosamine (|imol/L) +23.4(7.9) 0.81 +25.5 (9.1) 0.95
BMI (kg/m2) -0.17(0.64) 1 +0.1 (0.36) 1
Comparison ofgeometric means; data log transformed for analysis
139
Table 5.3. Mean fasting metabolite concentrations
Gemfibrozil Placebo
pre post pre post
Insulin (pmol/L)* 85.0 84.0 116.3 113.1
Glucose (mmol/L) 6.85 7.16 6.56 6.81
Lactate (pmol/L) 736.0 858.4 787.8 799
Alanine (pmol/L) 342.9 308.4 345.8 344.8
Glycerol (pmol/L) 49.2 47.8 55.2 57.2
NEFA (mmol/L) 0.79 0.64 0.76 0.69




This study was hampered by the high dropout rate during the dietary run-in phase,
largely due to the improvement in fasting triglyceride levels brought about by diet
alone leading to many subjects being rendered ineligible. Nonetheless, despite the
small numbers of subjects completing the study, gemfibrozil reduced triglyceride
concentrations to a significant degree, and was shown to bring about significant
overall reductions in NEFA and ketone concentrations. It seems most likely that this
is a direct effect of the drug on fatty acid synthesis rather than any indirect effect
mediated by enhanced insulin sensitivity. The small size of this study makes it
impossible to exclude a type 2 error in analysis, particularly with respect to effects on
glycerol metabolism, although the consistency with other published data suggests that
these findings are likely to be true.
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Figure 5.1. Changes in blood glucose concentration (mmol/L; mean ± SEM) with time
(minutes) during low-dose insulin infusion: top - gemfibrozil group (■ before
treatment, □ after treatment); bottom - placebo group (A before treatment, A after
treatment).
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Figure 5.2. Changes in plasma insulin concentration (pmol/L; geometric mean ±
SEM) with time (minutes) during low-dose insulin infusion: top - gemfibrozil group (
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Figure 5.3. Changes in blood lactate concentration (pmol/L; mean ± SEM) with time
(minutes) during low-dose insulin infusion: top - gemfibrozil group (■ before
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Figure 5.4. Changes in blood alanine concentration (pmol/L; mean ± SEM) with time
(minutes) during low-dose insulin infusion: top - gemfibrozil group (■ before
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Figure 5.5. Changes in blood glycerol concentration (pmol/L; mean ± SEM) with time
(minutes) during low-dose insulin infusion: top - gemfibrozil group (■ before
treatment, □ after treatment); bottom - placebo group (A before treatment, A after
treatment).
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Figure 5.6. Changes in plasma NEFA concentration (mmol/L; mean ± SEM) with
time (minutes) during low-dose insulin infusion: top - gemfibrozil group (■ before
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Figure 5.7. Changes in blood 3-hydroxybutyrate concentration (pmol/L; geometric
mean ± SEM) with time (minutes) during low-dose insulin infusion: top - gemfibrozil
group (■ before treatment, □ after treatment); bottom - placebo group (A before
treatment, A after treatment).
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Figure 5.8. Changes in blood acetoacetate concentration (pmol/L; geometric mean ±
SEM) with time (minutes) during low-dose insulin infusion: top - gemfibrozil group (
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Figure 5.9. Changes in blood total ketone concentration (pmol/L; geometric mean ±
SEM) with time (minutes) during low-dose insulin infusion: top - gemfibrozil group (
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Figure 5.10. Regression slopes for blood glucose (mmol/L) against plasma insulin
concentration - calculated for individual regression lines (top) and for common slope
(bottom).
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Figure 5.11. Regression slopes for blood lactate (pmol/L) against plasma insulin
concentration - calculated for individual regression lines (top) and for common slope























Figure 5.12. Regression slopes for blood alanine (pmol/L) against plasma insulin
concentration - calculated for individual regression lines (top) and for common slope
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Figure 5.13. Regression slopes for blood glycerol (pmol/L) against plasma insulin
concentration - calculated for individual regression lines (top) and for common slope
(bottom). Legend as for fig. 5.10. (Parallel lines for placebo overlie.)
Figure 5.14. Regression slopes for plasma NEFA (mmol/L) against plasma insulin
concentration - calculated for individual regression lines (top) and for common slope
















Figure 5.15. Regression slopes for blood total ketones (pmol/L) against plasma
insulin concentration - calculated for individual regression lines (top) and for common
slope (bottom). Legend as for fig. 5.10.
Chapter 6




Abdominal obesity, and more particularly visceral obesity, is widely regarded as a
risk factor for the development of non-insulin-dependent diabetes and may also be
associated with increased cardiovascular risk. It has been proposed that this risk is
mediated at least in part by increased insulin resistance although the evidence to
support this hypothesis appears to come largely from population studies screened
using an oral glucose tolerance test; formal assessments of insulin resistance to assess
this have rarely been used.
Assessment of abdominal obesity can most easily be made by measuring the waist-
hip ratio. Although the value of this method has been criticised when compared with
more specific means of assessing visceral fat (such as magnetic resonance imaging) it
is widely accepted as a useful guide to regional adiposity, and is claimed by some to
be a better indicator of insulin resistance and risk of diabetes than indices oftotal body
obesity such as body mass index (BMI).
This study attempted to address the question ofwhether insulin resistance in subjects
with non-insulin-dependent diabetes is related to body fat distribution by measuring
insulin resistance in two ways, namely the euglycaemic hyperinsulinaemic clamp and
the low-dose incremental insulin infusion.
Subjects and Procedures
Subjects were recruited from the Diabetic Clinic at the General and Selly Oak
Hospitals, Birmingham between August 1995 and April 1996. Ethical approval was
received before the study commenced and all subjects gave signed informed consent
to take part after receiving written and verbal details of the study procedure.
158
Caucasian men aged approximately 35-65 years were considered eligible if they had
non-insulin-dependent diabetes of at least two years duration treated with diet alone.
Subjects had to be in good general health, on no regular oral medication and have
BMI approx. 25-32kg/m2. Subjects with known or suspected secondary diabetes were
excluded.
Fourteen volunteers were studied; each attended for one clamp study and one insulin
infusion. In one subject (subject 4) the clamp procedure had to be terminated because
difficulty in maintaining a patent hand vein cannula meant that a steady state blood
glucose concentration was not achieved for the required period. For this subject only
insulin infusion data are therefore available.
Subjects attended after an overnight fast for both visits; studies were scheduled to
start between 8 and 9am.
At visit 1 demographic details were obtained and the following examined: height,
weight, waist and hip circumferences, skinfold thicknesses (triceps, biceps,
subscapular^, suprailiac and thigh) and resting blood pressure. Waist circumference
was determined at the midpoint between the lowest palpable rib border and the
superior iliac crest in the mid-axillary line; hip circumference was measured at the
level of the greater trochanters. Body density was estimated using the equations of
Durnin and Womersley (1974) applied to the skinfold measurements obtained at
triceps, biceps, subscapular and suprailiac sites; percent body fat was then calculated
using the Siri equation (Siri, 1956).
Fasting blood samples were taken for general biochemical profile, HbAlc,
fructosarnine, serum total and HDL-cholesterol, triglycerides, thyroid function (T4
and TSH), testosterone, SHBG (sex hormone binding globulin) and Cortisol
concentrations.
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Subjects then proceeded to either a euglycaemic hyperinsulinaemic clamp or low-
dose incremental insulin infusion (as described in Chapter 2 - Methods). Clamp
studies were more often carried out first but no fixed order was determined. All blood
samples were obtained via cannulae sited in warmed dorsal hand veins giving
arterialised venous blood. On completion of the procedure subjects were given lunch
prior to leaving the hospital. The second procedure was carried out a minimum of 7
days, and where possible not more than 30 days, after the first.
Insulin sensitivity values (M) for the clamp study were obtained from the mean rates
of glucose infused during the final thirty minutes of the test (DeFronzo et al, 1979)
during which period blood glucose is assumed to be stable at approximately 5mmol/L.
Infusing 20% dextrose, M can be calculated as glucose infusion rate per minute
(1/min) x 200 (grams glucose/litre infusate); dividing this value by the subject's
measured weight (in kg) allows M to be expressed as mg/kg/min. Alternatively, M can
be expressed in pmol/kg/min from the molecular weight of glucose (which is 180;
thus multiply previous value by 1000/180).
Laboratory analysis
Analyses of plasma insulin and NEFA, and metabolites (in deproteinated whole
blood) were made as described previously (Chapter 2); samples were separated and
frozen on the day of the study to be stored until analysis. Samples for baseline
measures were sent on the day of sampling at visit 1.
Data analysis
Data from the low-dose insulin infusions were analysed in groups. Subjects were
divided into two categories - either 'high' or 'low1 for the variable under analysis. The
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variables of interest studied were waist-hip ratio, body mass index, percent body fat
and mean fasting blood glucose. After subjects had been ranked by the variable of
interest, the middle two subjects were removed from assessment in order to obtain a
clear separation between the high and low groups (since all of the four variables
studied are continuous rather than discrete). Each group analysed therefore consisted
of six subjects. Analysis of variance applied to the regression lines of metabolite
concentration against log mean insulin was then carried out. Data from each subject
was thus used for up to four analyses. Scheffe's test was used for significance testing,
allowing for multiple comparisons.
hi order to demonstrate clear and adequate separation between 'high' and 'low1
groups comparison of means for fasting glucose, BMI, waist-hip ratio and percent
body fat was made by one-tailed Student's t-test; the one-tailed test was used because
the division into 'high' and 'low1 groups necessarily indicated that the difference could
lie only in one direction.
Correlation coefficients were obtained using Spearman's rank correlation test to
examine interrelationships between variables, with particular reference to effects of
the four variables above on insulin resistance data obtained from the euglycaemic
clamp studies.
Results
General characteristics of the study population are shown in table 6.1.
161
Table 6.1. General characteristics ofthe study group (14 subjects)
mean range
Age (years) 56 40 - 67
Years since diagnosis ofNIDDM 2-10
BMI (kg/m2) 28.7 23.8 - 32.8
Waist-hip ratio 1.01 0.93-1.09
% body fat 29.72 24.24 - 38.38
HbAlc (%)* 6.93 4.6- 10.4
Fasting blood glucose (mmol/L)^ 7.26 4.85 - 10.65
Fasting triglycerides (mmol/L) 1.82 1.04 - 3.89
Fasting plasma insulin (pmol/L)^ 78.9 43.5 - 165
for two subjects HbAl was measured (prior to change in method); HbAlc derived
by subtracting 1.85 from HbAl value.
+
mean of fasting values from each visit.
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Insulin infusion data
Figures 6.1-6.4 show the metabolite and insulin profiles for each sampling point of the
low-dose insulin infusion. From these the infused insulin appears to have little effect
on lactate, alanine and pyruvate concentrations. This impression was supported by
calculation of the regression fines for these variables, for which the steepness of the
regression slope did not differ significantly from zero; i.e. changes in mean plasma
insulin concentration did not result in significant changes in metabolite concentration.
These data are therefore not further examined here. For all the other metabolites
(glucose, NEFA, glycerol and TKB) regression slopes were compared for 'low1 and
'high' groups according to fasting blood glucose, waist-hip ratio, BMI, and percent
body fat.
Effect ofhigh versus low waist-hip ratio
Table 6.2 (a) summarises the comparisons of the common slopes for each
metabolite, comparing the low WHR and high WHR groups (mean WHR 0.961 vs.
1.057; p<0.0001). Only for total ketones was a statistically significant separation
between slopes observed, and for all concentrations of insulin, ketone body levels
were higher in the low WHR group (p=0.019). A similar observation was apparent
when the two individual regression slopes were compared.
Blood glucose concentrations showed a similar trend, with higher concentrations in
the low WHR group, but this finding just failed to reach statistical significance
(p=0.067).
There were no significant differences between the two regression lines for NEFA or
for glycerol. Figure 6.5 (a and b) shows the slopes for 'low' and 'high' WHR groups
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Figure 6.1. Top: mean (—), SEM (box) and range (vertical lines) for blood glucose
concentration (mmol/L) at each time point during low-dose insulin infusion. Bottom:





























Figure 6.2. Top: mean (—), SEM (box) and range (vertical lines) for blood lactate
concentration (pmol/L) at each time point during low-dose insulin infusion. Bottom:
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Figure 6.3. Top: mean (—), SEM (box) and range (vertical lines) for blood glycerol
concentration (pmol/L) at each time point during low-dose insulin infusion. Bottom:
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Figure 6.4. Top: mean (—), SEM (box) and range (vertical lines) for blood pyruvate
concentration (pmol/L) at each time point during low-dose insulin infusion. Bottom:
total blood ketones (pmol/L); layout as above (geometric mean).
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There were no significant differences between 'low1 and 'high' groups for mean
fasting blood glucose or (geometric) mean fasting plasma insulin concentrations.
Effect ofhigh versus lew body mass index
There were no differences observed between the two groups (low BMI vs. high
BMI; mean 26.16 vs. 31.26; p<0.0001) for the regression slopes for glucose, nor for
ketones.
Clear differences were present between the parallel slopes for glycerol (p=0.038),
with low BMI associated with lower blood glycerol concentrations, and there was a
trend, not quite reaching statistical significance, for low BMI to be associated with
lower NEFA levels (p=0.059).
These data are summarised in table 6.2 (b); regression slopes for the two groups are
shown in figure 6.6 (a and b) for each metabolite.
There were no significant differences between 'low1 and 'high' groups for mean
fasting blood glucose or (geometric) mean fasting plasma insulin concentrations.
Effect ofhigh versus low percent body fat
There was a clear separation between 'low' and 'high' percent body fat (mean
26.19% vs. 33.23%; p=0.0007). However, no differences emerged between
regression slopes for any of the four metabolites studied (table 6.2 (c)). (Regression
slopes are not shown.)
There were no significant differences between 'low1 and 'high' groups for mean
fasting blood glucose or (geometric) mean fasting plasma insulin concentrations.
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Effect ofhigh versus lowfasting bloodglucose
Mean fasting glucose concentration was significantly lower in the 'low1 glucose than
in the 'high' glucose group (5.77 vs. 8.77mmol/L; p=0.0001) and this was reflected in
lower blood glucose levels at all insulin concentrations (p=0.002). However,
concentrations of none of the other metabolites differed between the two groups
(summarised in table 6.2 (d)). The regression slopes for 'low1 versus 'high' FBG are
shown in figure 6.7 (a and b).Differences between 'low' and 'high' groups for mean
fasting plasma insulin concentration were not statistically significant.
Correlation of influencing variables with insulin sensitivity assessed by euglycaemic
clamp
Figure 6.8(a) shows whole blood glucose concentrations during the euglycaemic
hyperinsulinaemic clamp, as measured at the bedside using the YSI glucose analyser.
The desired blood glucose concentration of 5mmol/L was usually reached within 60
minutes of starting the insulin infusion. The glucose infusion rates are shown in figure
6.8(b); clearly because of the range of fasting blood glucose levels in these subjects
the infusion rates varied considerably between individuals. Figure 6.8(a) also shows
plasma insulin concentrations reached during the procedure (measured at baseline,
approx. 40 and 60 mins, and at 10 minute intervals during the final 20 minutes of the
procedure). The tendency for an initial overshoot in insulin concentrations before
settling to stable levels after the initial loading infusion accords with that originally
described by DeFronzo et al (1979).
Having calculated M values from the clamp studies, and ranked all variables in
ascendhig order, correlation coefficients were obtained for relationships between the
clamp-derived index of insulin sensitivity and indices ofbody fat. M values showed no
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statistically significant association with BMI (rs=-0.11; p=0.71), waist-to-hip ratio
(rs=-0.05; p=0.87) or percent fat (rs=-0.13; p=0.67), nor with fasting blood glucose
(rs=-0.44; p=0.1) but M value was significantly related to fasting plasma insulin
concentration (rs=-0.74; p=0.0002).
Regression slopes for M on each of the body fat indices were calculated, using the
actual values rather than ranks. None of these slopes showed a statistically significant
difference from zero. Data are shown in table 6.3 with scattergraphs for M against
BMI and percentage body fat in figure 6.9, and M versus waist-hip ratio and waist in
figure 6.10.
Conclusions
In this group of subjects with established NIDDM no clear pattern emerges to show
an influence of any index of body fat on insulin sensitivity with respect to the
metabolites studied. Surprisingly, lower waist-hip ratio was associated with greater
insulin resistance to glucose and ketone metabolism, although lower body mass index
was associated with greater insulin sensitivity for NEFA and glycerol metabolism.
Greater numbers of subjects may be needed to confirm these findings, and a type I
error cannot entirely be excluded. While other factors not considered here may be
important, the diabetic state per se may have an overwhelming effect which obscures
any influence of these factors.
Because of the small size of this study it has not proved possible to comment with
any confidence (eg. using multiple regression analysis) on the relative contributions of
the variables studied. In particular, the effect of fasting blood glucose and the impact
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Figure 6.5 (a). Comparison of group regression slopes of metabolite against insulin
concentrations calculated for low vs. high waist-hip ratio. Top - glucose (mmol/L);
bottom - ketones (fimol/L). Legend - low WHR ; high WHR - - - -

























Figure 6.5 (b). Separate regression slopes for low vs. high waist-hip ratio: top










Figure 6.6 (a). Comparison of separate group regression slopes of metabolite against
insulin concentrations calculated for low vs. high body mass index. Top - glucose

























Figure 6.6 (b). Separate regression slopes for low vs. high body mass index: top -

















Figure 6.7 (a).Comparison of separate group regression slopes ofmetabolite against
insulin concentrations calculated for low vs. high fasting blood glucose. Top - glucose
(mmol/L); bottom - ketones (pmol/L). Legend as for fig. 6.5.
Figure 6.7 (b). Separate regression slopes for low vs. high fasting blood glucose: top -
NEFA (mmol/L); bottom - glycerol (pmol/L). Legend as for fig. 6.5.
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Table 6.2. Effects ofvariables shown on separation between common regression lines
(arithmetic means shown for glucose, NEFA and glycerol; geometric means for
ketones and insulin). Corrected mean metabolite concentrations at overall mean
insulin concentration are shown; means for insulin are those for 'low1 and 'high' groups
respectively.
(a) comparison by WHR
corrected mean
low high separation E
Glucose 6.74 5.58 1.16 0.067
NEFA 0.42 0.42 0.008 0.63
Glycerol 34.7 35.7 1.06 0.48
*Ketones 133.1 73.5 0.26 0.019
Insulin 128.7 103.4 n/a


























































































Figure 6.8(a). Mean (± SEM) whole blood glucose (•, mmol/L), and geometric mean
(± range) plasma insulin (0, pmol/L) concentrations achieved against time (minutes)
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Figure 6.8(b). Mean (and range) glucose infusion rate during the clamp procedure.
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Table 6.3. Regression slopes for M values on indices ofbody fat.
r2 a slope (b) confidence limits p
WHR 0.004 7.72 -1.7 -19.8- 16.4 0.84
BMI 0.013 7.62 -0.06 -0.38- 0.27 0.71
%fat 0.004 6.63 -0.021 -0.25 - 0.21 0.84
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Use of the low-dose incremental insulin infusion in assessment
of insulin resistance in NIDDM
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Introduction
Several methods are currently available for the assessment of insulin resistance,
almost all of which address only the role of insulin in glucose metabolism and give
little or no attention to its contribution to other aspects ofmetabolism. The low-dose
incremental insulin infusion (Hale et al, 1986) was developed to examine insulin
action over the physiological range of insulinaemia, fulfilling the requirement for
Kahn's definition (Kahn, 1978) of insulin resistance to assess insulin action over a
range of concentrations, and allowing examination of changes in concentration of
several metabolites with changes in plasma insulin levels.
This method has not hitherto been subjected to comparison with other techniques
for assessing insulin resistance. In this chapter, using data obtained from one of the
studies described elsewhere in this manuscript, I propose to address this area.
Subjects and Methods
For comparison with other techniques ofmeasuring insulin resistance, data from the
subjects studied in chapter 6 have been used. In this study, as described, subjects
underwent a low-dose incremental insulin infusion and a euglycaemic
hyperinsulinaemic clamp in random order, separated by 7-35 days. From the fasting
blood samples at each visit an estimate of insulin resistance by homeostasis modelling
assessment (HOMA-R; Matthews et al, 1985) was also obtained.
Statistical methods
Data from the low-dose insulin infusion procedure are analysed by calculation of the
regression line for metabolite on log insulin concentrations, with subsequent analysis
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of variance applied to the regression line obtained. This has normally been used for
data from groups of subjects with regression lines derived on log mean insulin
concentrations. However, calculation of individual regression lines is possible, and I
have done this here primarily in order to obtain ranks for subjects. When individual
regression lines are calculated several options become available and the choice of
which measure to use becomes to some extent arbitrary. The individual regression
slopes for glucose on log [insulin] are shown in figures 7.1 and 7.2.
Here regression lines have been calculated for glucose for each individual on his
own plasma insulin data. Both separate and common slopes have been used, and three
measures of insulin resistance used for comparison with each other and with other
methods: firstly, rank order within the group based on the common regression slope
(i.e. where the regression line is determined byy = a + bx, the common slope derived
from a pooled value of b means that this measure is dependent on the individual value
for a); secondly and thirdly, from the separate regression lines, estimates of insulin
resistance based on the blood glucose concentrations obtained from calculation of the
regression equation at insulin concentrations of 100 and 400pmol/L (13.4 and
53.6mU/L), designated here 1100 and 1400 respectively.
Insulin resistance estimated from the euglycaemic hyperinsulinaemic clamp is
calculated as a value M from the quantity of glucose infused during the last 30-60
minutes of the procedure while maintaining a constant measured blood glucose
concentration. Higher values ofM therefore indicate greater sensitivity to insulin.
Insulin resistance estimated by HOMA-R is calculated from fasting blood glucose
and plasma insulin concentrations using the equation insulin resistance value =
[glucose (mmol/L)] x [insulin (mU/L)] / 22.5. Higher values indicate greater degrees
of insulin resistance.
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Figure 7.1. Relative positions on common slope for individual insulin sensitivity to





Figure 7.2. Individual slopes for blood glucose on log [insulin] from which data for
1100 and 1400 were obtained. (Legend as for figure 7.1.)
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Values obtained by each of these methods were ranked in ascending order and
correlation coefficients obtained using Spearman's rank correlation test. The critical p
value for statistical significance after correction for multiple comparisons was 0.0025.
Using the original data, regression lines were also obtained to examine further the
interrelationships between fasting glucose and insulin concentrations and insulin
resistance data obtained.
Results
The three estimates of insulin resistance derived from the low-dose insulin infusion
were all highly correlated with each other (rs >0.85; p<0.000001), and all correlated
well with insulin resistance estimated from HOMA-R (rs >0.85; p<0.000001).
Although M values from the euglycaemic clamp correlated to a significant extent with
HOMA-R values (rs = -0.66; p=0.023), relationships with insulin infusion-derived
indices of insulin resistance did not reach statistical significance (rs for the three
comparisons between -0.42 and -0.44; p=0.10-0.12).
Fasting plasma insulin concentration did not relate closely to any of the insulin
infusion-derived indices, but was closely linked to M values (rs = -0.74; p = 0.0002).
Since HOMA-R values are obtained by calculation directly from fasting plasma insulin
concentrations, a close relationship is to be expected (rs = 0.72; p = 0.0002), as was
also the case for fasting blood glucose (rs = 0.78; p = 0.00002). Fasting blood glucose
concentration was also closely related to all three insulin infusion indices (rs > 0.79; p
< 0.00001) but not to M values (rs = -0.44; p = 0.10).
Regression lines were calculated using the original data obtained, without ranking or
transformation, to clarify fiirther the extent ofthe relationships between these factors.
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Table 7.1. Calculated regression lines.
r* slope (b) a
1400 on M 0.21 -0.39 6.70
FBG 0.75 0.6 0.034
FPI 0.031 0.01 4.80
HOMA-R 0.54 0.42 2.91
M on FBG 0.17 -0.35 8.51
FPI 0.07 -0.01 6.79
HOMA-R 0.43 -0.44 7.55
1100 on HOMA-R 0.55 0.69 4.18
confidence limits (b) p
-0.89-0.11 0.113
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Figure 7.4. Relationships for 1400 (y axis) with HOMA-R values (top) and M values
(bottom).
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Statistically significant associations were obtained for regression of 1400 on fasting
glucose and HOMA-R, and for M on HOMA-R (see table 7.1 for details).
Scattergraphs showing the relationships for 1400 with fasting glucose and insulin are
shown in figure 7.3, and for 1400 with M values and HOMA-R values in figure 7.4.
Conclusions
Assessment of the use of the low-dose insulin infusion technique in this way is
necessarily limited and it has not been possible with data from these studies to assess
repeatability of the technique.
The three measures of insulin resistance used to assess this technique are all highly
correlated, and also correlate well with the HOMA-R values obtained. The
relationship with clamp values is less strong, although this is a small dataset and
NIDDM subjects may form a special category. It is important to remember that the
two methods are assessing different phenomena and to some extent any comparison
may be invalid. The strengths of the insulin infusion method he in its ability to assess
effects of insulin on several metabolic variables simultaneously, and at approximately
physiological concentrations of insulin. The complexity of the calculations involved







These studies have all been carried out in subjects with NIDDM, all recruited from a
general hospital diabetic clinic. This is perhaps an innately heterogeneous group,
particularly in terms of fasting blood glucose, and risk factors for both diabetes and
coronary heart disease. This very heterogeneity, while in some respects problematic,
does nonetheless make the population studied potentially representative of that seen
in regular clinical practice.
In this concluding chapter I review each of these studies in turn, to draw conclusions
from the evidence presented and relate these to the published literature.
Epidemiology of coronary risk factors in new NIDDM (chapter 3)
Concepts of coronary risk factor clusters are not new (Vague, 1956), although
claims for the pre-eminence of one factor over others are more recent (Modan et al,
1985; Reaven, 1988; Kaplan, 1989; Ferrannini et al, 1991; DeFronzo and Ferrannini,
1991). In particular, Reaven's description of 'Syndrome X' stimulated widespread
interest in addressing these multiple risk factors, and data have been presented from
population studies to support the existence of a syndrome (Zavaroni et al, 1989;
Hafiher et al, 1992).
While most previous studies of insulin resistance, metabolic syndromes and coronary
risk factors have addressed primarily a non-diabetic or perhaps 'potential diabetic'
population, once the presence of diabetes is recognised coronary risk increases and it
is important to address the needs of this large population. Even in newly-diagnosed
diabetes the prevalence of coronary heart disease has been estimated at three times
that of the normal population (Uusitupa et al, 1985).
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Clustering of metabolic risk factors in terms of Syndrome X or the metabolic
syndrome has not previously been studied in a diabetic population. The group chosen,
comprising subjects within three months of diagnosis, was intended to examine
subjects who would have at least relatively preserved insulin secretory capacity, and in
whom confounding influences of diabetes itself and its treatment would not have been
superimposed. Thus I believe this to be the most homogeneous diabetic population to
study, and perhaps also the 'least diabetic'.
The data from this study show a number of features in broad agreement with those
reported elsewhere. A similar prevalence figure for hypertension to that found here
(50%) has been reported by the United Kingdom Prospective Diabetes Study (1985),
with rates of 40% for men and 53% for women. The pattern of lipid abnormalities,
with high rates of hypertriglyceridaemia and low HDL-cholesterol concentrations has
also been previously described (Uusitupa et al, 1986; Gibbons, 1986) and it has been
suggested that (familial) hypertriglyceridaemia may predict the development of
NIDDM (Sane and Taskinen, 1993).
The finding of a normal distribution pattern for the number of features of syndrome
X present is at variance with the data from the San Antonio Heart Study (Ferrannini
et al, 1991) which reported in a large biethnic (white and Hispanic) population
considerable overlap between diabetes or impaired glucose tolerance, obesity,
hypertension, hypertriglyceridaemia and hypercholesterolaemia. The authors found a
tendency to multiple combinations, and concluded that hyperinsulinaemia was the key
unifying factor. The present study gives a certain amount of support to this view in
that both hyperinsulinaemia and hypertriglyceridaemia were much more likely to be
associated with multiple additional risk factors than with only one other; hence
hyperinsulinaemia or hypertriglyceridaemia in conjunction with glucose intolerance
(here frank diabetes), seem likely to predict the presence of additional risk factors for
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coronary heart disease. In contrast, the other risk factors studied, most notably
hypertension and insulin resistance, appeared here not to predict the presence of
additional risk factors. The number of additional risk factors in the presence of either
hypertension or insulin resistance followed an approximately normal distribution.
A tendency to clustering of metabolic risk factors is shown by the data presented
here, although the distribution differs from that described elsewhere (Ferrannini et al,
1991). The distribution was similar for both Caucasian and Asian subjects; the group
ofblack subjects, although too small to analyse formally, showed a tendency to fewer
coronary risk factors than the others.
Long-term follow-up data from the San Antonio Heart Study (Haffher et al, 1992)
supports the predictive value of hyperinsulinaemia for the development of both
hypertriglyceridaemia and low HDL-cholesterol but the relationship with the
development of hypertension was weak. Saad et al (1991) have suggested that this
association may be present only in some racial groups, and Lind et al (1993)
contended that insulin resistance is more closely related (than hyperinsulinaemia) with
hypertension. Every et al (1993) found a relationship for higher insulin and C-peptide
concentrations with higher diastolic blood pressure among non-diabetic subjects; this
association was modified by obesity.
In keeping with previous studies, and notably in support of Reaven's exclusion of it
from his original definition of a metabolic syndrome (Reaven, 1988), serum
cholesterol concentration had a limited relationship with other coronary risk factors,
as did age. It is posible that total/HDL-cholesterol ratios may be a more useful
indicator of risk in this context, although I did not address this possibility here.
Obesity, however, was related to hyperinsulinaemia and to greater frequency of risk
factors. The index of obesity used appeared to be less important; body mass index
was at least as good an indicator of risk as was waist-hip ratio, suggesting that obesity
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per se rather than fat distribution may be important; this contrasts with the finding of
Baynes et al (1991a) who reported that, at least in men with NIDDM, waist-hip ratio
was a better predictor of the presence of atherogenic risk factors.
The use of'number of features of the metabolic syndrome' as the dependent variable
in multiple regression analysis here may appear at first sight somewhat specious.
However, I would contend that it has allowed exploration of the relative importance
of the known contributory factors, notably highlighting insulin and triglycerides, and
raising the possibility of a female propensity, albeit modest. The failure of other
factors, such as obesity, to take on a significant independent role seems to be
accounted for by their associations with existing features of the syndrome (notably
insulin concentration in the case of obesity).
The use of factor analysis adds an extra dimension to consideration of the metabolic
syndrome and here I have been particularly interested in comparing these data with
the findings of Meigs et al (1997). Both studies appear to yield remarkably similar
results, with a three-component model based on essentially the same contributory
factors. The apparent association of a raised HDL-cholesterol concentration with
hypertension and obesity in this study may be anomalous, although it is worth noting
that a similar trend was present in Meigs' study. This may warrant further
examination.
Clearly this procedure can only be regarded as a descriptive technique to explore
interrelationships between features measured or observed. Indeed, when I attempted
to develop a model including all the factors used in the multiple regression analysis a
highly complex multi-component model resulted with mutually exclusive groups
(table 3.7 (b)). Overloading of this procedure appears to run the risk of producing a
model which merely describes in complex patterns the population studied.
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Probably the most important conclusion from these data, other than the remarkable
consistency between these data and those of Meigs et al, is the stark disagreement
between these findings and those of others (Ferrannini et al, 1991) over the
distribution of risk factors in the respective populations studied. The data presented
here, on the definitions used, clearly show an approximately normal distribution of
risk factors. It seems reasonable to infer from this that diabetic individuals, like non-
diabetics, vary considerably in their coronary risk, and not all will need to be
automatically considered at high risk. This may accord better with the'Common Soil'
hypothesis than with concepts based on syndromes of risk factor clustering. This
conclusion may render the concept of a metabolic syndrome less usefixl in a clinical
context, but the lack of a clear dichotomy between high-risk and low-risk subjects
should only add to clinicians' vigilance in coronary risk prevention.
While these data describe relationships between risk factors, clearly only longitudinal
data can fully address the impact of these on outcomes. The proportion of the group
studied having previously diagnosed coronary heart disease was small (28 of 231),
and the definition ofpreviously diagnosed coronary heart disease weak (self-report of
such a diagnosis having been given), allowing only limited interpretation of data
comparing subjects with and without known CUD. However, the absence of any
significant differences between this and the rest of the study population, other than
greater age and obesity (BMI) may raise doubts as to the importance of a metabolic
syndrome, although any impact of treatment of heart disease cannot be determined.
There are few longitudinal data in the literature, although recently the UKPDS group
(Turner et al, 1998) identified five important modifiable risk factors for coronary heart
disease in their diabetic population, namely hyperglycaemia, hypertension, low HDL-
cholesterol, raised LDL-cholesterol and smoking.
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A number of limitations to this study should be recognised. Although every effort
was made to apply the duration of (known) diabetes criterion strictly, the often
insidious mode of onset of this condition inevitably means that many subjects will
have had abnormal glucose tolerance for a considerable time prior to diagnosis.
Nonetheless, 84% of the subjects studied were assessed within 2 months of a
diagnosis of diabetes being applied. Again where possible all insulin-requiring subjects
were removed from analysis. Although subjects were asked to omit diabetic
medication, no adjustment has been made for effects of that medication in the analyses
shown. Nor has any adjustment been made for any confounding effect of other
treatments (eg. effects of antihypertensive treatments on lipid values).
The thresholds defining presence or absence of individual factors is inevitably open
to criticism, especially when the variables studied are continuous. I have attempted
where possible to use accepted cutoff points, as determined in other epidemiological
studies which should aid comparison with other data.
In conclusion I have for the first studied a population of newly-diagnosed type 2
diabetic subjects for features of Reaven's metabolic syndrome and examined
interrelationships between the known features and additional features considered of a
priori importance. I have identified important associations between the coronary risk
factors defined, but have seen no separation into 'few risk factor' and 'multiple risk
factor' categories as reported in other populations; instead a normal distribution of
risk factors is observed. Analysis of these data has identified a 3-component model for
risk factor clustering, almost identical to that reported from the Framingham
Offspring Study. Long-term follow up of this population will help to establish whether
such a model is indeed predictive of coronary disease.
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Use of insulin secretagogues (chapter 4)
A number ofpotential new oral hypoglycaemic drugs are currently under evaluation.
Despite their usefulness, the sulpkonylureas have important disadvantages, notably a
propensity for weight gain and risk of hypoglycaemia as their action on insulin
secretion is not glucose-dependent. The biguanides too have important limitations, as
does acarbose. The meglitinide family has attracted particular interest (Malaisse,
1995a); the main property of this group appears to be stimulation of insulin secretion,
but other characteristics have not previously been determined. A4166, a short-acting
agent of this group, was studied here primarily to confirm its effects on insulin
secretion in diabetic man, and also to examine its effects on glucose and other
intermediary metabolites.
Insulin secretion in response to an intravenous glucose bolus in normal subjects is
biphasic (Porte and Pupo, 1969) with an early acute insulin release measurable during
the first 10 minutes after injection of glucose. This acute or first phase is
characteristically lost in NEDDM (Pfeifer et al, 1981); indeed a paradoxical decrease
in insulin secretion may occur (Metz et al, 1979), as observed here in the studies with
placebo. It has been suggested that first phase insulin response is lost with fasting
plasma glucose concentrations above 6.5 mmol/L (115 mg/dl; Brunzell et al, 1976)
and the defect may therefore be expected to have become established before diabetes
is diagnosed in most cases. The second phase response to glucose, being related
primarily to the duration of the hyperglycaemic stimulus, is usually better preserved
and tends not to deteriorate until markedly higher fasting blood glucose levels are
reached (Pfeifer et al, 1981). Insulin secretory responses to other stimuli are usually
preserved in NIDDM, although most of these are enhanced by the presence of
adequate circulating glucose concentrations (Pfeifer et al, 1980).
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The data presented here clearly show the ability of A4166 to stimulate insulin
secretion and restore first phase insulin response to glucose in non-insulin-dependent
diabetic subjects. Studies of sulphonylurea agents have reported enhancement or
partial restoration of the first phase insulin response to intravenous glucose. Turtle
(1970) described in three patients an increased early insulin response (measured at 10
minutes) to 50g IV glucose given 3 horns after 250mg tolazamide given orally.
Chiasson et al (1991), using an intravenous glucose tolerance test with minimal
modelling, found increased acute and total insulin responses to glucose both in healthy
volunteers and NIDDM subjects 90 minutes after administration ofgliclazide (80mg).
Tolbutamide, which may be expected to be the most closely comparable
sulphonylurea agent to A4166 in terms of rate of onset and duration of action, has
been relatively little studied in this way. Siegal et al (1972) reported significantly
enhanced insulin secretion, and also enhanced glucose clearance rates in healthy
volunteers, after submaximal (but not maximal) (3 cell stimulation by intravenous
glucose given 2 hours after lg oral tolbutamide. Gadgil et al (1983) were able to
demonstrate, again in healthy volunteers, lower plasma glucose concentrations
following intravenous glucose loading 30 minutes after oral tolbutamide (lg),
although insulin concentrations were not measured. In their study this effect was not
observed when the IVGTT was performed 4 hours after tolbutamide dosing, and
again was only present when (3 cell stimulation by glucose was submaximal.
Effects of A4166 on metabolite conentrations have not previously been examined.
We observed, prior to diet, a rise in lactate concentrations and a fall in NEFA,
glycerol and ketone body concentrations. It seems likely that most of these effects are
secondary to enhanced insulin secretion in the presence of the drug, although direct
effects ofA4166 or improvements in insulin sensitivity cannot be ruled out. The lack
of a statistically significant effect with A4166 after diet may also, or alternatively, be a
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result of the diet treatment itself No data exist to indicate whether any effects of
A4166 on metabolite concentrations may be demonstrable in subjects with established
diabetes. Effects of diet on metabolite concentrations have been previously described
(Sheppard et al, 1983) with falls in concentrations of lactate, pyruvate, alanine and
glycerol observed after 6 weeks of dietary treatment in newly-diagnosed diabetic
subjects. These changes were associated with a fall in blood glucose concentrations
and with reduction in subjects' body weights. It is notable, albeit disappointing, that
the attempts in the present study at vigorous dietary management had no significant
impact on either fasting or overall blood glucose concentrations and subjects' body
weights did not change. Although this was not a primary objective of this study, the
trend towards lower blood glucose concentrations with A4166 suggests that a larger
study may be better able to demonstrate a glucose-lowering effect.
Bakkali-Nadi et al (1994) have reported from isolated rat islet studies that the
insulinotropic effects of the meglitinide analogues are glucose-dependent, which
would appear to be at variance with the findings here, as indicated by the rise in
plasma insulin concentration observed following A4166 administration even before
onset of glucose injection (figure 1). However, in our study fasting blood glucose
concentration in all cases was at least 6 mmol/L and it seems likely that this
concentration provides an adequate co-stimulus for insulin release.
Effects on glucose clearance are also of interest, since any drug to be used in
NIDDM may have considerable advantages if it can be shown to beneficially affect
insulin sensitivity. The findings here must be regarded as somewhat equivocal, since
glucose clearance was only enhanced in the studies following diet treatment. Whether
this is a reflection of enhanced insulinaemia overcoming insulin resistance is not clear;
if this is so the absence of an effect prior to diet cannot be explained. The variability
seen in absorption of the drug is also likely to be important. That some individuals
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appear to be non-absorbers and hence non-responders to A4166 is clearly shown here
although reasons for this are not apparent. This was an unexpected finding of this
study and requires further elucidation in future ifA4166 is to come into clinical use.
The size of this study has adequately demonstrated the ability of A4166 given prior
to IVGTT to enhance significantly endogenous insulin secretion in NIDDM subjects
whose secretory responses are otherwise grossly impaired. Further work is necessary
to elucidate the mechanism of action of A4166 in enhancing insulin secretion and
whether the metabolic improvements suggested by this study are specific to A4166 or
rather a consequence ofhigher circulating insulin concentrations.
Effects on insulin resistance of reducing hypertriglyceridaemia (chapter 5)
Associations between insulin resistance and hypertriglyceridaemia have been
previously described (Olefsky et al, 1974; Bernstein et al, 1978; Steiner et al, 1980).
With the increased interest in this relationship further stimulated by concepts of
clustering of metabolic coronary risk factors, an attempt to assess whether insulin
resistance might be modifiable by reducing serum triglyceride concentrations seemed
appropriate. Previous studies have yielded conflicting data for any effect of
bezafibrate on glycaemic control (Jones et al, 1990; Karhapaa et al,1992) with no
effect on insulin resistance (Karhapaa et al, 1992). With gemfibrozil no effect (Eisalo
et al, 1982; Lintott et al, 1992) or a deleterious effect (Marks and Howard, 1982) has
previously been shown on glycaemic control; no effect has been reported on insulin
resistance (Shen et al 1991; Vuorinen-Markkola et al, 1993), although Shen et al
(1991) reported some improvement in insulin sensitivity in a less well-controlled
diabetic subgroup of their study.
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The mechanism of action of the fibrate family has only recently been elucidated. It is
now clear that fibrates exert most if not all of their effects via stimulation of
peroxisome proliferator activated receptors (PPAR) of the mainly hepatic a subgroup
(Staels et al, 1997). This results in a number of effects on lipid metabolism. Hepatic
synthesis of apolipoprotein A-II, a major constituent ofHDL, is increased (Vu-Dac et
al, 1995) and apolipoprotein C-III synthesis reduced. This latter effect correlates
closely with fibrate-induced falls in triglyceride concentrations; gemfibrozil can be
shown to reduce plasma apo C-III concentrations as well as reducing hepatic apo C-
III mRNA synthesis (Haubenwallner et al, 1995). In vitro fibrates inhibit certain key
enzymes in fatty acid synthesis; gemfibrozil is particularly potent in this respect
(Sanchez et al, 1992). In cell culture VLDL-receptors are upregulated by fibrates, an
effect shared with insulin (Wittmaack et al, 1995).
In this study a significant reduction in triglyceride concentrations has been
demonstrated with gemfibrozil; this effect has been well documented in both diabetic
(Marks and Howard, 1982; Garg and Grundy, 1989; Shen et al, 1991; Lintott et al,
1992; Vinik et al, 1993; Lahdenpera et al, 1993) and non-diabetic populations (Frick
et al, 1987; Tsai et al, 1992). An association between impaired NEFA suppression
and hypertriglyceridaernia in NIDDM has also been described previously (Yki-
Jarvinen and Taskinen, 1988; Baynes et al, 1991b).
The triglyceride reduction shown here was associated with a statistically significant
reduction in mean concentrations ofNEFA and ketone bodies during insulin infusion.
The downward and leftward shift of the insulin dose-response relationship could
initially be interpreted as showing that insulin sensitivity has improved (i.e. that
metabolite concentrations are lower after gemfibrozil treatment at each concentration
of insulin achieved). However ,the absence of concomitant changes in glycerol
concentrations which would then be expected makes this hypothesis less likely.
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Gemfibrozil appeared to have no effect on glycerol concentrations nor on the
relationship between insulin and glycerol. Since circulating glycerol levels reflect
predominantly lipolysis, a process particularly sensitive to inhibition by insulin, the
absence ofany observed change in this relationship suggests that gemfibrozil does not
influence the sensitivity of lipolysis to insulin.
Circulating NEFA concentrations reflect both lipolysis and also hepatic synthesis. In
the context ofwhat is now known about the mode of action of fibrates it seems most
likely that the changes observed here are the result of a direct effect on hpid
metabolism - particularly hepatic fatty acid synthesis - by the drug. This finding
contrasts with the findings ofVuorinen-Markkola et al (1993) who reported no effect
on glucose or NEFA metabolism despite a similar reduction in triglyceride
concentrations with gemfibrozil. Nonetheless, the findings from the present study are
in accord with the emerging evidence for the role of PPARs in insulin sensitivity of
lipid metabolism.
No effect on insulin stimulated glucose clearance has been shown, nor was there any
change in overall glycaemia as measured by fasting blood glucose, HbAlc and
fructosamine concentrations. These findings are broadly in keeping with those
previously reported (Shen et al 1991; Vuorinen-Markkola et al, 1993).
Important limitations to this study centre around its size, as a result of problems in
recruitment. Effects of treatment with other oral hypoglycaemic and antihypertensive
drugs are unlikely as these remained stable throughout the study. (Only
sulphonylureas were used by the subjects in this study.) Although a type II error is
possible because of its small size, the data presented, and the evidence from other
studies, suggest that the overall lack of effect on glucose metabolism is likely to be a
true finding. Gemfibrozil may have important advantages in NIDDM if these effects
on fatty acid metabolism can be confirmed.
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Body fat distribution and insulin resistance in NEDDM (chapter 6)
Vague's description of android (upper body) obesity and its association with other
metabolic derangements (Vague, 1956) has been supported by more recent
observations on coronary risk and insulin resistance among non-diabetic subjects.
Whether body fat and its distribution remain relevant once diabetes is estabhshed is
less clear.
In this study a group ofmen with estabhshed NIDDM on no medical treatment was
studied; a deliberate attempt was made to ensure homogeneity in as many aspects as
possible, allowing a limited range for BMI (24-33) and age (40-66) to minimise
confounding factors.
No consistent effect of any of the indices of obesity or body fat distribution used
(BMI, waist-hip ratio or percentage body fat) was shown on the assessments of
insulin resistance. There appears to be no clear explanation for the apparently reduced
insulin sensitivity to glucose and ketone metabohsm shown by the 'low' waist-hip ratio
group; previous experience with this methodology suggests that the group size was
adequate to show a true effect, and the finding is supported by the trends in the other
variables including insulin, hi contrast the greater insulin sensitivity for NEFA and
glycerol metabohsm in the 'low' BMI group suggests more efficient triglyceride
metabohsm among less obese individuals. However, these findings are of questionable
clinical significance set against the absence of an overall effect on insulin sensitivity
shown by any index ofbody fat.
The powerful effect of basal glycaemia suggests that the diabetic state per se may
well have an overwhelming effect on insulin sensitivity, at least to glucose
metabolism, and this accords with concepts of glucose toxicity (Yki-Jarvinen, 1992)
suggesting that hyperglycaemia itselfmay inhibit normal metabohc response to insulin.
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This is in keeping with studies previously reported addressing effects of body fat on
insulin sensitivity in NIDDM (Hollenbeck et al, 1984; Firth et al, 1987; Ludvik et al,
1995), concluding that the contribution of obesity was dwarfed by that of diabetes
itself. Even among non-diabetic offspring of individuals with NIDDM the family
history may be an important contributor to insulin sensitivity to glucose metabolism
(Osei et al, 1991). While this effect of glycaemia was prominent with the low-dose
insulin infusion it should be noted that it was not seen with the euglycaemic
hyperinsulinaemic clamp.
A further possible explanation for the apparent inconsistency in these findings is the
possibility that different factors may influence different aspects of insulin resistance,
and there is no a priori reason to suppose that all modifiers of insulin resistance will
influence it in the same direction. Thus, obesity (measured by BMI) may only be
relevant for insulin sensntivity to fat metabolism in this population, and fasting
glucose only for glucose metabolism. Similarly, reducing triglyceride concentrations
would appear from the data presented above only to influence insulin sensitivity to fat
and not to glucose metabolism. There are few data in the literature concerning
relationships between sensitivities to different aspects of insulin action, and further
study is warranted.
This was a small study and it may be that the range of values for waist-hip ratio and
percent body fat studied were too narrow, and those for glucose too wide.
Interpretation of the findings is limited by the inability (small study size) to compare
the relative contributions of factors studied (by multiple regression). There are
conflicting reports on whether BMI is important in non-obese subjects (Bogardus et
al, 1985; Campbell and Gerich, 1990); here again better control of ranges may have
allowed differences to be observed. Nonetheless it seems likely that hyperglycaemia is
a more important determinant than body fat of insulin resistance, and only where basal
207
glycaemia is more homogeneous (i.e. among non-diabetic subjects or those with
impaired glucose tolerance) will effects ofbody fat emerge.
Role of the low-dose incremental insulin infusion (chapter 7)
The use of both low-dose insulin infusions and euglycaemic hyperinsulinaemic
clamps in the study ofbody fat and insulin resistance allowed comparison between the
two techniques, as well as comparison with fasting insulin concentrations and the
HOMA-R method. The validity ofmany measures of insulin resistance, perhaps most
notably the FSIGT (minimal model), become questionable in diabetic subjects.
Before making direct comparison between the two methods it is important to note
that they are designed to assess different aspects of insulin resistance. The
euglycaemic clamp is designed to assess insulin-mediated glucose clearance at a fixed
normal blood glucose concentration, using supraphysiological concentrations of
insulin. This is clearly artificial, and problems can immediately be seen to arise with
the question as to whether blood glucose in diabetic subjects should be set at
normoglycaemia (i.e. 5mmol/L as in this study) or at euglycamia for each individual
(i.e. at fasting glucose level; in this study 4.8-10mmol/L). The use ofnormoglycaemic
concentrations here may have introduced confounding metabolic perturbations
conceivably rendering the procedure invalid. However, the use of individual
euglycamic concentrations would inevitably have made comparison between subjects
more difficult.
The low-dose incremental insulin infusion is designed to assess effects on several
metabolic variables of a range of insulin concentrations broadly within the
physiological range (Hale et al, 1986). It has been used to study subjects with normal
and impaired glucose tolerance, and with LDDM and NIDDM; with this method the
208
fasting blood glucose of the individual is less important. Comparison of the two
techniques therefore has important limitations which include the need to derive
arbitrary point values from the insulin infusion to create comparable units for
matching with M values.
It is therefore not surprising to find only limited correlations between the indices of
insulin resistance derived from insulin infusion and the clamp-derived M values. That
both are well correlated with HOMA-R indicates a useful role for each of the three
methods in appropriate circumstances. The low-dose insulin infusion has usually been
used to compare groups and it is probably invidious to use individual values as applied
here; the slopes obtained from the regression equations for individuals will all have
wide confidence intervals (although these have not been formally calculated here). Its
strengths appear to he in giving more reliable assessments of insulin resistance in
diabetic subjects than do many of the alternative methods, and in its ability to yield
dose-response relationships not only for glucose but for other metabolites
simultaneously.
The close relationship observed in the present study between fasting blood glucose
and individual insulin sensitivity seems likely to reflect the impact of chronic
hyperglycaemia itself in diabetic subjects on insulin sensitivity, i.e. glucose toxicity
(Yki-Jarvinen, 1992).
It has not been possible here to make any assessment of repeatability for the insulin
infusion method, and this remains for future study. Other methods, notably HOMA
(Matthews et al, 1985) and CIGMA (Hosker et al, 1985), and the IVGTT with
minimal modelling (Steil et al, 1994) have been subjected to repeatability assessments
and may prove less reliable than might be expected, with reported coefficients of
variation exceeding 20%. The short insulin tolerance test appears to be the most
reliable of those tested in this way with quoted intra-individual coefficients of
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variation of 5-15% (Akinmokun et al, 1992; Hirst et al, 1993). All of these methods
may be better suited to comparison ofgroups than of individuals.
Concluding remarks
Despite the myriad of confounding factors present, some clear findings emerge. The
metabolic syndrome appears not to be homogeneous, even in a diabetic population,
and is probably composed of 'subsyndromes', each contributing to coronary risk.
Obesity, measured by either body mass index or waist-hip ratio, belongs in tis
grouping of risk factors, although other important contributors such as cholesterol
appear to exert an effect independently.
Once diabetes is estabbsbed, obesity becomes ofmuch lesser significance in relation
to insulin resistance. It remains to be estabhshed whether improvements in glycaemic
control without changes hi body fat would improve insulin sensitivity. Improving
hypertriglyceridaemia with gemfibrozil probably reduces fatty acid concentrations
directly rather than by any improvement in insulin sensitivity; this effect may
nonetheless be valuable.
Restoration of a more normal insulin response to glycaemic stimulus by the insulin
secretagogue A4166 may improve glucose clearance but overall has bttle effect on
intermediary metabohsm other than that resulting from increased insulin
concentrations.
The various techniques used here to assess insulin action can all provide valuable
information, although comparison of results obtained with different methods must be
cautious. Appropriate use of each technique requires careful consideration of the
question to be addressed, and importantly of the population studied.
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